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Periaxin was first identified as a 147 kDa protein which was subsequently
found to be a relatively abundant component of myelinating Schwann cells.
Periaxin displays a pattern of expression that is highly regulated both spatially and
temporally in the developing peripheral nervous system of the rat. After the
protein's initial localization to the periaxonal membranes of Schwann cells as they
begin axonal ensheathment (hence the name periaxin), it becomes predominantly
abaxonal as the myelin sheaths mature. This shift in the localization of the protein
in the Schwann cell after completion of the spiralization phase of myelination
suggests that periaxin may participate in the membrane-protein interactions that
are required to stabilize the mature sheath.
Although earlier studies had been focused on rat periaxin, in this thesis the
structure of the mouse periaxin gene (Prx) has been determined. This was in order
to facilitate further studies on the molecular genetics of periaxin expression and
function. Analysis of the structure and expression of the mouse periaxin gene has
revealed that the gene encodes two polypeptides and the mechanism by which
these two proteins are encoded has been established. Furthermore, the localization
of these two proteins has been shown to differ in myelinating Schwann cells.
A mouse genomic library constructed in the bacteriophage replacement vector
Lambda Dash II was screened by plaque in situ hybridization using a full length rat
periaxin cDNA as probe. Clones covering the entire length of the gene were isolated
and fully characterized. The murine periaxin gene spans 20.6 kb, includes seven
exons and encodes two mRNAs of 4.6 and 5.2 kb. The largest of these exons is
4 kb in length and encodes 90% of the protein coding sequence and all of the 3'
untranslated region.
Sequence analysis of the gene's core promoter identified several interesting
features. A TATA-box motif is absent; hence the murine periaxin gene promoter
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belongs to the TATA-less family. Direct comparison with the promoters of myelin
genes expressed in Schwann cells detected several common motifs, the most
important of which is known to bind the transcription factor SCIP/Oct-6. This
factor has been shown to have a vital role in the regulation of myelination by
Schwann cells. Such features underline the potential importance of periaxin in the
myelination process.
The 4.6 kb mRNA includes all seven exons and encodes the previously described
protein of 147 kDa (now termed L-periaxin). The 5.2 kb mRNA, in addition to the
seven exons, also includes an intron comprising 600 bases located between exon 6
and 7. The inclusion of this intron introduces both novel amino acid sequence and a
new stop codon and results in the translation of a truncated form of the periaxin
protein with a unique C-terminus which was previously undetected. During post¬
natal development of the sciatic nerve, the level of expression of this protein
(named S-periaxin) was shown to parallel that of L-periaxin. In contrast, the
localization of the S-periaxin, determined by indirect immunofluorescence, was
neither periaxonal nor abaxonal, but restricted to the Schwann cell cytoplasm.
The differential localization of L-periaxin and S-periaxin indicates that they







The past two decades has seen an explosion of new information about the
organization, structure, and regulation of genes in eukaryotic organisms. The reason
for this enormous increase in our knowledge has been the concurrent development of
recombinant DNA techniques and methods for determining nucleotide sequences.
Despite these great advances however, our understanding of the exact genetic
processes involved in the growth and development of highly differentiated
multicellular organisms remains fragmentary at best and is most likely still naive.
Given that each cell contains the same complement of genes and originates
from a single fertilized egg, a major challenge is to understand how different types
of cells express widely different proteins. In addition, these differential patterns of
protein synthesis occur at different developmental stages of the same cell.
Therefore, the mechanisms of gene regulation which exist in eukaryotes must be
exquisitely intricate and complicated. So much so in fact, that these mechanisms are
not understood for even one mammalian gene to the extent that they are understood
for many prokaryotic operons. Clearly, the task for researchers is a difficult one.
Sequencing the entire genome of an organism will rapidly provide the knowledge of
the individual constituents, but showing how the expression of each and every one
is integrated and coordinated with respect to the whole animal is a feat which may
take many years.
The most sensible way forward perhaps, is to consider a multicellular
organism not as a whole but more as a sum of its parts. In other words, determine
the developmental processes of the individual cell types. It should then be possible
to discern the underlying mechanisms, thus providing a basis for a complete
understanding of the entire system. The Schwann cell, the myelin-forming cell of the
peripheral nervous system of higher vertebrates, is an ideal cell type to study
cellular differentiation given its distinctive developmental phenotype and the
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associated highly coordinated, highly selective pattern of gene expression.
Characterization of the programme of gene expression involved in the myelination
process will also be of tremendous value to those seeking to understand, at the
molecular level, the large number of neurological diseases caused by defects in the
myelin sheath. Ultimately, it is hoped that such information will lead to new
therapies. The following is therefore a review of our current knowledge of Schwann
cell development, differentiation and myelination and the molecular basis thereof.
1.2 THE SCHWANN CELL AND MYELINATION
1.2.1 An Introduction to Myelin
The rapidly conducting nerve fibres of higher vertebrate animals possess a
segmental myelin sheath which is a lipid-rich, multilamellar organelle (Morell, 1984).
This substance serves principally as an electrical insulator, greatly increasing the
velocity of impulse propagation by facilitating saltatory conduction (Ranvier, 1878;
Stampfli, 1981; Ritchie, 1984, 1987; Waxman and Ritchie, 1985). To this purpose,
myelin is found in both the central nervous system (CNS) and in the peripheral
nervous system (PNS). In the CNS, myelin is elaborated by highly specialized, non-
neuronal cells known as oligodendrocytes (Bunge et al, 1962). Importantly, the
myelin-forming cells of the PNS comprise a completely different lineage and are
known as Schwann cells (Geren, 1954). Despite this fact, both cell types form
myelin by repeatedly wrapping a flattened extension of their plasma membrane in a
spiral around the nerve axon. The subsequent extrusion of cytoplasm from within
the spiral, leads to the apposition of both adjacent cytoplasmic membrane surfaces
and adjacent extracellular membrane surfaces, forming mature compact myelin. At
the macroscopic level therefore, CNS and PNS myelin are very similar (Kirschner et
al, 1984; Readhead et al, 1987). However, this is not the case at the molecular level,
where striking compositional differences between the two myelins are observed.
These compositional differences occur primarily within the complement of myelin
(and myelin-associated) proteins utilized by each cell type, and whose functional
properties collectively bring about the formation and maintenance of the respective
multilamellar structures. To a certain extent therefore, Schwann cell myelin and
oligodendrocyte myelin can be considered an example of convergent evolution, much
like the echolocation of bats and dolphins - the same function, brought about in a
similar way, but developed independently. Thus, PNS and CNS myelin, and the
cells responsible for their elaboration, must be treated as distinct but related
entities.
1.2.2 From Neural Crest to Schwann Cell
Like the peripheral neurons they are destined to myelinate, Schwann cells
have their origins in the neural crest (Le Douarin, 1982, 1986; Le Douarin et al,
1991; Fraser and Bronner-Fraser, 1991; Frank and Sanes, 1991; Anderson, 1993).
This transient and relatively small, pluripotent population of cells located dorsal to
the neural tube (the origin of oligodendrocytes [Pringle and Richardson, 1993]),
migrate widely throughout the embryo during development (Weston, 1963;
Rickmann et al, 1985; Bronner-Fraser, 1986; Loring and Erickson, 1987), and give
rise to a number of other distinct cell types including melanocytes, smooth muscle
cells, endocrine cells, and osteoblasts. Crest cells destined to follow the Schwann
cell lineage migrate into the PNS at a very early stage of development (Le Douarin et
al, 1991; Stemple and Anderson, 1992) and become closely associated with
embryonic peripheral nerves (Dahm and Landmesser, 1988). Concomitant with
this process, these cells undergo extensive differentiation (Jessen et al, 1994; Dong et
al, 1995; Gavrilovic et al, 1995), forming Schwann cell "precursors", which represent
a distinct intermediate in the generation of Schwann cells from neural crest cells




















Figure 1. Stages in Schwann cell (SC) differentiation. This diagram summarises the
profile of markers used to define distinct developmental stages in both myelinating and
non myelinating Schwann cell lineages. Markers are as follows: NCAM, neural cell
adhesion molecule; LI, an immunoglobulin-related adhesion protein; S100, a Schwann cell
calcium binding protein; Krox20 and SCIP, transcription factors; GalC, galactocerebroside;
MG, Myelin structural proteins. After Scherer (1997).
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Interestingly, Schwann cell precursors maintain certain crest cell features
including a flattened morphology and high motility. The importance of such
characteristics is demonstrated by a rapid phase in which these cells begin to
invade large nerve bundles (Peters and Muir, 1959; Gamble and Breathnach, 1965;
Gamble, 1966; Ziskind-Conhaim, 1988), extending finger-like processes which
progressively subdivide, segregate and envelop the individual axons (Ashbury,
1975; Raine, 1984). In the rat sciatic nerve, this takes place during embryonic day
14 to 15 (E14-E15) (Jessen et al, 1994). Each Schwann cell precursor eventually
forms processes around many axons which, at this stage of development, are
relatively thin (0.2-0.5 pm). As the cells continue to proliferate, the number of
axons associated with each cell decreases. By E16/E17 each cell is associated with
relatively few axons which lie within separate furrows, indenting the outer cell
membrane (Webster, 1971). Phenotypically, the cells at this stage are radically
different from the precursors (Jessen et al, 1994), particularly with respect to the
antigenic markers they express which are more typical of mature, fully
differentiated Schwann cells e.g. S100 (a calcium binding protein) and the 04
(sulphatide) antigen (Sommer and Schachner, 1981; Jessen et al, 1990; Mirsky et al,
1990). These cells are thus defined as embryonic Schwann cells (Figure 1).
As development progresses, embryonic Schwann cells continue to divide,
transferring axons to their progeny after each division until a 1:1 Schwann celkaxon
relationship is reached. Subsequently, these cells exit the cell cycle and synthesize a
basal lamina (Bunge et al, 1982; Bunge et al, 1986). Progression from this
promyelinating phenotype to mature myelin-forming Schwann cells occurs in the
first week of post-natal life in the rodent sciatic nerve, and within the third foetal
trimester in humans, and is associated with the high level synthesis of myelin-
associated proteins and membrane components (Webster, 1971; Wood and Engel,
1976; Lemke and Axel, 1985; Lemke and Chao, 1988; Willison et al, 1987; Trapp et
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al, 1988) and the downregulation of embryonic Schwann cell markers (Lemke and
Chao, 1988; Taniuchi et al, 1988; Jessen et al, 1990).
The commencement of myelin formation is first visualized at the membrane
bound lip on one side of the neck of the Schwann cell mesaxon (the extracellular
space connecting the axonal furrow to the cell surface), which flattens and then
tucks under the opposite side (Webster, 1971) (Figure 2A). This cytoplasmic
process then progresses in a spiral around the surface of the axon, displacing the
previous turns (Bunge et al, 1989; Webster and Favilla, 1984). Once 2-6 turns are
elaborated membrane compaction begins (Peters and Muir, 1959; Webster, 1971;
Webster and Favilla, 1984), giving rise eventually to a mature myelin segment
(Figure 2B).
In all developing nerves, a small population of embryonic Schwann cells fail
to form myelin, and instead develop a non myelinating phenotype. These cells
retain many characteristics of the embryonic Schwann cell, including association
with multiple thin axons (Ochoa, 1976; Webster and Favilla, 1984; Pannese et al,
1988), the expression of shared antigenic markers and importantly, they do not
upregulate myelin proteins (Brockes et al, 1979; Jessen and Mirsky, 1991; Mirsky
and Jessen, 1996). However, they do acquire the cell-surface marker
galactocerebroside (GalC) (Jessen and Mirsky, 1985; Jessen et al, 1987). The choice
between a myelin-forming phenotype or this non myelin-forming phenotype has
been shown to be determined by the axons with which the cells find themselves in
contact (Aguayo et al, 1976; Weinberg and Spencer, 1976; Lemke and Chao, 1988;
Voyvodic, 1989). Indeed, initiation of a myelinating fate is only observed in
embryonic Schwann cells that associate with axons that grow larger than 1 pm
(Peters and Vaughn, 1970; Martin and Webster, 1973; Webster et al, 1973); the
multiple axons associated with non myelin-forming Schwann cells are significantly
thinner. This is further supported by the finding that non myelinating Schwann cells





that normally contains many myelinating Schwann cells (Langley and Anderson,
1903; Simpson and Young, 1945; Aguayo et al, 1976; Weinberg and Spencer, 1976).
It is clear therefore, that all embryonic Schwann cells have the potential to form
myelin, but they will do so only upon induction by signals from appropriate
peripheral axons.
Although the molecular nature of these signalling molecules remains unknown,
they are likely to act in part by activating the adenyl cyclase cytoplasmic pathway
within the Schwann cell, since the presence of agents that elevate intracellular cAMP
levels (e.g. forskolin, dibutyryl cAMP and cholera toxin) in Schwann cell cultures
lacking neuronal support, mimics many of the effects of axonal contact (Sobue and
Pleasure, 1984; Lemke and Chao, 1988; Schuman et al, 1988; Trapp et al, 1988;
Monuki et al, 1989; Morgan et al, 1991; Jessen et al, 1991), in particular the
induction of myelin-specific genes. A long gap (> 12 hours) between intracellular
cAMP elevation and gene activation is observed in such cells, suggesting that this
induction occurs indirectly, most probably via a cascade of intermediate, cAMP-
induced regulatory molecules (Lemke and Chao, 1988; Morgan et al, 1994).
From the cell-specific induction of myelin formation and the synchronized
nature of the myelinating events it is evident that myelination is subject to an
extremely high level of control. As shown, the role of axons in this regulation cannot
be understated, with axonal contact an essential prequisite for terminal
differentiation of Schwann cells and the maintenance of this state (Wood and
Bunge, 1975; Salzer and Bunge, 1980; De Vries et al, 1982; Pleasure et al, 1985;
Jessen and Mirsky, 1991). Schwann cell-axon contact is also thought to be vital in
the progression from precursor to embryonic Schwann cell, communicating signals
which dictate survival, proliferation and the timing of maturation (Zorick and
Lemke, 1996; Topilko et al, 1996; Mirsky and Jessen, 1996). Research aimed at
deciphering the precise nature of these molecular signals is growing rapidly in
importance. Given that cell-cell contact and communication is a vital component of
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the coordinated development of most body systems not just the PNS this is hardly
surprising.
1.3 THE STRUCTURE OF PNS MYELIN
1.3.1 The Segmental Nature of the Myelin Sheath
Myelinated PNS fibres possess a highly distinctive morphology, with myelin
clearly discernible as a segmental sheath around the axon by light microscopy even
at low power. Each individual myelin segment (known as an internode) is
generated by a separate Schwann cell (Geren, 1954; Webster, 1971). The entire
length of the axon is therefore myelinated by a chain of Schwann cells lying parallel
to the fibre. Importantly, this discontinuity in the way myelin is laid down i.e. as
consecutive internodes, is the key to rapid saltatory nerve impulse propagation
(Stampfli, 1981; Ritchie, 1984; Waxman and Ritchie, 1985; Ritchie, 1987). Adjacent
internodes do not abut one another directly but instead are separated by a small
region of axonal membrane which remains bare (Figure 3). These are the nodes of
Ranvier (Ranvier, 1871), which are the foci of all electrical activity, with practically
all of the axonal Na+ and K+ ion channels being concentrated in these regions.
When an action potential is triggered at a node, the local current generated cannot
flow through the adjacent membrane due to the high electrical resistance of the
myelin. Instead, the current can only leave at the next node. As this node
depolarizes, enough current is generated to excite the next more distant node.
Because the excitation of the membrane therefore jumps from node to node, the
conduction velocity of impulses is significantly faster than that of unmyelinated
nerve fibres; myelinated axons conduct impulses about lOx faster than
unmyelinated axons of a comparable calibre (for review see Ritchie, 1984).
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Figure 3. PNS node of Ranvier of a large diameter axon from a rabbit anterior spinal nerve
root. Note the lateral termination of the loops of Schwann cell cytoplasm and the
condensation of axoplasmic organelles within and to one side of the node. From Raine
(1984).
Figure 4. Cross section through mature PNS myelin showing its multilamellar structure.
During compaction, the major dense line (MDL) is formed by the apposition of adjacent
cytoplasmic membrane surfaces, whereas the intraperiod line (IPL) is formed by the
apposition of adjacent intracellular membrane surfaces. From Raine (1984).
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1.3.2 Compact Myelin
Schwann cells elaborate myelin by repeatedly wrapping a flattened extension
of their plasma membrane in a spiral around the nerve axon. The subsequent
extrusion of cytoplasm from within this spiral leads to the apposition of the
membrane bilayers, forming mature compact myelin. These apposed membrane
surfaces are highly visible on electron micrographs of myelin in cross section where
they appear as regularly alternating light and dark bands (Napolitano and Scallen,
1969; Peterson and Pease, 1972) (Figure 4): the intraperiod line is derived from the
fusion of the extracellular membrane surfaces and the major dense line is derived
from the fusion of the intracellular membrane surfaces. Like counting the growth
rings on a tree trunk, it is possible to calculate the number of times that the Schwann
cell has encircled the axon by counting these lines. Interestingly, there is a direct
correlation between the thickness of the axon and the number of membrane turns
(and hence the thickness of the sheath), with large diameter axons possessing
thicker myelin than thinner ones (Friede and Samorajski, 1967; Matthews, 1968;
Friede, 1972; Friede and Bischhausen, 1982). Once again this provides good
evidence for the existence of axonal regulatory influences over Schwann cells and
myelination.
1.3.3 Uncompacted Myelin
Although myelin is essentially a compact structure, Schwann cell cytoplasm-
filled regions do persist, most notably within the periaxonal and adaxonal spaces,
within the paranodal loops (Figure 5) and within Schmidt-Lanterman incisures
(Figure 6). These morphological features define regions of imperfect myelin
compaction where the adjacent cytoplasmic membranes have failed to abut. The
necessity for retaining these cytoplasm-filled structures remains unclear, but given
that they occur in the regions of direct cell-cell contact an involvement in
intercellular communication has been suggested.
11
Figure 5. Diagram of the PNS node showing the regimented organisation of the paranodal
loops. These lateral specializations of the myelin sheath form tight (glial-glial)
junctions with neighbouring loops. Because of their proximity to the excitable axolemma of
the node of Ranvier, the paranodal loops may be involved in the ion fluxes that occur
during nerve impulse propagation (or axon-glial communication). From Raine (1984).
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Figure 6. Electron micrograph of longitudinal section through a myelinated nerve fibre
from an adult human sural nerve showing a Schmidt-Lanterman incisure (I) traversing the
myelin sheath. These cytoplasm filled channels remain due to imperfect compaction of
the major dense line. Often they provide a direct connection between the Schwann cell
body and the periaxonal region. Thus, these channels are pefectly suited to function as a
transport network throughout the compact myelin sheath. From Dyck et al (1993).
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1.4 THE BIOCHEMISTRY AND MOLECULAR BIOLOGY
OF PNS MYELIN
Myelin is an extension of a eukaryotic plasma membrane. Therefore, like the
plasma membrane (and all other cellular membranes), myelin is composed of a
heterogenous group of lipids and proteins whose interactions and associations -
both within the membrane and with the underlying cytoskeleton - determine the
macroscopic structure of the organelle. Given that myelin is structurally highly
distinct, it is reasonable to presume that the lipids and proteins of which it is
constructed must also be highly distinct. Indeed, it has been clear for many years
that the chemical composition of the myelin membrane is remarkably different to the
cellular membrane from which it originates (see Smith, 1983; Morell, 1984 for
reviews). This composition is undoubtedly fundamentally related to the process of
myelinogenesis and to the unique biochemical and biophysical properties of myelin
which are essential for its role as an insulator of nerve fibres and mediator of
saltatory nerve impulse conduction.
1.4.1 PNS Myelin Lipids
The dominant feature of myelin composition relative to other cell-surface or
intracellular membranes is the high ratio of lipid to protein. Typically, cellular
membranes contain approximately equal amounts of proteins and lipids (Finean et
al, 1984), but in myelin, protein may be as little as 20% of the total dry mass
(Smith, 1983). In purely functional terms, this is unsurprising given that the major
role of myelin is to provide high-resistance, low capacitance insulation around the
nerve (Ritchie, 1984). Since a high concentration of lipid effectively restricts the
passive flow of water and conducting ions (Na+, K+), the lipid content of myelin
contributes to these electrical properties essential to myelin's function as an
insulator. However, although the lipids of myelin supply the physical properties
14
necessary for this insulating barrier, their known heterogeneity is a clear indication
of a more dynamic role, particularly during assembly and maintenance of the myelin
sheath (for reviews see Morell, 1984; Martenson, 1992).
The lipid composition of myelin has been extensively studied in a great many
species (reviewed by Norton and Cammer, 1984). As for cell membranes generally,
the major lipid constituents of myelin membrane are cholesterol, phospholipids, and
glycolipids (Table 1).
(a) Cholesterol
On the basis of weight percent, cholesterol is the most abundant single lipid
molecule, comprising about 25%. This figure is similar in both mammalian and non-
mammalian species (Norton and Cammer, 1984) and is comparable to the values
given for most eukaryotic plasma membranes (Finean, 1984).
Functionally, cholesterol is believed to be an important determinant of
membrane fluidity via interactions with the hydrocarbon chains of the bilayer
(Benga and Holmes, 1984). In addition, cholesterol decreases the permeability of
lipid bilayers to small water soluble molecules and is thought to enhance both the
flexibility and the mechanical stability of the bilayer.
(b) Phospholipids
Second to cholesterol, the next most abundant lipid components of the myelin
bilayer are phospholipids (Table 1). These comprise four major families of lipid
species: the phosphatidylethanolamines, the phosphatidylcholines, the
phosphatidylserines and the sphingomyelins. Collectively these lipids constitute
more than half the mass of lipids, outnumbering cholesterol molecules nearly 2:1
(although individually no species predominates outright). Across animal species,
the phospholipid composition of myelin is much the same, with a few exceptions.
For example, rat myelin has much less sphingomyelin than bovine or human myelin
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TABLE 1
Composition of PNS myelin from several species
(Norton and Cammer, 1984)
Rat Human Bovine
Component (Smith and (Spritz et al, (O'Brien et al,
Curtis, 1979) 1973) 1967)
Total Protein^ -a 28.7 24.1
Total Lipid -a 71.3 75.9
Cholesterol0 27.2 23.0 24.7
Total Glycolipid0 21.5 22.1 16.6
Galactocerebroside0 15.8 .a 14.1
Sulfatide0 5.7 .a 2.5
Total Phospholipid0 50.6 54.9 58.2
PT Ethanolamine°'d'e 19.2 19.2 16.3




PT Inositol0^ 2.5 .a
Sphingomyelin0'^ 8.6 18.7 15.7
a(-) Not analysed
b Total protein and total lipid expressed as percentage of dry weight
c Figures are expressed as percentage of total lipid
d (PT) Phosphatidyl
e Mostly ethanolamine plasmalogen (Horrocks, 1972)
f PT serine and PT inositol were analysed together.
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(Table 1) and is more comparable to that of plasma membranes generally. Other
phospholipid families such as the phophatidylinositols are also present in PNS
myelin but in relatively minor quantities.
The presence of such a wide variety of phospholipids, whose head groups
differ in size, shape, and charge suggests that these molecules are involved in
important interactions. Further evidence for an active role in myelin structure is
provided by the intriguing finding that the different families of phospholipids are
known to be asymmetrically distributed within the bilayer: lipid molecules that have
choline in their head group (sphingomyelin and phosphatidylcholine) are
predominantly found in the outer, extracellular half of the bilayer, while
phospholipid molecules that contain a terminal primary amino group
(phosphatidylethanomlamine, phosphatidylserine and phosphatidylinositol)
predominantly reside in the inner half (Zachowski and Devaux, 1989; Kirschner and
Ganser, 1982). Asymmetry of these molecules therefore generates asymmetry in the
biochemical and biophysical nature of the lipid bilayer. Although the function of
this asymmetry is largely unknown it has been postulated to reflect the requirements
of proteins associated with the membrane, particularly the cytoskeleton (for review
see Brophy, 1992).
(c) Glycolipids
The remaining lipid component of myelin are the glycolipids (Table 1).
Galactocerebroside (GalC) and its sulphate derivatives (sulphatides) represent
upwards of 20% of the dry weight of PNS myelin lipids from most species (Radin,
1983; Kishimoto, 1983; Norton and Cammer, 1984). In other plasma membranes
this figure is seldom greater than 5% (Finean, 1984). Indeed, although no lipids are
'myelin-specific' this enrichment of GalC and sulphatide is one of few distinguishing
features of myelin with regards to lipid composition. Like the phospholipids, the
glycolipids are asymmetrically distributed within the myelin membrane, and are
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found only in the outer half of the bilayer with their sugar moieties exposed at the
cell surface. PNS myelin also contains minor quantities of complex glycolipids
known as gangliosides (Fong et al, 1976), which are distinguished by a sugar chain
and sialic acid. Because of the growing knowledge that glycolipids (particularly
those containing sialic acid residues) are important in a wide variety of cell surface
phenomena including cell-cell and membrane-membrane interactions, it has been
suggested that their presence may be functionally significant during myelinogenesis
(Wiegandt, 1982). Unfortunately, for GalC and its derivatives at least, this may
not be true: a number of groups have recently developed null mouse mutants lacking
the enzyme UDP-galactose: ceramide galactosyltransferase (CGT) which is
responsible for the synthesis of GalC. Although these animals form myelin with an
apparently normal ultrastructure they display a relatively severe clinical phenotype
with progressive demyelination (Coetzee et al, 1996; Bosio et al, 1996). This
indicates that GalC and/or sulphatide may be involved in myelin maintenance and
function, but not ensheathment.
Given that many of the compositional characteristics of myelin in regards to
its major lipid constituents are similar to those of eukaryotic plasma membranes in
general it is difficult to assign any lipid species a specific role in myelinogenesis.
Furthermore, other naturally occurring membrane assemblies that exhibit orderly
and close stacking like myelin, such as rod outer segment disk membranes (Chabre,
1975; Daemon, 1973) and the grana thylakoid membranes of the chloroplast (Li,
1978), display distinctly different compositional characteristics. Neither assembly
has appreciable amounts of cholesterol (Daemon, 1973; Li, 1978). Moreover, while
the rod disk membranes contain very little glycolipid, the grana membrane lipids are
nearly two-thirds glycolipid by weight. From these findings, it would appear that
the multilamellar stacking in myelin and these other systems does not correlate with
a particular lipid composition. The specific membrane interactions in myelin are
therefore likely to be brought about and modulated by the particular protein
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components, with the lipid heterogeneity simply reflecting the requirements of these
components.
1.4.2 PNS Myelin Proteins
As discussed, the protein content of myelin membrane is consistently lower
than that of other cell-surface or intracellular membranes (Smith, 1983). However,
this does not mean that the protein constituents are relatively unimportant, far from
it. While the lipids are responsible for the function of myelin ie insulating nerve
axons, it is the proteins which determine the structure via their specific molecular
interactions (for reviews see Morell, 1984; Sutcliffe, 1987; Mikoshiba et al, 1991;
Lemke, 1988; 1993). A great deal of effort and time has therefore been spent
characterizing the protein constituents of myelin membrane with the belief that these
molecules hold the key to the understanding of the myelination process.
Due to the extreme susceptibility of purified PNS myelin to proteolysis only
the most abundant and/or resistant proteins have been studied in any great depth
(Norton and Cammer, 1984). These major proteins are glial cell-specific (in
particular myelinating glia-specific) and are primarily structural in nature.
Furthermore, these proteins tend to be highly conserved among the higher vertebrate
species, suggesting essential roles in the formation and maintenance of myelin.
(a) Peripheral Myelin Protein Zero (PO)
PO is the single most abundant protein of PNS myelin, accounting for roughly
40-50% of the total protein content (Greenfield et al, 1973; Ishaque et al, 1980).
Although it is expressed at such high levels in the PNS, PO protein or its mRNA has
not been detected in the CNS. PO protein is further restricted within the PNS itself,
being expressed wholly by myelinating Schwann cells (Lees and Brostoff, 1984;
Politis et al, 1982). In particular, it is predominantly localized to the compact
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myelin formed by these cells, where it is believed to be responsible for the formation
and maintenance of both the intraperiod and the major dense lines.
First identified by lectin binding studies carried out on PNS myelin (Everly et
al, 1973; Wood and Dawson, 1973; Brostoff et al, 1975; Kitamura et al, 1976), PO
is a glycoprotein. The full sequence of this 219 amino acid protein (Mr = 28,500
kDa) has been determined using conventional protein sequencing techniques
(Sakamoto et al, 1987) and has also been deduced from cDNA clones isolated from
man (Hayasaka et al, 1991) and many animal species including rat (Lemke and
Axel, 1985), chicken (Barbu, 1990), and shark (Saavedra et al, 1989). Several
features of the primary structure of PO have subsequently been shown to be related
to its localization and function in the myelin membrane.
The first 28 amino acids encoded by the open reading frame of the PO cDNA
do not appear in the mature PO protein (Lemke and Axel, 1985). This domain
comprises a cleavable signal sequence which is necessary for directing PO to the
rough ER and Golgi apparatus for glycosylation (Poduslo, 1984), translocation, and
its oriented insertion into the myelin membrane (Lemke and Axel, 1985; D'Urso et
al, 1990). Hydrophobicity profiles show that PO is an integral membrane protein,
with a single transmembrane domain (Lemke and Axel, 1985). This divides the
protein into an N-terminal extracellular domain and a C-terminal cytoplasmic
domain. Each domain possess distinct physical properties. The extracellular
domain contains the canonical sequence for N-linked glycosylation (Asn-Gly-Thr),
which occurs only once in the deduced PO structure. Indeed, PO has been shown to
be glycosylated at a only a single position via N-linked attachment, and also, that
the attached oligosaccharide is extracellularly positioned (Wood and McLaughlin,
1975; Peterson and Grevner, 1978; Ishaque et al, 1980). Interestingly, the
oligosaccharide chain bears the carbohydrate epitopes L2 and HNK-1 (Lemke and
Axel, 1985). These epitopes are commonly associated with 'self-adhesive'
molecules such as LI, neural cell adhesion molecule (NCAM), and myelin-
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associated glycoprotein (MAG) (Edelman, 1983; Ueymura et al, 1987), and it has
been suggested that these glycans may mediate homophilic adhesive interactions
between PO molecules on adjacent extracellular myelin membrane faces (Lemke
and Axel, 1985; Filbin et al, 1990; Filbin and Tennekoon, 1991).
Further evidence of the adhesive nature of PO is provided by the sequence of
the extracellular domain itself, which exhibits significant similarity to the
immunoglobulin (Ig) domain of members of the immunoglobulin superfamily (Lai et
al, 1987; Lemke et al, 1988). These proteins are known to mediate a variety of
homotypic and heterotypic interactions in the nervous system (Barclay et al, 1987)
including cell migration, axonal guidance and myelination (see Salzer and Colman,
1989). Direct evidence for PO mediated membrane adhesion has been provided by
transfection studies involving expressing PO in HeLa cells (D'Urso et al, 1990; Filbin
et al, 1990). The cells form unusual aggregates, coincident with concentration of PO
at the points of cell-cell contact as demonstrated by immunofluorescence analysis.
Of the 69 residues comprising the PO cytoplasmic domain, 21 are basic and
only 6 are acidic. This portion of the molecule therefore carries a very strong net
positive charge. With the sequestering of negatively charged lipids
(phosphatidylserine) to the cytoplasmic face of the apposed myelin bilayer (Norton
and Cammer, 1984), it is highly likely that PO will interact electrostatically with
these lipids (Ding and Brunden, 1995; Wong and Filbin, 1996). Certainly, when PO
is isolated from myelin it is complexed with a set of very tightly bound acidic lipids
(Ishaque et al, 1980), particularly phosphatidylserine. Furthermore,
phosphorylation of serine residues in the cytoplasmic domain of PO by protein
kinase C (which reduces the overall positive charge of the domain), has been shown
to prevent compaction (Suzuki et al, 1990; Hilmi et al, 1995; Rowe-Rendlemann and
Eichberg, 1994; Eichberg and Iyer, 1996). It has been postulated that the degree to
which P0 is phosphorylated at its C-terminus regulates the strength of electrostatic
interaction between P0 and the anionic phospholipids, with progressive diminishing
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of PO phosphorylation resulting in greater myelin compaction. Indeed,
developmental dephosphorylation of PO is known to be concomitant with formation
of the major dense line and the maturation of myelin (Suzuki et al, 1990; Hilmi et al,
1995; Rowe-Rendlemann and Eichberg, 1994; Eichberg and Iyer, 1996). However,
although this type of electrostatic lipid-protein interaction seems very
straightforward, it is possible that apposed PO cytoplasmic domains connect
intracellular membrane surfaces with each other via protein-protein interactions.
Indirect evidence to further support the role of PO in the maintenance of the
major dense line is given by the myelin basic protein (MBP)-deficient shiverer mouse
(see below). This mutant is characterized by markedly diminished myelination of
axons in the CNS (Bird et al, 1978). Where CNS myelin is formed, the major dense
line is absent. In contrast, PNS myelin is fully elaborated, has a compact structure
with normal periodicity, and is functionally normal (Ganser and Kirschner, 1980).
These findings have led to the suggestion that MBPs are involved in compaction of
CNS myelin at apposed cytoplasmic faces and that some functionally related
component of PNS myelin, not present in the CNS serves this function in the
periphery. This component is likely to be PO, given that it is the only abundant
protein remaining in isolated PNS myelin from shiverer (Mikoshiba et al, 1981), it
localizes at the cytoplasmic surface of the bilayer, both PO and MBP contain many
basic amino acid residues that have been proposed to interact with the
phospholipids of the opposing cytoplasmic faces of Schwann cell membranes (Ding
and Brunden, 1994), and of course, it is absent from the CNS.
The gene for PO has been isolated from both rat (Lemke et al, 1988) and
mouse (You et al, 1991) and consists of 6 exons distributed over 7 kb (Figure 7).
The gene, which is located on mouse chromosome 1 (Kuhn et al, 1991; You et al,
1991) does not show linkage with any known neurological mouse mutation.
However, a complete loss-of-function mutation has been engineered by
homologous recombination (Giese et al, 1992). These knockout mice develop a
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Figure 7. Gene structure of the major myelin protein, PO. Protein coding exons are
represented by filled boxes. Unfilled exons correspond to untranslated sequence. After
Lemke et al (1988).
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dysmyelinating peripheral neuropathy, characterized by poor motor coordination,
tremors, and occasional convulsions, all of which develop after the third post¬
natal week (Giese et al, 1992). Most larger diameter (>1 mm) peripheral axons
are surrounded by multiple loops of membrane that remain uncompacted at what
(in normal myelin) would be the intraperiod lines. This failure to achieve
intraperiod compaction in the absence of PO gives further support to the
hypothesis that the Ig-related extracellular domain of PO does indeed function as
an adhesion protein during myelin spiralling. Importantly, the absence of PO does
not prevent Schwann cells from segregating axon bundles or from assuming a 1:1
relationship with the larger diameter axons or from initiating spiral formation.
Recently, double knockout mutant mice lacking both MBP and PO have been
created from ma tings of the above mice with shiverer (Martini et al, 1995). In these
animals both the major dense line and the intraperiod line are lost. As the major
dense line is retained in the PO knockout alone (Giese et al, 1992) it would appear
that MBP is involved or can substitute for PO in compaction of this structure,
much as PO can substitute for MBP in shiverer (Ganser and Kirschner, 1980;
Mikoshiba et al, 1981). Since MBP does not have an extracellular domain it is
unsurprising that it cannot replace the cell-surface related function of PO relating
to compaction of the opposing extracellular faces (Giese et al, 1992; Martini et al,
1995).
Overall therefore, PO is bifunctional within the myelin membrane, mediating
the association of both apposed extracellular and cytoplasmic membrane surfaces
by a different molecular mechanism in each case.
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(b) Myelin Basic Proteins (MBPs)
The MBPs are a family of small (14 - 23 kDa), membrane-associated proteins
(de Ferra et al, 1985; Takahashi et al, 1985; Newman et al, 1987; Kitamura et al,
1990; Aruga et al, 1991). In the PNS, this group can make up almost a fifth of all
myelin proteins (Greenfield et al, 1980; Lees and Brostoff, 1984). An identical
complement of MBPs are expressed in the CNS (Greenfield et al, 1982), although
here they often comprise more than a third of the total myelin proteins.
As their name implies, the MBPs have an unusually high percentage of basic
residues (>20%) (Lees and Brostoff, 1984; Smith, 1992). Therefore, like the
cytoplasmic tail of P0, these proteins carry a very strong overall positive charge. As
a result, the MBPs show a high affinity for acidic lipids within the myelin
membrane, such as the sulphatides and the gangliosides (Ong and Yu, 1984; Maggio
and Yu, 1992; Mendz, 1992). Given the localization of the MBPs to the cytoplasmic
apposition (Lees and Brostof, 1984), and the predominance of acidic lipids on the
cytoplasmic face of the myelin bilayer (Norton and Cammer, 1984), it is highly
likely that electrostatic interactions between these two elements become involved in
myelin compaction, bringing about the fusion of apposed cytoplasmic surfaces to
form the major dense line (Lees and Brostof, 1984; Smith, 1992). This is further
borne out by the finding that the in vivo phosphorylation of MBPs (which decreases
their net positive charge) effectively destabilizes compact myelin lamellae structure
(Diebler et al, 1990; Martenson et al, 1983; Kobayashi, 1984). The regulation of
MBP phosphorylation and dephosphorylation may clearly play a pivotal role in the
stabilization of the myelin structure.
The MBP gene consists of 7 exons distributed over 32 kb (Takahashi et al
1985; de Ferra et al 1985; Kimura et al, 1985). In mouse and human, the gene maps
to chromosome 18 (Roach et al, 1985; Sparkes et al, 1987). The rat MBP gene maps
to chromosome 1 (Koizumi et al, 1991). At least six transcripts are expressed from
this gene in the mouse through alternative splicing of three exons (Roach et al, 1983;
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Zeller et al, 1984; de Ferra et al, 1985; Takahashi et al, 1985; Newman et al, 1987;
Kitamura et al, 1990; Aruga et al, 1991) (Figure 8). Interestingly, this "classic" MBP
gene has recently been found to be part of a much larger genetic locus, called the
golli-mbp gene complex (for gene in the oligodendrocyte lineage) (Campagnoni et al,
1993; Pribyl et al, 1993). This locus exceeds 100 kb in length and contains two
promoters, one of which gives rise to the MBP mRNAs and another that produces
at least 3 alternatively spliced golli mRNAs (Figure 8). These MBP-like isoforms are
expressed widely outside the nervous system and may serve functions completely
unrelated to myelination (Campagnoni et al, 1993; Pribyl et al, 1993; Landry et al,
1996).
MBP isoforms are heterogenous, not only at the level of their primary
structure but also as a result of numerous posttranslational modifications
including methylation, glycosylation, deamidation and N-acylation (Toews and
Morell, 1987; Smith, 1992) which indicates that a single, straightforward role for
the MBPs is unlikely. However, the demonstration that mice displaying the
shiverer phenotype (characterized by a total lack of myelin-associated MBP
isoforms and a resulting absence of CNS myelin [Bird et al, 1978]) can be
'rescued' by the expression of an MBP minigene encoding only the smallest MBP
protein (14 kDa) (Kimura et al, 1989), casts some doubt on the necessity for this
heterogeneity.
(c) Myelin Protein 2 (P2)
Myelin protein 2 (P2) is a small (14 kDa) extrinsic membrane protein (Morell
et al, 1989). In the mouse and rat, P2 comprises less than 1% of the total PNS
myelin protein content; in the human PNS this value is approximately 14%
(Greenfield et al, 1973). Although it is most abundant in the PNS, P2 has been
detected in CNS myelin, where it constitutes <1% of the total protein content
(Martenson and Uyemura, 1992).
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Figure 8. Structure and splicing pattern of the Golli-mbp gene. Exons 5-11 encompass the
'classic' MBP gene whereas exons 1-4 are Golli. Bracketed numbers after mRNAs indicate
the molecular weight of the translated product. From Campagnoni (1995)
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P2 protein has been purified from various species, including cow (Kitamura et
al, 1980), rabbit (Isaque et al, 1982), and human (Suzuki et al, 1982). Its deduced
amino acid sequence shows a striking homology (40-70%) to a large family of lipid-
binding proteins that includes cellular retinol binding proteins, retinoic acid-binding
proteins (Crabb and Saari, 1981; Eriksson et al, 1981) and fatty acid-binding
proteins (FABPs) (Veerkamp et al, 1981). The related finding that purified bovine
P2 can bind oleic acid, retinoic acid and retinol (Uyemura et al, 1984) has therefore
prompted the suggestion that the P2 protein is a member of the FABP family with a
specific function involving the transport of fatty acids to the myelin membrane
and/or the metabolism of myelin lipids (Morell et al, 1989; Narayanan et al, 1988;
Martenson and Uyemura, 1992).
The structure of the P2 gene has been determined in the mouse (Narayanan
et al, 1991) and in humans (Hayasaka et al, 1993) (Figure 9). In each case the
structure is similar and consists of four exons. However, due to a more lengthy
intron 1 within the human gene, these 4 exons are distributed over 8 kb in humans
compared to only 4.5 kb in the mouse. Interestingly, the mouse P2 gene structure
is significantly similar to the gene structures of members of the FABP family of
proteins (Narayanan et al, 1991). This finding provides further evidence to
support the hypothesis that P2 is a fatty acid-binding protein and indeed, is a
bona fide member of this family.
(d) Peripheral Myelin Protein 22 (PMP22)
This protein (or its corresponding cDNA) has been identified on at least five
separate occasions and has been given a similar number of different names: (1)
PASII (periodic-acid-Schiff protein II) (Kitamura et al, 1976); (2) gas3 (growth
arrest specific gene 3) (Manfioletti et al, 1990); (3) CD25 (crush denervated cDNA
25) (Spreyer et al, 1991); (4) SR13 (sciatic nerve regeneration clone 13) (Welcher et




Figure 9. Structural organization of the human P2 gene. Exons are shown as boxes and
numbered. Solid black boxes and white boxes indicate protein coding sequences and and
untranslated sequences, respectively. From Hayasaka et al (1993)
Figure 10. Genomic organisation of the human PMP22 gene. The proposed alternative
splicing that results in two different PMP22 transcripts is schematically indicated at the
bottom. PI and P2 refer to the location of promoter 1 and promoter 2. Schwann cell specific
expression is driven from promoter 1. From Suter et al (1994).
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Most abundant in the PNS where it comprises approximately 5-10% of the total
protein of isolated myelin (Kitamura et al, 1976; Snipes et al, 1992; Pareek et al,
1993) PMP22 has become the definitive label for this protein (Snipes et al, 1992).
The expression of PMP22 is not restricted to PNS myelin however, and indeed, the
multiple separate identifications of this protein reflect the wide expression of
PMP22 mRNA within the CNS also and in many non-neural tissues like lung, gut,
and heart (Manfioletti et al, 1990; Spreyer et al, 1991; Welcher et al, 1991; Patel et
al, 1992).
The open reading frame of the PMP22 mRNA predicts a protein with a
molecular weight of approximately 17,000 kDa (Suter et al, 1992). However, by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), PMP22
is seen to migrate at 22 kDa (hence the name). This discrepancy has been shown to
be due to N-glycosylation at a single site within the protein (Manfioletti et al, 1990;
Spreyer et al, 1991; Welcher et al, 1991; Pareek et al, 1993). From hydrophobicity
analyses, the deduced primary sequence of PMP22 indicates that it is a tetraspan
protein, traversing the myelin membrane four times (Spreyer et al, 1991). In contrast
to P0, a 26 amino acid signal sequence which directs this insertion of the protein
into the myelin membrane is not cleaved and is therefore present in the mature
PMP22 protein (Manfioletti et al, 1990).
Given that PMP22 exhibits no sequence homology to any previously identified
protein it has proved difficult to define its role within PNS myelin. Structurally,
PMP22 is remarkably similar to PLP, the major structural protein of CNS myelin
(Braun et al, 1984). PLP is believed to play a role in the formation and maintenance
of the intraperiod line of CNS myelin (Braun, 1984; Hudson et al, 1987) and it is
possible that PMP22 functions in a similar manner in the PNS. The finding that
PMP22 of the cat possess the HNK-1 carbohydrate epitope generally expressed by
adhesion proteins (Hammer et al, 1993) further suggests an involvement in
membrane-membrane interactions. Other speculations as to the role of PMP22 have
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included that it acts as an iori channel or pore (Manfioletti et al, 1990), but as yet
there are no direct experiments that address this possibility.
The structure of the human PMP22 gene has been characterized (Suter et al,
1994) (Figure 10). Interestingly, the transcription of the gene is regulated by two
promoters that are located immediately upstream of two alternatively spliced 5'-
non coding exons (exons 1A and IB). The polypeptides produced from these two
distinct mRNAs are identical (Suter et al, 1994). However, transcripts containing
exon 1A are preferentially expressed in myelinating Schwann cells, while
transcripts containing exon IB are preferentially expressed in tissues that do not
form peripheral myelin (Suter et al, 1994). It is likely that the promoter governing
expression of PMP22 in Schwann cells contains elements which respond to glial-
specific transcription factor(s).
The gene for PMP22 maps to mouse chromosome 11 (Suter et al, 1992),
within close proximity to the locus of the hypomyelinating PNS neuropathies
Trembler (Tr) and Trembler-j (Trj) (Davisson and Roderick, 1978; Falconer, 1951;
Suter et al, 1992b). Mice homozygous and heterozygous for these dominant
alleles display peripheral nerve development that is blocked at the promyelinating
stage, with Schwann cells singling out individual axons, but failing to proceed to
the next step of elaborating myelin (Henry and Sidman, 1988). Furthermore,
Schwann cell proliferation continues into adulthood (Aguayo et al, 1977; Henry
and Sidman, 1988). Suter and coworkers (1992) have shown that in both Tr and
TrJ mice, PMP22 exhibits point mutations: the mutation in Tr is within the fourth
putative transmembrane domain, replacing a glycine residue with an aspartic acid
residue (Suter et al, 1992) and in Tri it is within the first putative transmembrane
domain, replacing a leucine with a proline. Whether these mutant PMP22s, which
are presumably misfolded, are correctly incorporated into membrane is unknown,
and it remains to be determined what cellular mechanisms prevent myelination.
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The continued proliferation of Schwann cells in trembler mice is particularly
interesting given that PMP22 was previously identified as gas3, a growth-arrest
specific protein whose expression has been shown to be negatively correlated with
cellular growth (Manfioletti et al, 1990; Suter et al, 1992). It has been suggested
therefore that PMP22/gas3 may play a dual role in myelination: at later stages it is
involved in the maintenance of the myelin structure and in the early stages it
controls Schwann cell proliferation and progression from a promyelinating
phenotype.
1.4.3 Minor Constituents of PNS Myelin
Although the vast majority of the protein content of PNS myelin comprises
these major proteins, the remaining 1% contains a multitude of minor proteins,
splice products, and posttranslationally modified proteins. Such proteins are far
less involved in maintaining the compact myelin structure. From their expression
and localization patterns it is believed that these proteins perform many of the
complex interactions required during the myelination process itself e.g. interacting
with the cytoskeleton to drive ensheathment, transducing signals of axonal contact,
guiding the membrane tongue as it spirals around the axon, lipid synthesis etc.
(a) Myelin-Associated Glycoprotein (MAG)
In the PNS, MAG comprises only about 0.1% of the total myelin protein
content (Figlewicz et al, 1981). However, this belies the fact that MAG is highly
concentrated in several areas of the myelinating Schwann cell, including the
periaxonal regions, Schmidt-Lantermann incisures, paranodal loops, and the inner
and outer mesaxons (Schober et al, 1981; Sternberger et al, 1979; Trapp and
Quarles, 1982). MAG is absent from compact myelin. A common characteristic of
these regions is that they are filled with Schwann cell cytoplasm (ie they are
uncompacted) (see section 1.3.3). Indeed, there is a strict correlation between the
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presence of MAG and the periodicity of these membranes (Trapp and Quarles,
1982). It has been suggested therefore that MAG plays a role in maintaining these
spaces by preventing compaction (Trapp and Quarles, 1982; Trapp et al, 1984).
The necessity for retaining cytoplasm-filled regions through the myelin sheath
remains unclear, but given that turnover of the sheath components is known to occur
(Smith, 1968; Benjamins and Smith, 1984; Miller et al, 1977), it possible that these
regions act as channels for transport of the necessary materials throughout the
compact myelin structure (Hirano, 1982).
During SDS-PAGE of PNS myelin proteins, MAG is seen to migrate as a
characteristically broad band of approximately 100 kDa (Barbarash et al, 1981).
When enzymatically deglycosylated, MAG resolves as two isoforms of 72 and 67
kDa, the latter of which is by far the most abundant (Frail et al, 1985; Tropak et al,
1988). Both MAG isoforms are also found in CNS myelin but interestingly, the
larger 72 kDa isoform is present at much higher levels (Salzer et al, 1990; Quarles et
al, 1992) and indeed is the predominant isoform during the most active period of
myelination (Tropak et al, 1988).
The primary structure of each isoform has been deduced from cDNA clones
isolated from a number of species including human (Sato et al, 1989; Spagnol et
al, 1989), rat (Lai et al, 1987; Salzer et al, 1987) and mouse (Arquint et al, 1987).
Both isoforms share a common 17 amino acid N-terminal signal sequence,
followed by a large extracellular N-terminal region, and a 23 amino acid
membrane spanning domain. It is in the sequence of their respective C-terminal
cytoplasmic tails that the isoforms show divergence, with the final 53 amino acids
of the large MAG isoform (named L-MAG) being replaced by a different sequence
of 9 amino acids in the small MAG isoform (named S-MAG) (Lai et al, 1987;
Salzer et al, 1987). From the deduced structure of the MAG gene, it clear that
these two isoforms arise through alternative splicing.
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In both the rat and mouse, the MAG gene contains 13 exons and spans
approximately 16 kb (Lai et al, 1987; Nakano et al, 1991) (Figure 11). As
shown, the mRNA coding for L-MAG contains all exons except exon 12, whereas
the mRNA coding for S-MAG consists of all exons except exon 2 (Lai et al,
1987). For L-MAG, the termination codon is present in exon 13. The presence of
exon 12 in the S-MAG mRNA introduces an earlier in-frame termination codon,
and results in the formation of a smaller protein. The presence of exon 2 does not
affect the polypeptide produced from the L-MAG mRNA as it is part of the 5'
untranslated region and indeed, alternative splicing of this exon seems to be
regulated independently of the splicing of exon 12 (Lai et al, 1987; Tropak et al,
1988). This is supported by the finding of a MAG mRNA without either exon 2 or
12 (Fujita et al, 1989) (Figure 11).
It is reasonable to assume that the different cytoplasmic tails of the two
isoforms bestow different physical (and perhaps functional?) properties and
certainly, the C-terminal tail of L-MAG is known to be phosphorylated to a greater
extent than the C-terminal tail of S-MAG (Edwards et al 1988; Lai et al, 1987;
Salzer et al, 1987; Arquint et al, 1987; Fujita et al, 1989; Agarawal et al, 1990). As
MAG has been postulated to interact with the cytoskeletal elements of myelin-
forming cells such as actin and spectrin (Trapp et al, 1984; Salzer et al, 1987;
Quarles et al, 1992), it is possible that the phosphorylation state of each isoform
may modulate its interactions with these elements during different stages of the
myelination process. Furthermore, the cytoplasmic tail of L-MAG also contains a
unique tyrosine residue that is surrounded by a sequence highly homologous to an
autophosphorylation site present in the cytoplasmic domain of the epidermal
growth factor receptor and which is suggested to play a role in signal transduction
(Arquint et al, 1987; Salzer et al, 1987; Lai et al, 1987). However, although these
finding may be of importance to myelination in the CNS where both L-MAG and S-
MAG reach comparable levels, their relevance to PNS myelination is questionable
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Figure 11. Structure and alternative splicing of the rat myelin-associated glycoprotein
(MAG) gene. Exon sizes are exaggerated and not proportional. Three alternatively spliced
products are shown. Splicing of exons 2 and 12 is not coordinately regulated. After Sutcliffe
(1987) and Fujita et al (1989).
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given that L-MAG is an extremely minor component. To define a precise role for the
MAGs in myelination, the greatest attention has therefore been focused on the
common extracellular domain.
Detailed analysis of the sequence of the MAG extracellular domain has
identified 5 sub-domains with varying degrees of homology to each other. Like PO,
each sub-domain also shares significant similarity with the immunoglobulin (Ig)
domain of members of the immunoglobulin superfamilv (Arquint et al, 1987; Lai et
al, 1987; Salzer et al, 1987). As previously stated, these proteins are known to
mediate cell-cell interactions in the nervous system. Given the localization of MAG
to the periaxonal region of the Schwann cell, it has been suggested that MAG must
therefore be involved in recognition and/or adhesion between the myelinating glial
cells and the axons destined to be myelinated (Arquint et al, 1987; Lai et al, 1987;
Salzer et al, 1987).
The adhesive nature of the extracellular domain of MAG is further supported
by its complement of carbohydrate moieties, which contains the L2/HNK-1 epitope
(Sutcliffe et al, 1983; Salzer et al, 1987; Lai et al, 1987). This epitope is shared by a
number of nervous system cell adhesion molecules including N-CAM, LI, contactin
(Milner et al, 1990; Kruse et al, 1984), and is believed to be itself a ligand of
adhesion. Direct experimental evidence of the adhesive nature of MAG with
regards to neurons has been provided by a number of groups, including Poltorak
and co-workers (1987) who demonstrated that purified MAG reconstituted in
liposomes can bind axons.
The most intriguing finding to date as regards MAG function has been
gained from the analysis of null MAC mutant mice (Montag et al, 1994; Li et al,
1994). Although these mice do form compact PNS myelin, the organization of the
periaxonal region is partially impaired. Importantly, these animals display
significant peripheral nerve abnormalities indicative of degeneration by the time
they are 8- to 10-months old (Fruttiger et al, 1995). These findings seem to
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suggest that MAG is not critical for myelin formation in the PNS but rather is
necessary for maintenance of the cytoplasmic collar and periaxonal space which
may be essential for the prolonged maintenance of normal interactions between
axons and myelinating SC.
(b) 2',3'- cyclic nucleotide-3'-phosphodiesterase (CNPase)
The early view held of myelin was that of a metabolically inert material.
However, since the discovery of CNPase enzyme in purified myelin preparations
(Kurihara and Tsukada, 1967) this belief has been refuted. Forming 0.5-1% of PNS
myelin proteins and 2-5% of myelin proteins from the CNS (Vogel and Thompson,
1988; Sprinkle, 1989; Tsukada and Kurihara, 1992), CNPase is by far the most
abundant of more than 40 myelin-associated enzymes that have since been found.
CNPase is also detectable at very low levels in cells outside of the nervous system,
most notably in lymphoid tissue, erythrocytes, and platelets (Bernier et al, 1987;
Sprinkle et al, 1985). CNPase is therefore not strictly myelin-specific although,
within the nervous system, it is found only in myelin-forming glia. Indeed, CNPase
is one of the first reliable markers of these cells (Kurihara and Tsukada, 1968;
Olafson et al, 1969; Kurihara and Tsukada, 1969), becoming concentrated in the
periaxonal region, paranodal loops and the inner mesaxon during myelination
(Sprinkle et al, 1989; Braun et al, 1990). CNPase is not observed in compact myelin
(Sprinkle, 1989; Braun et al, 1990; Tsukada and Kurihara, 1992).
In terms of its enzymatic activity, CNPase hydrolyses 2', 3'-cyclic nucleotides
to generate 2' nucleotides (Sprinkle, 1989; Tsukada and Kurihara, 1992). However,
as no 2',3'-cyclic nucleotides or 2'-nucleotides have been found in myelin, it has been
postulated that the enzymatic activity of CNPase is vestigial and irrelevant and
that the protein's true function is still to be discovered (Norton and Cammer, 1984;
Braun et al, 1990; Tsukada and Kurihara, 1992).
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SDS-PAGE of purified CNPase under reducing conditions resolves two
bands, designated CNP1 and CNP2. These polypeptides show apparent molecular
weights between 42 and 49 kDa respectively, depending upon the species studied,
with rat CNPase having the highest molecular weights (47 kDa and 49 kDa) and
human CNPase the lowest (42 kDa and 45 kDa) (Muller at al, 1981; Muller et al,
1982; Tsukada and Kurihara, 1992). It is believed that CNP1 and CNP2 are
subunits of the native CNPase enzyme since electrophoresis under non-denaturing
conditions resolves a single high molecular weight band only.
Analysis of cDNAs encoding each CNPase isoform has demonstrated that
CNP1 differs from CNP2 by the presence of an additional 20 amino acid residues
at the amino terminal end of CNP2 (Kurihara et al, 1990; Gravel et al, 1994). The
sequence of each isoform reveals no significant regions of hydrophobicity that could
serve as a transmembrane domain, confirming a cytoplasmic localization.
Interestingly, a high concentration of dicarboxylic acid residues suggests that the
proteins must be amidated (Kurihara et al, 1981). Like MBP and P0 therefore,
CNPase has strongly charged groups available for interactions with acidic lipids of
the myelin membrane bilayer (Lees and Brostoff, 1984). The relevance of this
finding to the role of CNPase is unknown.
A number of functions have been postulated for CNPase, including a role in
tRNA ligase reactions, cell adhesion, or kinase reactions (reviewed by Vogel and
Thompson, 1988; Sprinkle, 1989; Tsukada and Kurihara, 1992) but none are
conclusive. The most compelling evidence for CNPase function involves the
isoprenylation of CNP1 at a C-terminal cys-X-X-X-COOH site (Braun et al, 1991).
Other proteins known to be isoprenylaled at the C-terminus, such as ras proteins
and some G protein subunits, are associated with signal transduction pathways
(Braun et al, 1991). Together with the presence of potential nucleotide-binding
domains (Sprinkle, 1989), this finding provides evidence for the hypothesis that
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CNPase may exert a regulatory influence on myelination by serving as a link
between extracellular signals and intracellular effector molecules.
(c) Proteolipid protein (PLP)
Proteolipid protein (PLP) is the major protein component of CNS myelin,
accounting for more than 50% of the total protein content (Folch-Pi and Lees, 1951;
Agarawal et al, 1972; Agarawal and Hartman, 1980). This extremely hydrophobic,
integral membrane protein (Braun et al, 1984) is believed to play a role in the
formation and maintenance of the intraperiod line of CNS myelin (Braun, 1984;
Hudson et al, 1987). To a certain extent therefore, PLP is considered to be the CNS
equivalent of P0 (Braun, 1984; Lemke and Axel, 1985). Like P0, PLP was
considered highly cell-type specific, in as much as it was detectable solely in
oligodendrocytes (whereas P0 is expressed solely in myelinating Schwann cells).
However, a number of studies have recently shown that PLP mRNA is transcribed
in small but significant quantities in Schwann cells (Puckett et al, 1987; Agarawal
and Agarawal, 1991) and that PLP protein is actively translated, subjected to the
same post-translational modifications as its CNS counterpart, and is incorporated
into compact PNS myelin (Agarawal and Agarawal, 1991; Tetzloff and Bizzozero,
1993).
The role of PLP in the PNS is puzzling, especially when considering the minute
amounts of protein present in this tissue compared to CNS myelin. However, the
recent discovery of a PLP null mutation in humans which presents as a
demyelinating peripheral neuropathy (Garbern et al, 1997) indicates that this role is
nevertheless vital.
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1.5 HUMAN PERIPHERAL NEUROPATHIES
1.5.1 Myelin Neuropathies
Given the importance of myelin to the normal functioning of the nervous
system, in particular rapid impulse conduction, any loss or injury of myelin sheaths
is likely to have a deleterious effect. Unfortunately, the complexity of myelin, both
in terms of its structure and the developmental programme by which it is
elaborated, provides many opportunities for such damage to arise. This is clearly
evident from the distressingly high number of human neurological diseases known to
be caused by demyelination (the loss of previously formed myelin) or
dysmyelination (the failure to elaborate functional myelin) such as multiple
sclerosis, the adrenoleukodystrophies, Pelizaeus-Merzbacher disease, Guillain-Barre
syndrome, the Charcot-Marie-Tooth neuropathies, Dejerine-Sottas syndrome, and
many more (for reviews see Raine, 1984; Allen, 1984; Scriver et al, 1989; Scolding et
al, 1994; Suter and Snipes, 1995).
Importantly, many of the above diseases predominantly affect either the
oligodendrocyte myelin of the CNS or the Schwann cell myelin of the PNS. For
instance, multiple sclerosis (MS) is a demyelinating neuropathy of man which
selectively targets only myelin sheaths of the CNS (Martyn, 1991). With more than
80,000 sufferers (1 person in every 1000) in the UK alone, and an estimated
2.5 million worldwide, MS is the most prevalent of these disorders, presenting
symptoms which may include spasticity, fatigue, visual problems, and impaired
cognitive function, but which all reflect impairment of the CNS. The most common
PNS-specific human neuropathy belongs to a genetically heterogenous group of
disorders known as the Charcot-Marie-Tooth (CMT) diseases. The most prevalent
form, CMT1A, affects approximately 1 in 2500 people (Skre 1974; Vance et al,
1991) which is lower than the prevalence of MS. Symptoms include progressive
40
muscular atrophy and weakness, reduced nerve conduction velocities, and
segmental demyelination and remyelination.
1.5.2 Origins
From the overlapping but not identical composition of myelin elaborated by
Schwann cells and oligodendrocytes, it is probable that it is the unique proteins and
epitopes which are responsible for the selective pathology of these diseases.
Indeed, from linkage studies and gene sequence analysis, mutations of many of
these unique components have shown strong associations with myelin dysfunction
(Nave, 1994; Griffiths, 1996; Scherer, 1997).
As discussed in section 1.4, Schwann cells express a number of proteins which
are predominantly found in PNS myelin including PO, PMP22 and P2. To a greater
or lesser extent, mutations of each of these proteins are believed to be involved in
the most common peripheral neuropathies:
(a) PMP22
As discussed in section 1.4.2(d), point mutations of the murine PMP22 gene
have been implicated in the trembler and trembler-j phenotypes (Suter et al, 1992).
The region of mouse chromosome 11 that contains these mutations is syntenic with
a region of the proximal short arm of human chromosome 17 (17pll.2) which
interestingly, has been identified by linkage analysis as a locus for CMT1A (Vance
et al, 1989; Hoogendijk et al, 1991). Furthermore, it has been shown that the human
PMP22 locus is similarly located in this region and that it is mutated in patients
with CMT1A (Matsunami et al, 1992; Patel et al, 1992; Timmerman et al, 1992;
Valentijn et al, 1992a). For most, this mutation takes the form of a large
(approximately 1.5 Mb) duplication. Importantly, the PMP22 gene is duplicated in
its entirety within this region and does not appear to be interrupted or inactivated
(Chance et al, 1992; Lupski et al, 1992; Flanemann et al, 1994). This suggests that
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the CMT1A phenotype can arise through over expression of PMP22 protein (Vallat
et al, 1996). Moreover, homozygosity of the 1.5 Mb duplication (generating four
copies of the PMP22 gene) causes a much more severe demyelinating neuropathy
called Dejerine-Sottas syndrome (DSS) (Scherer et al, 1997).
As well as PMP22 overexpression, CMT1A has been attributed in some
families to point mutations in the PMP22 gene (Roa et al, 1993; Valentijn et al,
1992b, 1993; Gabreels-Festern et al, 1995; Marrosu et al, 1997; Navon et al, 1996),
some of which correspond precisely to those of trembler (Valentijn et al, 1992b).
Certain other mutations of the PMP22 gene have been implicated in another
peripheral disease, hereditary neuropathy with liability to pressure palsies (HNPP).
This recurrent demyelinating condition is believed to be associated with a deletion
of the same region of chromosome 17 that is duplicated in CMT1A patients
(Chance et al, 1993; Nicholson et al, 1994; Vallat et al, 1996; Schenone et al, 1997).
Further support for this association is demonstrated by a PMP22-null knockout
mouse which displays a remarkably similar phenotype to HNPP (Adlkofer et al,
1997a; Adlkofer et al, 1997b).
Thus, different alterations of the PMP22 gene, including point mutations,
duplications and deletions may give rise to distinct hereditary peripheral
neuropathies
(b) Protein zero (PO)
Although no naturally occurring mutations or neuropathies associated with
PO have been identified in animals, nearly 30 mutations of the human PO gene locus
(lq21-23) have been described (Warner et al, 1996). Moreover, this locus shows
linkage to Charcot-Marie-Tooth type IB (CMT1B) (Bird et al, 1982; Lebo et al,
1991; Hayasaka et al, 1993; Kulkens et al, 1993; Suter and Snipes, 1995).
Interestingly, mutations of PO have also been associated with Dejerine-Sottas
syndrome, not just PMP22 (see above).
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(c) Protein 2 (P2)
The genetic locus for P2 has been mapped to the long arm of human
chromosome 8 (8q21.3-q22.1) (Hayasaka et al, 1993). This region is closely linked
to a marker for the autosomal recessive Charcot-Marie-Tooth disease type 4A
(CMT4A) (Ben Othmane et al, 1993). The possibility that this peripheral
neuropathy is due to a defect in the P2 gene has therefore been raised, but not
confirmed.
(d) Connexin32 (Cx32)
The recent discovery of this gap junction protein within regions of non-
compact myelin (Schmidt-Lanterman incisures and paranodal loops) (Scherer et
al, 1995) has proved of great interest following the mapping of its locus to Xql3, a
region which shows association with X-linked Charcot-Marie-Tooth (CMTX).
Numerous studies have demonstrated a variety of mutations in the Cx32 gene of
people with this disease (e.g. Bergoffen et al, 1994; Fairweather et al, 1994;
Ionesescu et al, 1995; Bone et al, 1995), affecting all portions of the Cx32 protein.
As typical gap junctions are not seen in myelinating Schwann cells the
presence of Cx32 is intriguing. Given that null mutant mice for this gene display a
persistent peripheral demyelinating neuropathy (Nelles et al, 1996; Anzini et al,
1997) it is becomes obvious that connexin 32 does play an important role within
myelinating Schwann cells. Interestingly, the CNS myelin of these knockout animals
appears normal . This is surprising as oligodendrocytes also express Cx32.
However, oligodendrocytes also express another type of connexin, Cx45
(Kunzelmann et al, 1997) and it has been suggested that this molecule can substitute
Cx32 in these mice. Further studies are required to determine the precise role of
connexins in myelin-forming cells.
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1.5.3 Uncharacterized Neuropathies
Whereas the most common inherited peripheral neuropathies appear to be
caused by mutations in the genes for PMP22, PO, P2 and Cx32 there are probably
many rarer types associated with other myelin and/or Schwann cell proteins.
Indeed, the neuropathies described so far have only implicated mutations in genes
encoding the structural proteins of myelin, whereas it is just as likely that
mutations of regulatory genes and genes involved in the developmental program of
the Schwann cell will show linkage to other myelin diseases. Given the functional
information obtained from observing the effects of mutations on the myelin
structural genes and the resulting myelin that is formed (if any), the identification
of linkages between regulatory genes and myelin structure and function will prove to
be invaluable.
1.6 BACKGROUND TO PROPOSED STUDY
1.6.1 Periaxin is a recently described protein of myelinating Schwann cells
Schwann cells undergo major morphological changes during the development
of the PNS (Jessen and Mirsky, 1991). From their insinuation into nerve bundles, to
establishing the 1:1 relationship with the axon, to the repeated spiral wrapping
during the myelination process, all of these events necessarily involve massive
alterations in cell shape. Such changes are obviously an essential component of the
Schwann cell differentiative programme and it follows that the mechanisms
involved in effecting these changes must be vital in driving the development of the
PNS. Substantial evidence exists to show that these morphological alterations are
triggered by axon-Schwann cell interactions (Gould et al, 1992; Neuberger and De
Vries, 1992). However, the precise molecular nature of these interactions, in
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particular the mechanisms of signal transduction and the targets of such signals,
remain largely unknown.
For any cell, a change in shape requires remodelling of the cell cytoskeleton
and its associated proteins. In the case of Schwann cells, these elements would
appear to be ideal targets for modulating the developmental signals initiated
through axonal contact. It follows that the identification of Schwann cell
cytoskeletal and cytoskeleton-associated proteins whose patterns of expression
and localization are developmentally regulated during differentiation and
myelination could prove to be extremely useful. On this premise, Gillespie and co¬
workers (1994) have recently reported the molecular cloning of a relatively
abundant protein of myelinating Schwann cells which has properties of a
cytoskeleton-associated protein based on its insolubility in non-ionic detergent.
From its predominant localization to the periaxonal region of myelin-forming
Schwann cells in developing peripheral nerves, this protein has been named periaxin
(Gillespie et al, 1994; Scherer et al, 1995). Importantly, two other proteins with a
similar mobility by SDS-PAGE as periaxin have previously been isolated from PNS
myelin: P170 and Schwann cell associated glycoprotein (SAG) (Shuman et al, 1986,
1988; Dieperink et al, 1992). Based on similar apparent molecular weights,
immunohistochemical localizations, and triton X-100 insolubility, it is probable that
periaxin, P170 and SAG are one and the same protein (Dieperink, 1992; Gillespie et
al, 1994; Scherer et al, 1995).
The primary structure of rat periaxin has been deduced from a full length
cDNA clone (Gillespie et al, 1994). Neither the nucleotide nor the deduced amino
acid sequence of the encoded 147 kDa periaxin protein is significantly similar to
any other sequence in the Genbank or EMBL databases. From hydrophobicity plots,
periaxin does not appear to possess any transmembrane domains and is therefore
not believed to be an integral membrane protein. However, it does display an
interesting domain structure, including a highly basic region near the N-terminus
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between amino acids 118 and 196 and an acidic region encompassed by residues
1036-1163 towards the C-terminus (Figure 12A). The most interesting domain,
spanning approximately 300 amino acids and located towards the centre of the
molecule, displays a remarkable repeating series of a pentapeptide (aliphatic
nonpolar:pro:glu or asp: aliphatic nonpolar:variable) and a tripeptide spacer
(Figures 12A, B). Given that this domain is believed to be less flexible than the rest
of the periaxin molecule (Gillespie et al, 1994), it has been suggested that the
repeats serve to extend the protein, thus keeping the (functional?) basic and acidic
domains apart. Indeed, this bipolar structure may be indicative of a linking role for
periaxin within myelinating Schwann cells, with the domain at one end of the
protein connected to the Schwann cell plasma membrane and the domain at the
other associated with the cytoskeleton.
The most instructive features of periaxin as regards its function, is its
expression which is highly regulated both spatially and temporally in the developing
peripheral nervous system of the rat (Gillespie et al, 1994; Scherer et al, 1995).
Periaxin is first detected in Schwann cells after they establish a 1:1 relationship
with axons and are ready to proceed with myelination (Gillespie et al, 1994; Scherer
et al, 1995). As demonstrated by immunofluorescence microscopy, this precedes
the expression of the major myelin proteins P0 and MBP and may even precede the
very early expression of MAG (Scherer et al, 1995; Martini and Schachner, 1986,
1988; Hahn et al, 1987; Lamperth et al, 1990). Thereafter, the levels of periaxin
raRNA and protein closely parallel those of the myelin structural proteins which
become maximally expressed during the most active phase of PNS myelination
(post-natal days 1 to 15 in the rat) (Webster and Favilla, 1984). Like other myelin-
related proteins therefore, the expression of periaxin is tightly controlled by axon-
Schwann cell interactions (Scherer and Salzer, 1995).
Within the Schwann cell, periaxin protein is initially localized to the








432 GPEVX APK 531 VPEMK 627 IPDMA
440 GPEVK LPK 536 LPDMK LPK 632 VPDVR
448 VPEIK LPK 544 VPEMA 637 LPEVQ LPK
456 APEAA 549 VPDVH 645 VSELK LPK
461 IPDVQ 554 LPDIQ LPK 653 VPEMT
466 LPEVQ LPK 562 VPEMK 658 MPDIR
474 MSDMK LPK 567 LPDMK LPK 663 LPEVQ LPK
482 IPEMA 575 VPEMA 671 VPDIK
487 VPDVH 580 VPDVR 676 LPEIK LPK
492 LPEVK LPK 585 IPEVQ LPK 684 VPEMA
500 VPEMK 593 VSEVK LPK 689 VPDVP
505 VPEMK LPK 601 IPDMA 694 LPELQ LPK
513 IPEMA 606 VPDVR 702 VPQ
518 VPDVH 611 LPELQ LPK 705 VPDVH LPK
523 LPDIQ LPK 619 MSEVK LPK 713 VPEMK LPK
721 VPEAQ
Figure 12. The domain structure of periaxin. (A) Analysis of the primary structure of
periaxin indicates the presence of 3 domains (1) a strongly basic N-terminal domain from
118-196, (2) an acidic C-terminal domain from 1036-1163, and (3) a repeat domain
comprising multiple copies of a pentapeptide sequence and tripeptide spacer (Gillespie et
al, 1994). (B) Alignment of repeat region residues. The smallest repeating units are a
pentapeptide and a tripeptide spacer. The pentapeptide is comprised of the following
amino acids: aliphatic nonpolar:pro:glu or asp:aliphatic nonpolartvariable. The
underlined sequences substitute serine for proline. Residue numbers are indicated. From





is absent from compact myelin (Gillespie et al, 1994). As the myelin sheaths mature,
this localization becomes predominantly abaxonal (apposing the basal lamina)
(Scherer et al, 1995). This shift in the localization of the protein in the Schwann cell
after completion of the spiralization phase of axon ensheathment suggests that
periaxin may participate in the membrane protein interactions that are required to
stabilize and maintain the mature sheath.
1.6.2 Proposed Study
Of those genes that are typically expressed by myelin-forming Schwann cells,
the periaxin gene is one of the first to become transcriptionally active (Scherer et al,
1995). The means by which the gene is regulated is therefore of considerable interest
in evaluating how the expression of those genes required for initiating axonal
ensheathment and myelination is coordinated. Moreover, characterization of the
mechanisms and elements involved in determining the tissue-specific expression of
this and other genes will be central to our understanding of the processes involved
in vertebrate development. Analysis of the regulatory elements of the periaxin gene,
in particular the upstream promoter, may yield valuable information towards these
goals.
The initial aim of this study therefore, was to isolate and characterize the
mouse periaxin gene so as to provide a firm grounding for future studies on the
molecular basis of periaxin gene regulation. Furthermore, this information and
material would prove to be immensely useful in the generation of knockout mice in
an attempt to shed some light on the role of periaxin in myelinating Schwann cells.
Thus, this work involves the screening of a genomic library for clones encoding the
periaxin gene, followed by detailed structural and sequence analysis, especially of
the core promoter. Importantly, although earlier work has been focused on rat
periaxin, in this study the emphasis was placed on mouse periaxin to more readily
facilitate these future investigations.
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Methods
2.1 SCREENING OF GENOMIC LIBRARY
2.1.1 Special reagents and materials
Genomic library
The genomic library screened during this procedure was of mouse strain 129SV (a
gift from Dr W. Skarnes, Centre for Genome Research, Edinburgh University); it was
constructed in the replacement vector Lambda DASH EI (Stratagene; see appendix)
by ligation of a partial Sau3A1 restriction digest of 129SV genomic DNA into
BamHl cut X arms and then packaged with Gigapack Gold packaging extracts
(Stratagene). The titre of the library was 26,000 plaque forming units (pfu)/pl.
Host bacterium for library phage
NZY broth (Gibco BRL) containing maltose (0.2%) was inoculated with bacterial
strain NM675 then incubated at 37°C for 6 h with shaking.
Probe
A full length cDNA corresponding to the 4.6 kb rat periaxin mRNA (pAlBG;
Gillespie et al, 1994) was double-digested with the restriction enzymes Sail and
Xhol then electrophoresed on a 1% agarose gel in TAE. The 3 kb fragment
(corresponding to nts 1-2992 of the 4.6 kb rat periaxin cDNA) was excised and
purified with Qiaex II (Qiagen) according to the manufacturers instructions. The
purified fragment was subsequently labelled with [a-32p] dCTP by random priming
(Gibco BRL).
2.1.2 Method
Plating of library clones:-
1. Fresh host cell culture (100 pi) and genomic library (2 pi; -50,000 pfu) were
dispensed into 20 sterile bijous.
2. After incubating at 37°C for 10 min to allow phage particles to adsorb to the
bacteria, molten (50°C) NZY top agarose (0.7%; 6.5 ml) was then added to the first
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bijou, mixed by inversion and immediately poured on a 145 mm plate containing 50
ml of hardened NZY agar (1.5%). The plate was then swirled gently to ensure an
even distribution.
3. The above step was subsequently repeated for the other bijous.
4. When the top agarose had hardened (approximately 10 min), the plates were
inverted and incubated overnight at 37°C.
Plaque lifts:-
1. Following overnight incubation, the plates were chilled at 4°C for 2 h to prevent
the top agarose sticking to the filters during the plaque lifts.
2. Prior to performing the plaque lifts the nitrocellulose filters (137 mm circles;
Duralon, Stratagene) were labelled with a corresponding plate letter (A-T), and a
small (~ 1 cm) triangular portion carefully cut from their outside edge.
3. The first filter was laid onto the surface of the first plate, taking care not to trap
air bubbles. To establish future orientation, 3 holes were punched at asymmetric
positions around the filter edge, into the agar, using a 16-gauge needle. The position
of these holes and the triangular cut in the filter were then marked onto the
underside of the plate with indelible ink.
4. After 2 min, the filter was carefully removed with forceps and placed contact
side up on a large sheet of 3MM paper (Whatman) soaked in denaturing solution
(1.5 M NaCl, 0.5 M NaOH) for 5 min.
5. The filter was then transferred to a fresh sheet of 3MM paper soaked in
neutralizing solution (1.5 M NaCl, 0.5 M Tris HC1, pH 8.0). After 3 min, the filter
was transferred to a fresh sheet of 3MM paper, again soaked in neutralizing
solution, and left for a further 3 min.
6. Finally, the filter was rinsed briefly in 2x SSC (0.3 M NaCl, 30 mM sodium
citrate, pH 7.0), allowed to dry, then baked at 80°C for 2 h between sheets of 3MM
paper.
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7. Steps 3-6 were repeated with the second and subsequent filters and their
corresponding plates.
8. All plates were returned to storage at 4°C until required.
Prehybridization of plaque-lift filters:-
1. After briefly wetting with distilled water, the plaque-lift filters were arranged into
10 siliconized glass hybridization tubes (roller bottles; Hybaid).
2. QuikHyb solution (15 ml; Stratagene) was pipetted into each tube, ensuring the
filters were fully covered, and the tubes then incubated at 60°C for 30 min (with
constant mixing).
Hybridization ofplaque-lift filters:-
1. Sheared salmon sperm DNA (100 gl of 10 mg/ml stock; Stratagene) was added
to each of 10 microfuge tubes containing 12.5 ng of labelled probe (see special
reagents and materials).
2. After boiling for 5 min, the probes were immediately added to the
prehybridization solution in each tube, ensuring thorough mixing and filter coverage.
3. Tubes were then incubated for a further 1.5 h at 60°C.
Post-hybridization washes:-
Following the hybridization, filters were washed twice in 2x SSC/ 0.1% SDS (10






1. Filters were arranged in X-ray cassettes (with intensifying screens) and their
orientation marks outlined with Indian ink containing [a-^P]dCTP.
2. After carefully overlaying with food wrap (SARAN), the filters were exposed to
X-ray film (Fuji RX) overnight at room temperature
3. Autoradiographs were developed using LX24 X-ray developer and Industrex
manual fixer (both Kodak).
4. After identifying 'putative' positives from the autoradiographs (19), the films
were aligned with the plates using the orientation marks and a plug of agar taken,
corresponding to the position of the putative clones.
5. Each plug was then transferred to a separate large microfuge tube containing SM
buffer (500 pi; 50 mM Tris HC1 pH 7.5, 100 mM NaCl, 8 mM MgSC>4.7H20) and
chloroform (20 pi). Tubes were then incubated at room temperature for a minimum
of 6 h to allow phage particles to diffuse from the plugs.
NB. Primary agar plugs were taken using an inverted blue (200-1000 pi) pipette tip,
secondary plugs with an inverted yellow (0.5-200 pi) pipette tip and tertiary plugs
with a Pasteur pipette.
Titration of primary plugs:-
1. One third (6) of the putative clones were selected at random. A 10"^ dilution of
each (5 pi) was then used to infect fresh host cell culture (100 pi).
2. After incubating at 37°C for 10 min, each titration was then plated with molten
(50°C) NZY top agarose (0.7%; 3 ml) on a 90 mm plate containing 15 ml of
hardened NZY agar (1.5%),
3. Once the top agarose had hardened, the plates were inverted and incubated
overnight at 37°C.
4. Plug titres were subsequently calculated from the resulting numbers of visible
plaques. For the un-titred clones the average was used.
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Secondary screening ofprimary clones:-
1. Approximately 1000 pfu from each primary plug were plated on single 90 mm
NZY agar plates using fresh host cells (100 pi) and NZY top agarose (3 ml), then
incubated overnight at 37°C.
2. A nitrocellulose filter plaque-lift was then taken from each plate as before.
3. Prehybridization, hybridization, washes and probe detection were then carried
out, also as before.
4. After orienting the resulting autoradiography to their corresponding plates, a
single positive clone plug was taken from each plate and transferred to a separate
microfuge tube containing SM buffer (250 pi) and chloroform (10 pi). Tubes were
then incubated at room temperature for 6 h.
5. All secondary plugs (22) were subsequently titred (essentially as for the primaries
except using 1 pi of 10"! dilutions).
Tertiary screening ofsecondary clones:-
1. Approximately 100 pfu from each primary plug were plated on single 90 mm
NZY agar plates using fresh host cells (100 pi) and NZY top agarose (3 ml), then
incubated overnight at 37°C.
2. A nitrocellulose filter plaque-lift was then taken from each plate as before.
3. Prehybridization, hybridization, washes and probe detection were then carried
out, also as before.
4. After orienting the resulting autoradiographs to their corresponding plates, a
single positive clone plug was taken from each plate and transferred to a separate
microfuge tube containing SM buffer (250 pi) and chloroform (10 pi). Tubes were
then incubated at room temperature for 6 h.
5. All tertiary plugs (22) were subsequently titred (essentially as for the
secondaries).
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Preparation of a high titre stock of each clone:-
1. Approximately 150,000 pfu from each tertiary plug were plated on single 145
mm NZY agar plates using fresh host cells (300 pi) and NZY top agarose (6.5 ml),
then incubated overnight at 37°C.
2. Plates were subsequently flooded with SM buffer (8 ml) and incubated at room
temperature for 6 h (with gentle rocking).
3. High titre stocks were harvested from the plates using a 1 ml pipette and
transferred to 15 ml glass COREX tubes. After a 5 min spin at 9500 rpm the
resulting supernatants were dispensed into 1.5 ml screwcap tubes and stored at
4°C.
4. For long term storage, 100 pi aliquots of each high titre stock were mixed with
DMSO (at a final concentration of 8%), flash frozen in liquid N2 and transferred to
-70°C.
2.2 ISOLATION OF BACTERIOPHAGE DNA
2.2.1 Method
1. High titre stock from each putative periaxin gene clone (1 ml) was transferred to
a large microfuge tube containing 350 pi of 3M NaCl/30% PEG, mixed by inversion
and incubated on ice for 30 min.
2. Following a 10 min centrifugation at 13000 rpm and 4°C, the resulting phage
pellets were resuspended in 250 pi SM buffer. DNase I (2.5 pi of a 1 mg/ml stock;
SIGMA) was then added and the tubes incubated at 37°C for 30 min (with
occasional vortexing).
4. An equal volume of lysis solution (0.3 M Tris HC1 pH 9, 100 mM EDTA, 1.25%
SDS) was subsequently dispensed into each tube, mixed by inversion, and
incubated at 65°C for 10 min (with occasional mixing).
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5. Neutralizing solution (250 pi; 3M potassium acetate pH 5.5) was then added,
mixed thoroughly by inversion, and the tubes incubated on ice for 10 min.
6. After a 5 min centrifugation at 13000 rpm and 4°C supernatants were transferred
to fresh microfuge tubes and extracted twice with phenol-chloroform (1:1) and once
with chloroform.
7. Isopropyl alcohol (0.8 vol) was then added and the tubes incubated on ice for 30
min before centrifugation at 13000 rpm and 4°C for 10 min.
8. The phage DNA pellets were subsequently washed in 70% ethanol then allowed
to dry. The DNA was then gently suspended in 20 pi TE/RNase (10 mM Tris HC1
pH 8.0, 1 mM EDTA, 2% RNase cocktail (Ambion)).
9. Tubes were left at room temperature overnight to allow the DNA to dissolve
completely.
2.3 EXCISION AND SUBCLONING OF GENOMIC DNA INSERTS
FROM BACTERIOPHAGE LAMBDA DASH II
2.3.1 Method
1. DNA from each putative positive clone was digested with EcoRl.
In a 0.5 ml microfuge tube:-
3.0 pi EDNA
1.5 pi Buffer H
9.5 pi Sterile milli-Q water
0.5 plEcoRl restriction enzyme (10 U; New England Biolabs)
The tube was then incubated overnight at 37°C.
2. Digests were subsequently electrophoresed on 0.8% agarose gels in TAE
containing 0.5 pg/ml EtBr and visualized by UV transillumination.
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3. A comparison of the sizes of the resulting EcoRl fragments in all of the clones
demonstrated 3 distinct clone types. The EcoRl fragments from a representative
clone of each type were subsequently excised from the gel and purified by Qiaex II
(Qiagen) according to manufacturers instructions.
4. The following ligation was set up for each purified EcoRl fragment-
Purified fragment DNA (vacuum-dried)
1.0 pi EcoRl-dephosphorylated pIBI30 (Qiagen)
0.5 pi lOx ligase buffer (Promega)
3.0 pi Sterile milli-Q water
0.5 pi T4 DNA ligase (0.5 U; Promega)
The reaction was then incubated overnight at room temperature.
4. Ligations were subsequently transformed into CaCl2-competent XLl-blue (100
pi) and plated onto LB agar (1.5%; Gibco BRL) containing ampicillin (0.1 mg/ml),
X-gal (0.008%) and IPTG (300 pM).
5. Resulting white colonies were inoculated into LB-broth (5 ml) containing
ampicillin (0.1 mg/ml) and incubated overnight at 37°C with shaking.
6. Cultures were spun for 30 sec at 13000 rpm and the supernatants discarded. The
bacterial pellets were then resuspended in 300 pi TELT (50 mM Tris HC1 pH 8, 4%
Triton X-100, 62.5 mM EDTA, 2.5 M LiCl) by vortexing for 15 sec. An equal
volume of phenol-chloroform was then added, mixed by vortexing for 10 sec and
spun for 3 min at 13000 rpm.
7. Supernatants (270 pi) were transferred to fresh tubes and 3 vols of 0.1 M sodium
acetate in absolute ethanol added. After a brief mix, the tubes were spun for 45 min
at room temperature.
8. The resulting pellets were washed in 70% ethanol, allowed to dry and then
resuspended in 20 pi TE. The presence of a correct insert was subsequently
determined by restriction digest with EcoRl followed by electrophoresis on an
agarose in TAE gel.
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2.4 SEQUENCING OF GENOMIC SUBCLONES
2.4.1 Special reagents and materials
Sequencing primers
Short (15-25 nt) oligonucleotides for sequencing and PCR were synthesized on a
model 391 PCR-MATE (Applied Biosystems) and purified by butanol extraction
(Sawadogo and VanDyke, 1991)
2.4.2 Method
Template Denaturation
1. In a 0.5 ml microfuge tube:-
3 pg Plasmid DNA
3 pi NaOH (2 M)
Sterile milli-Q water to 15 pi.
2. After 20 min at room temperature, 1M sodium acetate pH 4.8 (15 pi) and
absolute ethanol (90 pi) was added and the tube incubated at -70°C for 30 min.
3. Following a 15 min spin at 13000 rpm (4°C), the DNA pellet was washed in 70%
ethanol and vacuum dried.
Primer annealing
DNA pellets were resuspended in milli-Q water (5 pi) and the following
additions made:-
1 pi Sequencing primer (5 pM)
1 pi Annealing buffer




The following were added to the tube containing the annealed template and
primer:-
1.5 pi Labelling mix A
0.3 pi Sterile milli-Q water
0.2 pi [a-35s]dATP (ICN Pharmaceuticals)
1.0 pi Diluted T7 DNA polymerase (1:4 with dilution buffer)
The tube was then incubated at room temperature for 4 min.
Termination reactions
1. After incubation, 4.5 pi was transferred to each prewarmed (39°C) sequencing
mix (1.3 pi). The tubes were then incubated at 39°C for 5 min.
2. Stop solution (2.5 pi) was then added and the tubes immediately frozen at -20°C.
Note. All reagents used were from a T7 sequencing kit (Pharmacia) unless otherwise
stated.
Gel electrophoresis
1. Reactions were boiled for 3 min then immediately loaded (2.5 pi) on adjacent
lanes of a sequencing gel (6% (v/v) acrylamide/bisacrylamide (19:1), 42% (w/v)
urea, 1 xTBE (0.09 M Tris HC1, 0.09 M boric acid, 2 mM EDTA pH 8.0), TEMED
(0.001% (v/v)), ammonium persulphate (0.02% (w/v)) assembled in an IBI Base
Runner Nucleic Acid Sequencer (60 cm x 21.6 cm plates) according to the
manufacturers instructions and with buffer reservoirs filled with Ix TBE.
Electrophoresis was for approximately 4 h at 60 W.
5. The sequencing gel was fixed for 15 min in methanol (5%) and acetic acid (5%),
blotted on 3MM paper and dried under vacuum for 90 min at 80°C.
6. The dried gel was then exposed to X-ray film (Fuji RX) for 48 h at room
temperature.
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7. The autoradiograph was developed using LX24 X-ray developer and Industrex
manual fixer (both Kodak).
8. Sequences were analyzed using Macvector sequence analysis software (Oxford
Molecular Group) and the University of Wisconsin GCG package (Devereaux et al,
1984).
2.5 SOUTHERN BLOT ANALYSIS
2.5.1 Method
1. DNA samples were electrophoresed on a 1% agarose gel in TAE for
approximately 4 h at 55V.
2. Resolved DNAs were subsequently transferred to Magna nylon membrane
(Micron Separations Inc.) using a vacuum blotting unit (VacuGene XL, Pharmacia
Biotech), according to manufacturers instructions. Transfer included 5 min in
depurination solution (0.25 M HC1), 10 min in denaturing solution (1.5 M NaCl, 0.5
M NaOH), 10 min in neutralization solution (1.5 M NaCl, 0.5 M Tris HC1 pH 8.0)
and 2 h in 20x SSC. The membrane was then baked at 80°C for 2 h.
4. After briefly wetting with distilled water, the membrane was arranged in a 50 ml
polypropylene tube, covered in 3.5 ml of Rapid-Hyb buffer (Amersham) and
incubated at 65°C for 30 min (with constant mixing). Labelled probe was then
added to the tube and the incubation continued for a further 1.5 h.
5. The membrane was subsequently washed twice in 2x SSC/0.1% SDS (10 min
per wash; room temperature) and twice in 0.2x SSC/0.1% SDS (30 min per wash;
65°C).
6. After sealing in food wrap (SARAN), the blot was exposed to X-ray film (Fuji
RX) for 1 week at room temperature.
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7. The autoradiograph was developed using LX24 X-ray developer and Industrex
manual fixer (both Kodak).
2.6 5'-RACE (Rapid Amplification of cDNA Ends)
2.6.1 Special reagents and materials
Sciatic nerve total RNA.
Total RNA was extracted from the sciatic nerves of 15-day-old mice using
RNAzol B (AMS Biotechnology) according to the manufacturers instructions. An
aliquot (2 pi) of the RNA solution was subsequently diluted to 1 ml with milli-Q
water and the absorbance at 260 nm measured. The concentration of RNA was
then calculated (1 OD = 40 pg/ml RNA).
2.6.2 Method
Reverse Transcription
1. The following were dispensed into a 0.5 ml microfuge tube:-
1 pi Random primers (150 ng; Gibco BRL)
5 pg Total RNA
Sterile DEPC-treated milli-Q water to 12 pi
The tube was then incubated at 70°C for 10 min then immediately quenched on ice.
2. After a brief centrifugation the following additions were made:-
4 pi 5x first strand synthesis buffer (Gibco BRL)
1 pi dNTP mix (each 10 mM)
2 pi DTT (100 mM)
The tube was subsequently incubated at 42°C for 2 min.
3. Superscript reverse transcriptase (200 U; Gibco BRL) was then added and the
reaction incubated at 42°C for 45 min.
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4. Following single phenol-chloroform and chloroform extractions, the cDNA was
precipitated by the addition of 3 vols of 0.1 M sodium acetate in absolute ethanol
and then pelletted by centrifugation at 13000 rpm for 45 min at 4°C.
5. After a wash in 70% ethanol, the pellet was vacuum-dried and then resuspended
in 10 pi DEPC-treated milli-Q water.
Terminal Deoxynucleotidyl Transferase (TdT ) tailing of cDNA
1. cDNA (10 pi) was incubated at 70°C for 10 min then immediately quenched on
ice.
2. After a brief centrifugation, the following additions were made:-
2 pi 5x first strand synthesis buffer (Gibco BRL)
7 pi dCTP (0.5 mM)
0.8 pi TdT (10 U; Gibco BRL)
The reaction was then incubated at 37°C for exactly 10 min.
3. The TdT was subsequently heat inactivated for 10 min at 70°C and the tailed
cDNA then kept on ice.
PCR amplification of poly(C) tailed cDNA
1. In a 0.5 ml microfuge tube:-
1.0 pi Tailed cDNA
2.5 pi LMD30 primer (5 pM; nts 426-406 of rat periaxin - see appendix)
2.5 pi 5' RACE anchor primer (5 pM; see appendix)
2.5 pi lOx reaction buffer
2.5 pi dNTP mix (each 2 mM)
13 pi sterile milli-Q water
1.0 pi Dynazyme polymerase (Flowgen; diluted to 0.25 U/pl with lx reaction
buffer)
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The reactions were then overlaid with mineral oil (15 pi) and subjected to the
following cycle conditions:-
94°C for 1 min; 60°C for 1 min; 72°C for 1 min } first 5 cycles
94°C for 40 sec; 60°C for 1 min; 72°C for 1 min } next 30 cycles
94°C for 40 sec; 60°C for 1 min; 72'C for 4 min } last cycle
2. After chloroform extraction, PCR products were electrophoresed on a 1%
agarose gel in TAE. Major products were excised, purified by Qiaex II and
subcloned into the pGEM T-Vector (Promega) according to manufacturers
instructions.
3. Subcloned PCR products were subsequently sequenced as before (see section 2.4).
2.7 SCREENING OF cDNA LIBRARY
2.7.1 Special reagents and materials
cDNA Library.
The cDNA library screened during this procedure was the same as that used by
Gillespie et al (1994) for the isolation of rat periaxin 5' sequence; sciatic nerve
poly(A)+ RNA from 15-day-old rats was reverse transcribed with random
hexamers and the resulting cDNA cloned into the Zgtll vector (Promega; see
appendix) before packaging with Gigapack Gold packaging extracts (Stratagene).
NB. Before use, it was necessary to determine a current titre for the library,
following its extended storage at 4°C.
Host Bacterium.
NZY broth containing maltose (0.2%) and ampicillin (0.1 mg/ml; Boehringer
Mannheim) was inoculated with bacterial strain Y1090 (Promega) then incubated at
37°C for 6 h with shaking.
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2.7.2 Method
Clones (3 x 10^) from the above library were screened by plaque hybridization
essentially as described in 2.1 except with bacterial strain Y1090 as the host and
using a restriction fragment spanning nts 1-599 of the 4.6 kb rat periaxin pAlBG





The following were dispensed into a 0.5 ml microfuge tube:-
1 pi CSG7 primer (10 pM; nts 547-569 of rat periaxin - see appendix)
2 pi 5x T4 polynucleotide kinase reaction buffer (Gibco BRL)
2.5 pi [y-32p]ATP (ICN Pharmaceuticals)
4 pi Sterile milli-Q water
0.5 pi T4 polynucleotide kinase (5 U; Gibco BRL)
The tube was then incubated at 37°C for 45 min and 65°C for 10 min.
Hybridization
1. The following were dispensed into a 0.5 ml microfuge tube:-
10 pg Mouse trigeminal nerve total RNA
5 pi Labelled primer (from above)
Sterile milli-Q water to 10 pi
1 pi Sodium acetate (3 M)
28 pi ethanol (100%)
The tube was then incubated at -70°C for 30 min.
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2. Following a 30 min spin at 13000 rpm and 4°C, the pellet was washed in 70%
ethanol and respun (2 min).
3. After drying, the pellet was resuspended in 10 pi formamide hybridization buffer
(0.9% formamide in 2.6x PIPES). The tube was then heated at 80°C for 10 min
before overnight incubation at 42°C.
4. Sterile milli-Q water (57 pi) and 100% ethanol (135 pi) was subsequently added
and the tube incubated at -70°C for 30 min.
5. Following a 30 min spin at 13000 rpm and 4°C, the pellet was washed in 70%
ethanol and respun (2 min). The pellet was then allowed to dry.
Reverse transcription
1. The pellet from the above step was resuspended in the following:-
7 pi Sterile milli-Q water
4 pi 5x first strand synthesis buffer (Gibco BRL)
2 pi DTT (0.1 M)
5 pi dNTP mix (each 2 mM)
1 pi Actinomycin D (1 pg/pl)
Superscript reverse transcriptase (200 U; Gibco BRL) was then added and the
reaction incubated at 42°C for 45 min.
2. Following ethanol precipitation as before, the resulting pellet was dissolved in TE
(10 mM Tris HC1 pFl 8.0, 1 mM EDTA; 3 pi) and Stop solution (T7 sequencing kit,
Pharmacia; 3pl).
3. An aliquot of this solution (2.5 pi) was subsequently electrophoresed on a 6%
sequencing gel (see 2.4.2) against a sequencing ladder comprising the 5'-end of
mouse periaxin (generated by priming the longest mouse periaxin subclone from 2.6
with CSG20 (nts 103-122 of mouse periaxin - see appendix)
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2.9 NORTHERN BLOT ANALYSIS
2.9.1 Method
1. Vacuum-dried RNA was resuspended in sample buffer (10 pi; lx MOPS [0.02 M
MOPS, 5 mM sodium acetate, 10 mM EDTA pH 7], 50% formamide, 7.4%
formaldehyde, 0.05 pg/pl ethidium bromide), incubated for 15 min at 65°C and
then quenched on ice.
2. After the addition of sterile loading buffer (1 pi) samples were electrophoresed
on a 0.8% agarose gel containing lx MOPS and formaldehyde (1.1%) in a lx MOPS
running buffer (Kroczek & Siebert 1990) for approximately 4 h at 55V.
3. Separated RNAs were subsequently vacuum-transferred to Magna nylon
membrane (Micron Separations Inc.) for 2 h in 20x SSC using a vacuum blotting unit
(VacuGene XL, Pharmacia Biotech), according to the manufacturers instructions.
The membrane was then baked at 80°C for 2 h.
4. After briefly wetting with distilled water, the membrane was arranged in a 50 ml
polypropylene tube, covered in 3.5 ml of Rapid-Hyb buffer (Amersham) and
incubated at 65°C for 30 min (with constant mixing). Labelled probe was then
added to the tube and the incubation continued for a further 1.5 h.
5. The membrane was subsequently washed twice in 2x SSC/0.1% SDS (10 min
per wash; room temperature) and twice in 0.2x SSC/0.1% SDS (30 min per wash;
65°C).
6. After sealing in food wrap (SARAN), the blot was exposed to X-ray film (Fuji
RX) for 1 week at room temperature.
7. The autoradiograph was developed using LX24 X-ray developer and Industrex
manual fixer (both Kodak).
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2.10 SODIUM DODECYL SULPHATE - POLYACRYLAMIDE GEL
ELECTROPHORESIS (SDS-PAGE)
2.10.1 Special reagents and materials
Sciatic nerve protein.
Sciatic nerves were taken from 15-day-old mice and solubilized by boiling in a
minimum volume of 2% (w/v) SDS containing proteinase inhibitors (10 pg/ml
leupeptin and 10 pg/ml antipain (both SIGMA)) for 3 min. Following a 5 min
centrifugation at 13000 rpm and 4°C, the resulting supernatant was dispensed into
small aliquots, fresh proteinase inhibitors added and flash frozen before storage at
-40°C. An aliquot from each preparation was subsequently taken and its protein
content estimated using a modified Lowry (Lowry et al 1951):-
Protein standards of 0-15 (ig Bovine Serum Albumin (BSA; New England
Biolabs) in 2% (w/v) SDS with proteinase inhibitors (100 pi) and dilutions of the
nerve preparation (in 100 pi of the same solution) were prepared in duplicate in 2
ml microfuge tubes. Following the addition of Reagent A (125 pi; 1M NaOH, 0.25%
SDS) the reactions were incubated at 60°C for 15 min. Fresh Reagent B (1.25 ml;
0.02% (w/v) potassium sodium tartrate, 0.01% (w/v) CuS04, 2% (w/v) Na2CC>3)
was then added and each tube incubated at room temperature for a further 15 min.
Finally, 125 pi of a fresh IN solution of Folin-Ciocalteu phenol reagent (Fisons) was
added and mixed rapidly by inversion. After a 45 min incubation at room
temperature the A750 of each reaction was measured. A standard curve was
subsequently generated, from which the protein content of the nerve preparation
was estimated.
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4-20% linear gradient polyacrylamide gels.
Linear gradient resolving gels (4-20%) were cast using an SE 615 multiple casting
chamber (Hoefer Scientific Instruments) according to manufacturers instructions and
based on the buffer system of (Laemmli 1970). The resulting gels were held between
18 x 16 cm glass plates and measured 14 cm x 12 cm x 1.5 mm thick.
For 10 gels:-
4% Stock 20% Stock
30% (w/v) acrylamide/
bis-Acrylamide (37.5:l)(Anachem) 16 . , 7 ml 83 . . 3 ml
Tris-HCl, pH 8.9 (1.5 M) 25 . . 0 ml 25 . . 0 ml
SDS (20%) 0 . 625 ml 0 . 625 ml
N^N'/NVTetramethylethylene diamine (TEMED) 0 .045 ml 0 .045 ml
milli-Q water 83 . 3 ml 16 ..7 ml
Ammonium persulphate (10% (w/v); fresh) 0 ..3 ml 0 . 06 ml
Final volume 125 ml 125 ml
A stacking gel was added to each individual resolving gel immediately prior to
electrophoresis. Per stacking gel:-
2.25 ml acrylamide/bis-acrylamide (37.5:1; 30%)
1.875 ml Tris HC1 pH 6.7 (0.5 M)
75 pi SDS (20%)
7.5 pi TEMED
Sterile milli-Q water to 15 ml
150 pi fresh ammonium persulphate (10%)
Immediately following the addition of the ammonium persulfate this solution was
rapidly pipetted into the space above the resolving gel to a level approximately 2
cm from the top.
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2.10.2 Method
1. Sciatic nerve protein from 15-day-old mouse (100 pg) and PNS myelin from 16-
day-old rat (20 pg; A gift from Dr S. Gillespie) were dispensed into separate
screwcap tubes and the following additions made:-
330 |il 3x Sample buffer (1% bromophenol blue, 20% glycerol, 0.2 M Tris-HCl ,
8% SDS)
167 pi dithiothreitol (DTT; SIGMA; 1M)
100 pi lOx proteinase inhibitors (0.1 mg/ml leupeptin and 0.1 mg/ml antipain)
Sterile milli-Q water to 1 ml
2. After boiling for 2 min the samples were spun for 5 min at 13000 rpm and 4°C.
3. The resulting supernatants were loaded across the surfaces of separate 4-20%
linear gradient polyacrylamide gels (see above) assembled in a SE 400 Sturdier Slab
Gel Electrophoresis Unit (Hoefer Scientific Instruments) according to the
manufacturers instructions and with buffer reservoirs filled with a solution
containing Tris-HCl pH 8.4 (12.5 mM), glycine (96 mM) and 0.1% SDS.
4. Proteins were subsequently electrophoresed for approximately 4 h at a current of
30 mA (until the bromophenol blue dye in the sample buffer was just off the bottom
of the gel).
2.11 WESTERN BLOT ANALYSIS
2.11.1 Method
1. Following SDS-PAGE, separated proteins were electrophoretically transferred to
0.45 pm nitrocellulose (Schleicher and Schuell) for 2 h at 45 mA in a buffer
containing Tris-HCl pH 8.4 (25 mM), glycine (192 mM) and 20% (v/v) methanol,
using a TE22 Mighty Small Transphor Electrophoresis Unit (Hoefer Scientific
Instruments) according to the manufacturers instructions (Towbin et al 1979).
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2. When the transfer was complete the nitrocellulose membrane was rinsed
thoroughly in lx PBS then blocked for 3 h in a blocking buffer of lx PBS containing
0.2% (w/v) gelatin and 0.1% (v/v) Triton X-100.
3. Thin (3-5 mm) strips were subsequently cut from the filter and incubated for 1.5 h
at room temperature in a solution of the appropriate primary antibody diluted in
blocking buffer.
4. Following 3x5 min washes in blocking buffer, the strips were incubated with a
solution containing a horse radish peroxidase (HRP)-conjugated donkey anti-rabbit
IgG secondary antibody (Scottish Antibody Production Unit (SAPU), Law
Hospital, Carluke), diluted 1:500 in blocking buffer.
5. After 1 h at room temperature the strips were washed once in blocking buffer and
then twice in lx PBS.
6. Immunoreactive proteins were visualized by incubating in a solution of 50 mM
Tris-HCl pH7.4 containing 1 mg/ml of 3,3'- diaminobenzidine (DAB; SIGMA) and
adding 30% (v/v) H2O2 (1 pi).
7. When sufficiently developed, the peroxidase reaction was stopped by the
addition of SDS to 2% (v/v).
2.12 IN VITRO TRANSCRIPTION
2.12.1 Special reagents and materials
Linearized template DNAs.
Linearized template DNA for the in vitro transcription of the 4.6 kb periaxin
mJRNA was generated from the pAlBG plasmid (Gillespie et al 1994). For the
transcription of the 5.2 kb periaxin mRNA, template DNA was generated from a
modified pAlBG plasmid in which the 0.2 kb Ssfll-HzrccII restriction fragment
between nts 633 and 734 of the 4.6 kb periaxin cDNA had been replaced with a 0.8
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kb Sstll-HincU fragment from the partial 5.2 kb periaxin cDNA clone F4 (which
includes the entire intron 6 sequence)
To prepare the linearized template DNAs, the following were dispensed into a 0.5
ml microfuge tube:-
10 pg plasmid midiprep DNA
5 pi Buffer H (Boehringer Mannheim)
Sterile milli-Q water to 47 pi.
Notl restriction enzyme (30 U; New England Biolabs) was then added, mixed
gently, and the tube incubated at 37°C for 6 h. After taking the volume to 200 pi
with TE (10 mM Tris HC1 pH 8.0, 1 mM EDTA), each digest was extracted once
with phenol-chloroform and then once with chloroform before precipitation with 0.1
M sodium acetate in absolute ethanol. The resulting DNA was suspended in 10 pi
of DEPC-treated milli-Q water. The concentration of linearized template was
subsequently determined by a visual comparison with a known standard following
electrophoresis on a 1% agarose gel in TAE.
2.12.2 Method
1. The following were dispensed into a 0.5 ml microfuge tube (on ice):-
lpg linearized template DNA (see above)
2 pi lOx transcription buffer (Boehringer Mannheim)
2 pi ATP (lOmM)
2 pi CTP (lOmM)
2 pi TTP (lOmM)
2 plGTP(lOmM)
2 pi RNA CAP Structure Analog (7 mG(5')ppp(5')G; 5 mM; New England
Biolabs)
1 pi RNasin RNase inhibitor (40 U; Promega)
DEPC-treated milli-Q water to 19 pi
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T7 RNA polymerase (15 U; Promega) was then added and the reaction incubated
for 1 h at 37°C.
2. RQ1 RNase-free DNase (2 U; Promega) was subsequently added and the tube
returned to 37°C for a further 15 min.
3. After taking the volume to 200 pi with DEPC-treated milli-Q water, the
transcriptions were extracted once with phenol-chloroform and then once with
chloroform.
4. RNA was precipitated by the addition of one tenth vol of 3M sodium acetate pH
4.8 and 1 vol. of isopropylalcohol followed by a 1 h incubation on ice.
5. After a 45 min spin at 13000 rpm and 4°C, the resulting RNA pellet was gently
washed (not resuspended) in 500 pi of ethanol (diluted to 70% with DEPC-treated
milli-Q water) and spun for 5 min at 13000 rpm.
6. The RNA was then allowed to air dry before finally suspending in 20 pi of
DEPC-treated milli-Q water. A fraction of this solution (4 pi) was subsequently
diluted to 1 ml with milli-Q water and the absorbance at 260 nm measured. The
concentration of RNA was then calculated (1 OD = 40 pg/ml RNA).
7. To confirm the integrity and relative quantities of the transcribed RNAs, a sample
of each (1 pg) was electrophoresed on a 0.8% agarose formadehyde gel (see section
2.9).
2.13 IN VITRO TRANSLATION
2.13.1 Method
1. Translation of the in vitro transcribed RNAs from 2.12 was carried out using the
'Flexi' rabbit reticulocyte system (Promega) according to the manufacturer's
instructions. Briefly:-
In vitro transcribed RNA (0.5 pg) corresponding to either the 4.6 or 5.2 kb periaxin
mRNA was dispensed into a 0.5 ml microfuge tube, denatured at 67°C for 10 min
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then quenched on ice. After a short pulse spin the following additions were made
(on ice):-
0.5 jj.1 Amino Acid Mixture Minus Methionine (ImM)
0.7 pi KC1 (2.5 M)
0-2 pi Magnesium acetate (25 mM; see notes)
0.5 pi RNasin RNase inhibitor (40 U; Promega)
2.0 pi 35s-methionine (22.74 pCi; ICN Radiochemicals)
DEPC-treated milli-Q water to 8.5 pi.
An aliquot of reticulocyte lysate was then thawed and 16.5 pi added rapidly to the
tube. After a gentle mix, the reaction was incubated at 30°C for 1.5 h.
2. An aliquot (1 pi) of the completed translation was then spotted onto a small
circle of Whatman filter and allowed to dry. The remainder was flash frozen in
liquid N2 and stored at -40°C.
3. After washing the filter in a large excess of ice-cold 10% (w/v) trichloroacetic
acid (TCA) for 10 min and then in a large excess of ice-cold 5% (v/v) TCA for 5
min the filter was then transferred to boiling 5% (v/v) TCA and boiled for 15 min.
4. Following two further 5 min washes in ice-cold 5% (v/v) TCA and 2x3 min
dehydrations in excess absolute ethanol, the filter was allowed to dry.
5. Hydrogen peroxide (5 pi of a 15% (v/v) solution) was then spotted onto the dry
filter and left for 30 min. This resulted in a decolourization of the translation (so as
to minimize colour quenching during scintillation counting).
6. After repeating the H2O2 bleaching, the filter was pushed to the bottom of a 1.5
ml microfuge tube and covered with 1 ml of liquid scintillant (Opti phase 'Hi-Safe',
Wallac). Radioactivity was then measured on a scintillation counter.
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2.13.2 Notes
- Titration of Mg2+ between 0-5 mM was required to achieve optimal translations
of the individual RNAs. It should be noted that the endogenous Mg2+ level of the
lysate displayed batch-to-batch variability and therefore re-titration was necessary
whenever a new batch was used.
- Background 35s-met incorporation was calculated from a translation reaction in
which template RNA had been omitted.
2.14 IMMU NO PRECIPITATION
2.14.1 Special reagents and materials
Protein A agarose
Protein A agarose (25 mg; SIGMA) was swollen for 1 h in Solution A (250 |il;
50 mM Tris-HCl pH 7.4, 2.5% (v/v) Triton X-100, 150 mM NaCl, 4 mM EDTA)
then centrifuged for 5 min at 13000 rpm. After discarding the supernatant, the
pellet was resuspended in 1 ml of Solution A. The tube was then spun again to
repellet. This wash step was repeated twice more. The final volume of the agarose
was subsequently determined and 2 vol of Solution A added before storage at 4°C.
2.14.2 Method
1. The following were dispensed into a 1.5 ml screwcap microfuge tube:-
50,000 cpm of 4.6 kb periaxin mRNA in vitro translation
200,000 cpm of 5.2 kb periaxin mRNA in vitro translation
200,000 cpm of a control in vitro translation (ELAV; a gift from Dr S. Tait)
12.5 pi SDS (20%)
2.5 pi 50x proteinase inhibitors (0.5 mg/ml leupeptin and 0.5 mg/ml antipain)
Sterile milli-Q water to 125 pi
73
2. After boiling for 2.5 min, 4 vol. of Solution A containing lx proteinase inhibitors
was immediately added and mixed by inversion. The tube was then spun at 13000
rpm for 5 min.
3. The resulting supernatant was transferred to a fresh screwcap microfuge tube and
protein A agarose (50 pi; see above) containing lx proteinase inhibitors added. The
tube was then rotated end-over-end on a bench-top windmill mixer for 1 h.
4. Following a 5 min spin the supernatant was again transferred to a fresh screwcap
tube. Anti-NTerm antiserum (10 pi; rat periaxin amino acids 2-14 (Gillespie et al,
1994)) was then added and the tube rotated for a further hour.
5. After the addition of protein A agarose (50 pi; see above) the tube was returned
to the windmill mixer, rotated for a third hour, and then spun for 5 min at 13000
rpm.
6. The resulting supernatant was then discarded and the pellet resuspended in 1 ml
of Solution A containing 0.1% SDS. The tube was then spun for 5 min at 13000 rpm
to repellet. This wash step was repeated twice more with Solution A containing
SDS and then once with Solution A minus Triton X-100.
7. Following the final wash, the pellet was suspended in SDS-PAGE sample buffer
containing 100 mM DTT (80 pi) then boiled for 3 min. After a 5 min spin at 13000
rpm, the supernatant was loaded onto a 4-20% gradient SDS-polyacrylamide gel
(see section 2.10). Samples of the 4.6 kb mRNA in vitro translation (25,000 cpm),
the 5.2 kb mRNA in vitro translation (100,000 cpm) and the control in vitro
translation (100,000 cpm) were also loaded on the same gel. Electrophoresis was
then carried out overnight at a current of 5 mA (See section 2.10).
8. When the bromophenol blue dye had reached the bottom of the gel,
electrophoresis was stopped. At this point, the glass plates were separated, the gel
removed and immersed for 30 min in Amplify (Amersham).
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9. The gel was subsequently dried under vacuum for 2 h (with heat lamp) on a
double thickness of 3MM paper and then exposed to X-ray film (Fuji RX) for 48 h at
room temperature.
10. The autoradiograph was developed using LX24 X-ray developer and Industrex
manual fixer (both Kodak).
2.14.3 Notes
- Only optimal translations were used (as defined by Mg2+ titration)
- All centrifugation and incubations were carried out at room temperature.
- All incubations during steps 2-5 were carried out in the presence of proteinase
inhibitors (10 gg/ml leupeptin and 10 gg/ml antipain (both SIGMA)).
2.15 ANTIBODY PRODUCTION
2.15.1 Special reagents and materials
Dialysed keyhole limpet haemocyanin (KLH).
A length of seamless dialysis tubing (> 12,000 mol wt retention; SIGMA) was
boiled for 5 min in approximately 500 ml of milli-Q water containing a small
quantity (about a spatula tip-full) of NaHC03 and EDTA. When the water had
cooled to room temperature, the tubing was rinsed thoroughly in an excess of fresh
milli-Q water then one end was closed with a double knot. Using a Pasteur pipette,
the tubing was then filled with 6 ml of a 10 mg/ml solution of KLH (produced by
dissolving 60 mg of KLH powder (SIGMA) in 6 ml of sterile milli-Q water). After
closing with a single knot, the tubing was suspended in 2.5 1 of lx PBS for 2 h at
4°C. The lx PBS was then replaced with a fresh 2.5 1 and the dialysis continued
overnight. The following morning, the lx PBS was replaced with 2.5 1 of 10 mM
potassium phosphate buffer (pH 7.0) and the dialysis continued for a further 6 h at
4°C. The tubing was then carefully re-opened with a cut just below the single knot
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and the dialysed KLH transferred to a 15 ml glass COREX tube using a Pasteur
pipette. Following a 10 min spin at 8500 rpm the supernatant was collected and
the absorbance at 280 nm measured. The final concentration of KLH in the
dialysed solution was then calculated (Ei%280 = 18 OD). The KLH was then
frozen and stored at -40°C until required.
Sephadex G25-50 gel-filtration column.
G25-50 Sephadex (12 g; SIGMA) was swollen for about 30 min in an excess of
0.1 M potassium phosphate buffer pH 6.0. The excess buffer was then poured off -
down to the level of the swollen gel - and replaced with fresh. After swirling for a
few seconds, the gel was allowed to sediment before the excess buffer was again
poured off and replaced with fresh. This process was repeated twice more.
Following the final wash, excess buffer was added, swirled quickly and the resulting
gel slurry poured into a large glass column (4 cm in diameter x 19 cm high), secured
in a vertical position with the tap at the bottom closed. When the gel had settled,
the bottom tap was opened and 100-150 ml of buffer was gently applied to the
column - this was then allowed to rim through, down to a final level about 2-3 cm
above the gel surface. The tap was then closed again and the column carefully
moved to 4°C until required.
Sulpho-m-maleimidobenzoyl-N-hydroxysuccinimide (sulpho-MBS)-activated KLH.
Sulpho-MBS (12.5 mg; Pierce) was dissolved in 10 mM potassium phosphate
buffer pH 7.0 (2.5 ml) then reacted with dialysed KLH (24 mg; see above) for 30
min at room temperature (with rotation). The G25-50 Sephadex column prepared
above was taken from 4°C, the bottom tap opened, and the level of buffer allowed
to drop to the surface of the gel. The sulpho-MBS-KLH was then carefully applied
with a Pasteur pipette. After opening the bottom tap to allow this solution to just
run into the gel, the tap was closed and the column filled with approximately 50 ml
of 0.1 M potassium phosphate buffer pH 6.0, taking care not to disturb the surface
of the gel. The tap was then re-opened and the eluate collected - the first 20 ml as a
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bulk fraction which was discarded and the next 22.5-30 ml as 1.5 ml fractions (in
1.5 ml microfuge tubes) which were kept on ice. The absorbance of each fraction
was subsequently measured at 280 nm - fractions were simply poured into the
cuvette, the absorbance measured and the fraction then poured back into its
microfuge tube (blank = 1st 1.5 ml fraction). A sharp peak in absorbance
encompassing about 6-8 fractions was clearly visible, representing the elution of the
MBS-activated KLH. These fractions were subsequently pooled and stored at
-40°C until required.
2.15.2 Method
1. The peptide acyl-Ala-Lys-Leu-Val-Arg-Val-Leu-Ser-Pro-Val-Pro-Val-Gln-Asp-
Ser-Pro-Ser-Asp-Arg-Val-Ala-Ala-Ala-Cys-amide (SPeri; 20 mg), synthesized by
Prof. N. Groome, Department of Biology, Oxford Brookes University, and identical
to amino acids 125 to 147 of the deduced mouse S-periaxin sequence (plus C-
terminal cysteine residue for coupling), was dissolved in 10 mM HC1 (2 ml) then
extracted with ether (2 ml).
2. The lower aqueous phase from step 1 (containing the ether-extracted peptide)
was subsequently transferred to a fresh tube and its pH adjusted to approximately
6.0 by the drop-wise addition of 0.1 M NaOH.
3. A sample (1.5 ml) of the peptide solution from the above step was then reacted
with sulpho-MBS-activated KLH (2.5 ml; see above) at 4°C overnight (with
rotation).
4. Ethanolamine (2 ml of 0.5 M) was then added to the KLH-coupled peptide from
step 4 and the tube incubated for a further 1 h at 4°C. The solution was then
dialysed twice against lx PBS. (The dialysis procedure was essentially as described
for the keyhole limpet haemocyanin up to the point of the dialysis against 10 mM
potassium phosphate pH 7.0).
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5. Dialysed KLH-coupled peptide (2.5 ml) was subsequently emulsified with
Freund's complete adjuvant (3.3 ml; SIGMA) by vigorous shaking overnight at 4°C;
the remainder was stored at -40°C until needed.
6. The resulting emulsion from the above step was used to immunize three New
Zealand white rabbits (1.9 ml per rabbit: 0.5 ml injected intramuscularly into each
hind limb; 0.9 ml injected subcutaneously into the scruff).
7. After 3 weeks, the immunization was repeated by injecting (in the same pattern
as before) 1.9 ml of an emulsion prepared from the dialysed KLH-coupled peptide
(2.5 ml) and Freund's incomplete adjuvant (3.3 ml; SIGMA).
8. Ten days later, a 2-5 ml test bleed was collected from each rabbit via an incision
in the posterior marginal vein of the right ear.
9. After allowing the bloods to clot at room temperature for 1-2 h, the clot was
detached from the sides of each container by ringing with a wooden cocktail stick.
The bloods were then left overnight at 4°C to allow the serum to separate out.
10. The resulting serum were transferred to 15 ml COREX tubes using a Pasteur
pipette and centrifuged at 8500 rpm for 15 min. The supernatants were then
collected and stored as small aliquots at -40°C.
11. A 1:500 dilution of each of these test bleed antisera was subsequently used for
western blotting protein from 15-day-old mouse sciatic nerves in order to determine
the strength of immunoreactivity and specificity for S-periaxin in each animal (for a
detailed method see section 2.11).
12. Specific but weak S-periaxin immunoreactivities as demonstrated by the above
western blotting necessitated further reimmunization until a reasonably high
antibody titre was achieved in at least one animal. To this end, all three animals
were re-injected with a 1.9 ml of dialysed peptide-KLH and incomplete Freund's
adjuvant emulsion one week after the initial test bleed. Steps 9-12 were then
repeated.
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13. Improved S-periaxin immunoreactivities demonstrated in step 13 led to a final
immunization with a further 1.9 ml of dialysed peptide-KLH and incomplete
Freund's adjuvant emulsion four days after the test bleeds from step 13.
14. Ten days later, rabbits were anaesthetized and fully bled by cardiac puncture
using a 16G needle. The 80-100 ml of blood collected from each animal was then
processed according to steps 9-11.
2.16 AFFINITY PURIFICATION
2.16.1 Special reagents and materials
Sepharose-SPeri peptide column .
A small, glass, gel filtration column (1.5 cm in diameter x 10 cm high) was
secured in a vertical position with the bottom tap closed. Aminohexyl-sepharose
4B suspension (3 ml; SIGMA) was then added and allowed to settle. After opening
the bottom tap, lx PBS (10 ml) was pipetted into the column and allowed to run
through. This wash was then repeated three more times and the tap closed. PBS (6
ml) and sulpho-MBS (500 Jil; 5 mg/ml in dimethyl fluoride) were then added, the
top sealed and the column incubated for 2 h at room temperature (with rotation).
With the column secured back in an upright position, four further 10 ml washes with
lx PBS were carried out. After closing the bottom tap, PBS (2 ml) and SPeri
peptide solution (2 ml; produced in essentially the same way as steps 1-3 of
'Antibody production' except that 15 mg of peptide was used instead of 20 mg)
were then applied, and the column incubated at room temperature overnight (with
rotation). In the morning, the column was secured upright, washed once with 1 M
Tris-HCl pH 7.5 (1 ml), twice with 0.1M glycine pH 2.6 (10 ml) and twice with lx
PBS (10 ml). The column was then stored at 4°C until required.
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2.16.2 Method
1. The Sepharose-SPeri peptide column (see above) was secured upright then
washed once with 1 M Tris-HCl pH 7.5 (1 ml), twice with 0.1 M glycine pH 2.6 (10
ml) and twice with lx PBS (10 ml).
2. PBS (1 ml) and final bleed antiserum (1 ml) from the rabbit giving the strongest
immunoreactivity against S-periaxin (as determined by western blotting; see steps
11 and 14 of 'Antibody production') were then applied (with the bottom tap
closed) and the column incubated for 2 h at room temperature (with rotation).
3. After securing upright, the column was washed through with an excess of lx PBS.
0.1 M glycine pH 2.6 (15 ml) was then carefully applied to the column and the
eluate collected as 1 ml fractions into large microfuge tubes containing 0.5 M Tris-
HCl pH 7.5 (0.5 ml). Fraction 1 was subsequently discarded; the remaining 10
fractions were kept on ice until the level of S-periaxin immunoreactivity present in
each was determined (by western blotting protein from 15-day-old mouse sciatic
nerves with a 1:50 dilution - for a detailed method see section 2.11).
4. The 3 fractions from the above step which showed the highest S-periaxin
immunoreactivity were pooled and stored as small aliquots at -40°C.
2.17 INDIRECT IMMUNOFLUORESCENCE
2.17.1 Special reagents and materials
3' Amino-propyl triethoxy-silane (TESPA)-subbed slides.
New, clean, glass microscope slides (BDH) were immersed in a IN solution of
hydrochloric acid in 70% ethanol for 20 sec, followed by a 20 sec wash in distilled
water and a 20 sec wash in 100% acetone. After drying, slides were dipped in a 2%
(v/v) TESPA solution (produced by diluting stock TESPA (SIGMA) to 2% with
acetone) for 20 sec then washed twice in 100% acetone (each for 20 sec). When dry,
80
slides were stored (at room temperature) in a clean, sealed box containing desiccant
until required.
2.17.2 Method
1. 20-day-old mice were anaesthetized then perfused by intracardiac injection of a
4% paraformaldehyde in 0.1 M sodium phosphate pH 7.4 (PFA) fixative. When
completed, sciatic nerves were dissected out and fixed for a further 2 h at room
temperature in an excess of PFA solution.
2. After 3 x 15 min washes in 0.1 M sodium phosphate buffer pH 7.4, nerves were
cryoprotected by immersion for 15 min in a 5% (w/v) and then a 10% (w/v)
solution of sucrose in phosphate buffer before incubating overnight in a 20% (w/v)
sucrose solution at 4°C.
3. Cryoprotected nerves were then cut into 2-3 short lengths which were then frozen
upright in OCT embedding compound (Tissue TEK) using liquid N2-cooled
isopentane.
4. Embedded nerves were subsequently cut into thin (7 pm) transverse sections and
collected onto TESPA-subbed glass microscope slides (6 sections per slide). Slides
were then allowed to dry for 1 h before further processing (or storage at -40°C).
5. Nerve sections were washed thoroughly with lx PBS to remove residual OCT
then blocked for 3 h at room temperature with a solution of 10% (v/v) goat serum
(SAPU) in blocking buffer (lx PBS containing 0.2% gelatin and 0.1% Triton X-100).
6. Following blocking, sections were incubated overnight at room temperature with
appropriate combinations of primary antibodies diluted in a solution of 4% goat
serum in blocking buffer.
7. Following 4x5 min washes in blocking buffer, slides were incubated with
secondary antibodies (FITC-conjugated goat anti-rabbit IgG (Cappel) at 1:200;
biotinylated goat anti-mouse IgG at 1:500 (Kirkegaard and Perry Laboratories)),
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diluted in 4% (v/v) goat serum in blocking buffer, for 1 h in the dark at room
temperature. Slides were then washed three times in blocking buffer.
8. Slides were subsequently incubated in streptavidin-Texas red (Vector
Laboratories), diluted to 1:1500 in blocking buffer containing 4% (v/v) goat serum,
for 1 h in the dark at room temperature, then finally washed three times in lx PBS.
9. A single drop of Vectashield mounting solution (Vector Laboratories) was then
put on a coverslip and placed over the sections. Edges were then sealed with clear
nail varnish.
10. Sections were subsequently examined with a Leica TCS4D confocal microscope.
2.17.3 Notes
- To minimize the quantities of precious antibodies and fluorochromes, incubation
volumes during steps 5-8 were kept low (150-200 gl) by creating a small chamber
over the tissue sections from a suitably sized coverslip raised at each end by a stack
of two narrow glass strips (roughly 3 mm x 22 mm). The chamber was then filled
gently by pipette. After each incubation the chamber was gently removed by
flooding the slide with the relevant washing solution. All subsequent washes were
carried out with the wash solutions in excess. A new chamber was therefore
assembled at the beginning of each separate incubation.
-To prevent evaporation during incubations (especially overnight), slides were




3.1 STRUCTURE OF THE MURINE PERIAXIN GENE
3.1.1 Characterization of Periaxin Gene Clones
As described in detail in the Methods, a murine genomic library was screened
with a 3 kb restriction fragment taken from a full-length rat periaxin cDNA
(Gillespie et al, 1994). From 10^ bacteriophage clones, 12 hybridization-positive
clones were identified and isolated. A restriction digest carried out on phage DNA
from each clone using EcoRl, revealed three independent clone types (Figure 13) -
type 1 (F2, Gl, G2, LI, N1 and Tl) containing genomic inserts of approximately 15
kb, which gave rise to EcoRl fragments of 11, 3.5, 0.6 and 0.1 kb, type 2 (Bl, F4, II,
J1 and Ql) containing inserts of approximately 18.5 kb, which gave rise to EcoRl
fragments of 10.8, 5, 1.5 and 1.3 kb, and type 3 (Fll) containing an insert of 22.5 kb,
which gave rise to EcoRl fragments of 11, 5.5, 3.5, 1.5 and 0.9 kb. The individual
EcoRl fragments from each of the three clone types were subcloned into pIBI30 and
their ends sequenced (200-300 bp). By comparing these sequences, many of the
fragments were shown to be identical to, or part of, fragments from the other clones
demonstrating a large amount of overlap between the genomic inserts. Figure 14
presents the linear arrangement of the three clone types as deduced from these
overlapping sequences, which cover a region of genomic DNA approximately 28 kb
in length. It is important to note that the EcoRl sites at the extreme ends of the
clones are derived from the lambda multiple cloning region and therefore do not
represent EcoRl sites in the genomic DNA. Such sites were readily identifiable by
the presence of an immediately adjacent Sau3Al site (a characteristic feature of the
library construction), which also allowed convenient orientation of the fragment.
Comparison of the sequences obtained from the ends of the EcoRl fragments
with the sequence of the periaxin cDNA demonstrated no similarity. This indicated
that either the periaxin gene was located wholly within one of the isolated fragments
or that the gene was split into a number of exons located within different fragments.
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Figure 13. EcoRl digestion of first screen genomic clones. Lambda DNA from each periaxin
positive bacteriophage clone (12) was digested with EcoRl and electrophoresed on both a
1.5% and 0.8% agarose gel in TAE. The small (<2 kb) EcoRl fragments resolved on the 1.5%
gel (bottom) and the large (>3.5 kb) fragments resolved on the 0.8% gel (top) indicate the
presence of 3 independent clone types. The intense bands at 9 and 20 kb are the left and




H H ■4—i Type 3
2 kb
Figure 14. Schematic representation of the structural relationship of periaxin genomic
clones. The 3 distinct periaxin-positive genomic clone types isolated from a Lambda
DASH II phage library show a high degree of overlap as defined by EcoRl digestion (E).
Dotted lines indicate shared restriction fragments. Note: The EcoRl sites shown at the
ends of each clone are vector derived and therefore not present within the gene.
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Southern blot hybridization of DNA from each distinct EcoRl fragment with
regional cDNA probes covering the entire rat periaxin sequence proved the latter to
be the case, as 5' periaxin sequence was localized to the 5.5 kb EcoRl fragment, and
central and 3' sequence was localized to the 11 kb EcoRl fragment (Figure 15). This
finding also confirms the orientation, with respect to the periaxin cDNA, of the
genomic DNA depicted in Figure 14.
The complete exonic-intronic organization of periaxin coding sequence within
the 11 kb and and the 5.5 kb EcoRl fragments was determined by PCR and
sequencing, using periaxin sequence-specific oligonucleotide primers, with the rat 4.6
kb cDNA sequence as a reference. The mouse periaxin sequence identified within
these fragments was shown to cover almost 94% of the gene from its homology to
nts 300 to 4642 (the beginning of the poly(A) tail) of the published rat periaxin
sequence. The absence of sequence homologous to nts 1-299 of the rat cDNA
(which encode the 5' untranslated sequence together with the initiator methionine in
rat periaxin) within the 5.5 kb fragment indicated two possibilities: either the
corresponding mouse sequence was present within the 5.5 kb fragment but was just
unrecognizable due to sequence divergence between the two species or, the
homologous sequence was located on another library clone with sequence 5' to those
isolated. Identification of the 5' end sequence of mouse periaxin by 5' RACE
showed the first possibility to be untrue, with the 300 nts showing more than 94%
homology to those of the rat. This meant the 5' end of the mouse periaxin gene was
located on an as yet unidentified clone and hence necessitated a re-screen of the
genomic library.
Using nts 52-300 of mouse periaxin as a probe (generated by PCR on the
cDNA obtained by 5' RACE), a further 6 x 10^ library bacteriophage were screened
as before. From this, 2 hybridization-positive clones (BB1 and HH1) were obtained.
An EcoRl digest on DNA from each revealed a single independent clone type
containing a 13.5 kb genomic insert, which gave rise to fragments of 7, 5 and 1.5 kb.
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Figure 15. Southern blot hybridization of each distinct EcoRl fragment from the type 1, 2
and 3 clones with regional cDNA probes covering the entire rat periaxin sequence. DNA
from each subcloned fragment was digested with EcoRl, electrophoresed on 1% agarose in
TAE gels, then transferred to nylon membranes. These membranes were subsequently probed
with restriction fragments corresponding to nts 1-602, 1-1323, 1323-2994 and 2994-4645 of
the published rat periaxin sequence, labelled with [a-^^P]dCTP by random priming.
Sequence from the 5'-end of mouse periaxin is localized to the 5.5 kb EcoRl fragment,
whereas central and 3' sequences are localized to the 11 kb EcoRl fragment. An intron of at
least 3.5 kb separates these sequences.
Extensive characterization by PCR, sequencing and Southern blot hybridization
successfully located the missing 300 nts of exonic sequence within these fragments,
but also revealed no overlap between this clone and the clones from the previous
screen. However, the HH1/BB1 and the HI were shown to be contiguous by PCR
performed on 129SV genomic DNA using a forward primer from the most 3' EcoRl
fragment of the HH1/BB1 clones (the 5 kb) and a reverse primer from the most 5'
EcoRl fragment of the HI clone (the 5.5 kb). Therefore, in the gene, these 2
fragments (the 5 kb and the 5.5 kb) abut to form a region flanked by EcoRl sites
10.5 kb apart (once again the EcoRl sites at the end of the 5 kb and 5.5 kb clones
are vector derived).
3.1.2 The Murine Periaxin Gene Contains 7 exons and Spans 20.6 kb
Figure 16 shows the complete structure of the murine periaxin gene (designated
Prx) as deduced from all of the isolated clones. The gene spans a region of genomic
DNA 20.6 kb in length - four and a half times the length of the 4.6 kb rat periaxin
mRNA - and contains 7 exons interrupted by 6 introns. Exon size increases
gradually through exons 1-6 (from 32 to 197 nts) which encode approximately 14%
of the mRNA including the entire 5' untranslated (5' UTR) (exons 1-4), the initiation
codon (exon 4) and the first 126 amino acids of the mouse periaxin protein (exons
4-6). Exon 7 is extremely large (4002 bp) and encompasses the remaining 86% of
the gene up to and including the translation stop codon and the entire 3'
untranslated region (3' UTR). The introns show similar extremes of size ranging from
88 bp (intron 2) to 7500 bp (intron 5). The nucleotide sequence around each exon-
intron junction conforms to the canonical GT/AG rule for eukaryotic nuclear genes
(Breathnach et al, 1978). This information is summarized in Table 2.
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Figure 16. Structure of the murine periaxin gene. Exons are numbered and indicated by solid
rectangles. Introns are shown as solid lines between the exons. EcoRl (E) restriction sites
are indicated and were used to subclone the genomic clones F2, HI and II (from the first
screen) and HH1 (from the second screen).
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TABLE 2
Exon No. cDNA 5' Splice Intron No. 3' Splice Codon Amino acid at
(size in bp) position donor (size in bp) acceptor phase splice site
1 (32) 1-32 CCACCGgtaaga 1(4900) tcctagAGCCCC - -
2 (44) 33-76 CCTCAGgtgaga 2 (88) tggcagGCAGCA - -
3 (99) 77-175 GAAGCGgtgagg 3(116) ccccagGCTCAG - -
4 (126) 176-301 GCTGAGgtgggt 4(2900) tcgcagGAGCTG 0 9-Glu/Glu
5 (157) 302-458 AAGAAGgtaggc 5(7500) ttgcagGGGACC 1 62-Gly
6 (197) 459-655 AAGCTGgtacgc 6(592) cctcagAACATC 0 127-Leu/Asn
7 (4002) 656-4657
Exon/intron position, size, and junction sequence structure of the mouse periaxin gene.
The intronic 5'-splice donor GT and the 3'-splice acceptor AG are bolded. The exonic
sequences are capitalized. The interruption of codons by introns is indicated by the phase.
A phase of 0 indicates no interruption, insertion of an intron after the first nucleotide of the
codon is indicated by phase 1. All numbering is relative to the deduced cDNA sequence of
the mouse 4.6 kb periaxin message.
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3.1.3 Prx is a Single Copy Gene
When compared to the size range of introns and exons in an average
vertebrate nuclear gene (Hawkins, 1988), the Prx intron sizes and the sizes of exons
1-6, are all typical. However, exon 7 is unusually long. To exclude the possibility
that the genomic clones isolated encoded a mouse periaxin pseudogene, a genomic
Southern blot was performed to characterize the periaxin gene in mouse
chromosomal DNA. Figure 17 illustrates a Southern blot of 129SV genomic DNA
cut with three different restriction enzymes and hybridized with a radiolabeled
restriction fragment corresponding to nts 1323-4641 of the rat periaxin cDNA.
Identified, are a single BamHl fragment, a single 11 kb EcoRl fragment and a single
9.1 kb Kpn 1 fragment. The number and size of each of these hybridizing fragments
are precisely predicted from restriction maps of the type 1, 2 and 3 clones. This
data, together with the recent mapping of the periaxin gene to a single locus on
mouse chromosome 7 (Gillespie et al, 1997), would seem to indicate that the
isolated clones do encode a bona fide, single copy mouse periaxin gene and that the
final exon is actually very large.
3.2 SEQUENCE OF THE MOUSE PERIAXIN GENE
3.2.1 Sequence Comparison of rat and Mouse Periaxin
The sequences of all exons shows a very high degree of similarity to the
sequence of the 4.6 kb rat periaxin cDNA used as a reference throughout the gene
characterization (Gillespie et al, 1994; see appendix for full comparison). Overall,
the mouse and rat periaxin DNA sequences are 93% identical. However, as can be
seen from Figure 18, this belies a high degree of variability, with the similarity
approaching almost 99% in some regions; elsewhere it is below 88%. This translates
into an equally high degree of regional variability between the deduced amino acid
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Figure 17. Periaxin is encoded by a single copy gene in the mouse. 129SV genomic DNA
(10 pg) was digested with either EcoRl, BamHl or Kpnl, electrophoresed on a 0.8%
agarose in TAE gel, then transferred to nylon membrane. The membrane was subsequently
probed with a restriction fragment corresponding to nts 1323-4641 of the rat periaxin cDNA.
The number and size of each of these hybridizing fragments are precisely predicted from
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Figure 18. Quantitative analysis of the sequence similarity of the murine periaxin gene
and the 4.6 kb rat periaxin cDNA. The number of nucleotide differences between rat and
mouse periaxin was calculated at intervals of 100 bp. These values are plotted
graphically as vertical bars. Overall, the sequences are 93% identical. However,
regional variation is clearly visible.
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sequence of the mouse periaxin (encoded by an mRNA comprising exons 1-7) and
the deduced amino acid sequence of rat periaxin (Gillespie et al, 1994) (Figure 19A
and B). The regions of highest and lowest similarity correspond well with the
domain structure of rat periaxin as deduced from the primary sequence (Gillespie et
al, 1994) (Figure 12). Conservation of the N-terminus (including the basic domain)
and the acidic domain towards the C-terminus, would suggest that these regions are
important to periaxin function.
The repeat domain (characterized by a repeating motif of a pentapeptide
[aliphatic nonpolar:pro:glu or asp: aliphatic nonpolanvariable] and a tripeptide
spacer (Gillespie et al, 1994) appears to show quite high variability. However, many
of the changes result in the inclusion of a conserved amino acid. Given that this
domain is thought to be physically inflexible (Gillespie et al, 1994) and has been
postulated to play an important structural role in periaxin (extending the
polypeptide and keeping the basic and acidic domains well separated), the
inclusion of conserved amino acids presumably serves to maintain this structural
property. Interestingly, the two species show some degree of polymorphism with
respect to the repeating units. The repeat region of the mouse periaxin is larger than
that of the rat by exactly two repeat units (which is necessary for retaining the
correct open reading frame). This finding is most likely due to 'slipped-mispairing'
during DNA replication (For review see Moore et al, 1983) and perhaps indicates
the mechanism by which the periaxin repeat region has evolved to its present length,
from a small number of ancestral units.
3.2.2 A Correction to the Published Rat Periaxin Sequence
A 19 bp sequence close to the 3' end of the coding region of the published rat
cDNA (bp 4337-4355) was found to be absent from the mouse gene. This altered
the reading frame of the mouse periaxin until base 4376 was reached, at which point
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PCRs carried out with primers spanning this region using S129 genomic DNA or a
reverse transcription of sciatic nerve RNA from 15-day-old mouse as template,
generated products which, when subcloned and dideoxy sequenced, were identical
to the corresponding region of the mouse gene, therefore confirming the genomic
clone sequence. A repeat of these experiments using rat genomic DNA or a reverse
transcription of sciatic nerve RNA from 15-day-old rat as template for the PCR
generated identical products which were structurally, much closer to the mouse gene
than the published rat periaxin sequence, in that the 19 bp were absent and an extra
bp was present at position 4376. Thus, these independent sources all appear to
indicate that the published rat periaxin cDNA sequence is incorrect.
3.3 ANALYSIS OF THE 5' END OF THE MOUSE PERIAXIN GENE
3.3.1 The Mouse Periaxin Gene has a Single Transcriptional Initiation Site
A comparison of the sequences of several mouse periaxin cDNA clones
obtained by 5' RACE showed that their 5' ends all terminated within a few
nucleotides of each other and similarly within a few nucleotides of the 5' end of the
published rat periaxin cDNA (Gillespie et al, 1994). To define accurately the
transcriptional initiation site of the mouse periaxin gene, primer extension was
performed. A 32pqabeqecj oligonucleotide complementary to nucleotides 50-71 of
the rat periaxin cDNA was hybridized with trigeminal nerve total RNA from 13-
day-old mice, and this primer was extended with reverse transcriptase. The size of
the products was determined by denaturing gel electrophoresis and
autoradiography (Figure 20).
A single major extension product of 75 nt was thus demonstrated, mapping
the transcriptional initiation site to 4 bp upstream of the putative exon 1. The
possibility that these 4 extra bp are not part of the putative exon 1 but actually
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Figure 20. Determination of the periaxin transcription initiation site by primer extension.
An oligonucleotide complementary to nts 50-71 of rat periaxin cDNA (Gillespie et al, 1994)
was end-labelled with [y-^^PJATP using T4 polynucleotide kinase. Total RNA (10 pg)
from the trigeminal nerves of 13-day-old mice was hybridized to labelled oligonucleotide
(5 pmol) and reverse transcribed. Extended products were resolved on a 6% polyacrylamide
sequencing gel adjacent to a sequencing ladder comprising the 5'-end of periaxin primed
using an oligonucleotide complementary to nts 55-76 of mouse periaxin cDNA. The
extended product for murine periaxin mRNA is shown in lane P.
form a separate exon is extremely remote. Further evidence against this is indicated
by the upstream gene sequence, which shows that the transcriptional initiation site
would correspond to an A residue of a CA dinucleotide, at which many eukaryotic
RNA polymerase II transcripts are observed to initiate (Corden et al, 1980)
3.3.2 The Murine Periaxin Promoter is TATA-less
Approximately 500 bp upstream of the deduced transcription inititation site
was sequenced and is shown in Figure 21. Several features of this region are of
interest. First, this putative core promoter does not contain a conventional TATA
box and hence belongs to the family of TATA-less promoters. Such promoters are
found mainly in 'house keeping' genes, which are genes expressed in a number of
tissues at low levels. Other features of such promoters include (i) multiple
transcriptional initiation sites, (ii) the absence of a canonical CAAT box and (iii) a
high G+C content (due in part to the presence of multiple binding sites for the
ubiquitous zinc finger transcription factor Spl (GGGCGG)). The mouse periaxin
promoter possesses none of these features even though it is TATA-less: (i) by primer
extension only a single major transcriptional intiation site is demonstrated; (ii) a
CAAT box consensus sequence is located from -86 to -76; (iii) the sequence is only
slightly G+C rich overall (54%) with no Spl binding sites present. This lack of
many of the features of house keeping gene promoters is unsurprising given the very
limited expression pattern of periaxin (Gillespie et al, 1994; Scherer et al, 1995).
An interesting feature of the G and C content of the periaxin promoter is that it
is very deficient in the dinucleotide 5' CG 3'. By random pairing, the expected
number of CG dinucleotides should be between 6-10 in every 100 nt. For the
periaxin promoter this value is 10 x lower at 0.6 CG dinucleotides per 100 nt. Such
suppression of CG pairs has been linked to transcriptional repression by
methylation (Bird, 1987; Busslinger et al, 1983; Yisraeli et al, 1986), and indeed this
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-491 ACAAC CTTCA AGAGG TAAGC ATTCT TACTA CTACT ATTTC AAAGA CAAAG
STATx
-441 AACTG AGGGC CCAGT GATGC CCTGT GATTG CTGAA GTTCC CGC-AG CCAGG
-3 91 AATGC CTGAG CTGGG...AC.T.XG...AA.C.CG...AAATT CTCAA GGAGA CAGTG TAAGA
GORE
-341 GGTTG TTTTG AGAGT CTCAG GGACT ATGTG OGCTA GGCCT GGGTC CAGGA
SREBP-1
-291 GCCCA GAGAT GATGG GGGTG GGGTG CTGAG TATTC GAATG GGGGT GGTAT
SCIP/Oct-6
-241 GCAAA TTCTT GAACT AAGGC TGGGG TGGAG GTCTG GGCTC TGGCA.AGGGA
-191 G.AGG.T TCATG TTTCC ACATC CCCAC GCCCT TGCAG ATGGA TGTAG TGCAC
-141 AGAAG GGGAT GTTTG TTTCC CCACC ACCCA CCC.1X.TGGGT GACAT CACAG
NF-Y/CAAT
-91 CAGGA CAGCC AATGG CCAGG GTCCC CCTTC TGCCC CCCCC TTCCC ATTCC
+ 1
-41 TTTTC CCTCC CAGCC CAAGG CTAGG ACTAA CAGAA CAGAC CAAGG AGCTC
+ 10 TGGAG GTGTC TGGAG GCCCA CCGfft
Figure 21. Nucleotide sequence of the mouse periaxin core promoter. Exon 1, which
comprises 32 bp (positive numbers), and 491 bp of the putative core promoter
(negative numbers) are shown relative to the position of the transcriptional
initiation site (+1) determined by primer extension. The sequences recognized by
STAT proteins (Horvath et al, 1995), SCIP/Oct-6 (Jaegle et al, 1996; Bermingham et
al, 1996; Blanchard et al, 1996), SREBP-1 (Kim et al, 1995) and NFY (Hooft van
Huijsduijnen et al, 1987) together with the concensus glial cAMP response element
(GCRE) (Li et al, 1994) are underlined The CAAT box is double underlined.
Sequences common to myelin gene promoters (but of unknown function) are
underlined with a dotted line.
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may be a very important mechanism for the tissue-specific and stage-specific
regulation of the periaxin gene.
An extensive comparison of the core promoter sequence with published
transcription factor binding sites (Faisst and Meyer, 1992; TFSEARCH web site,
Kyoto University (www.genome.ad.jp/SIT/TFSEARCFl.html)) identified several
potential elements. A number of the elements bind ubiquitous factors (NF-Y,
SREBP-1, STATx)(Horvath et al, 1995; Hooft van Huijsduijnen et al, 1987; Kim et
al, 1995 ); such factors are probably required for basal levels of transcription, acting
co-operatively with tissue-specific and stage specific factors. Of particular interest
with respect to myelination is the presence of an octamer motif (ATGCAAAT)
between -236 and -243. This is a potential binding site for the POU family of
transcription factors which often play an important role in cell-type specific
transcriptional regulation (Scholer, 1991; Ruvkun and Finney, 1991; Wegner et al,
1993). The only members of this family present in Schwann cells are Oct-1 and
SCIP/Oct-6 and of these only SCIP/Oct-6 is differentially regulated during
Schwann cell development (KuFm et al, 1991; Blanchard et al, 1996; Monuki et al,
1989) and indeed this protein has recently been shown to be a vital factor for the
maturation of Schwann cells from a premyelinating to a promyelinating phenotype
(Blanchard et al, 1996; Bermingham et al, 1996; Jaegle et al, 1996). Similarly,
between -317 and -306 the sequence shows a high degree of homology to the GCRE
element present in the promoters of several myelin genes where it is believed to
mediate their induction in response to the increased intracellular levels of cAMP
which result from the addition of forskolin to Schwann cell primary cultures (Li, et
al, 1994). This effect is believed to mimic some of the axonal signals required for
Schwann cell differentiation and may indicate a concerted pathway for the
activation of myelin gene expression (Lemke and Chao, 1988; Trapp et al, 1988).
The identification of this element, together with a number of other sequences
commonly found in myelin gene promoters, and the shared CG suppression, would
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appear to suggest that periaxin is regulated by the same pathway, underlining its
potential importance in the myelination process.
3.4 ANALYSIS OF MOUSE PERIAXIN GENE EXPRESSION
In postnatal rats, the periaxin gene is believed to be expressed exclusively in
the PNS as two distinct mRNAs of similar abundance (Gillespie et al, 1994). The
amounts of these mRNAs reflect the activity of Schwann cell myelin deposition,
given that they are seen to parallel those of the major myelin proteins in normal
sciatic nerves and in those subjected to axotomy and crush (Scherer et al, 1995;
Lemke and Axel, 1985). The spatial and temporal expression of the periaxin gene in
the mouse was thus examined. Total RNA from various tissues of a 15-day old
mouse was electrophoresed, transferred to nylon membrane and probed with a 32p.
labelled restriction fragment corresponding to nts 1-1323 of the 4.6 kb rat periaxin
cDNA (Gillespie et al, 1994).
As can seen in Figure 22, two distinct periaxin mRNAs are detected,
specifically in the PNS. This is in complete agreement with the previous findings in
the rat. Using the same probe as for the tissue Northern blot, the developmental
expression of these mRNAs in postnatal mouse sciatic nerve (PNS) was
investigated (Figure 23). Both periaxin mRNAs are detected in significant quantities
in newborn animals, increasing to a peak at P16-P18. Interestingly, this high level of
expression is maintained into adulthood (although the 5.2 kb mRNA appears to
slightly downregulate).
Given that the mouse is approximately 2 days more advanced,
developmentally, than the rat, the early postnatal expression of periaxin (during the
most active phase of myelin deposition) is reasonably similar in both species.







Figure 22. The mouse periaxin gene is specifically expressed in the PNS. Total RNA from
various tissues of a 15-day-old mouse was electrophoresed on a 0.8% agarose
formaldehyde gel (2 pg per lane; except sciatic nerve RNA, 0.5 pg), transferred to nylon
membrane and probed with a 1.3 kb restriction fragment corresponding to bases 1-1324 of
the published rat periaxin sequence, labelled with [a-^^P]dCTP by random priming.
Tissues are indicated at the top of the figure, and the ethidium bromide-stained 18S RNA
in each lane is shown in the bottom panel to show the similar RNA loadings. Periaxin is
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Figure 23. Mouse periaxin mRNAs are developmentally regulated. Sciatic nerve RNA
from mice of various ages was electrophoresed on a 0.8% agarose formaldehyde gel (2 pg
per lane), transferred to nylon membrane and probed with a 1.3 kb restriction fragment
corresponding to bases 1-1324 of the published rat periaxin sequence, labelled with [a-
32p]dCTP by random priming. Postnatal ages (in days) are indicated at the top of the
figure The levels of both periaxin mRNAs reach a peak between 2-3 weeks after birth,
after which they decline very slowly, a feature which is more pronounced for the 5.2 kb
message.
decline and are almost undetectable in the adult. This is in total contrast to the
mouse where levels remain elevated throughout the life of the animal. The reason for
this difference in the temporal pattern expression between such closely related
species is unclear. It is possible that other sciatic nerve mRNAs may be increasing
more in the rat than in mouse, so that total RNA will contain proportionately less
periaxin mRNA per gg. Indeed, there are still reasonable levels of periaxin protein
in the sciatic nerves of adult rats indicating continued gene expression (Scherer et al,
1995). The polarization of expression within these nerves from an adaxonal
localization in young animals to an abaxonal localization in the adult would seem
to suggest that periaxin has a long term role which therefore requires long term
expression.
3.5 ALTERNATIVE SPLICING OF THE MOUSE PERIAXIN GENE
3.5.1 Characterization of Periaxin mRNA structure
As Prx is a single copy gene in both rat and mouse (this thesis; Gillespie et al,
1994, 1997), it follows that the two mRNAs must be generated from this single gene
and must thus be products of alternative splicing. For the previously characterized
4.6 kb periaxin mRNA, splicing of the primary gene transcript results in the
incorporation of all seven exons shown in Figure 16. Therefore, to characterize the
exonic structure of the 5.2 kb mRNA, various possible alternative splicing
mechanisms (Breitbart et al, 1987) were investigated.
Northern blotting carried out on rat and mouse sciatic nerve total RNA with
regional probes spanning the entire 4.6 kb mRNA showed strong hybridization to
both messages (not shown). A particularly important implication from this was that
exon 7 is also present within the 5.2 kb mRNA and thus at least 86% of the 4.6 kb
mRNA (and more than 91% of the protein coding sequence) is shared with the larger
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message. The detection by Gillespie et al (1994) of only a single translated periaxin
protein from the two periaxin mRNAs of rat appeared to confirm this finding,
suggesting that the two mRNAs contain the same coding region and therefore encode
the same 147 kDa protein. The size difference of the mRNAs was thus presumed to
be most likely due to the presence of a longer untranslated sequence in the larger
message.
The 3' UTR of the 4.6 kb mRNA is defined by the stop codon (TGA) and the
start of the poly(A) tail and measures 210 and 205 bp in the mouse and rat
respectively. For the 5.2 kb mRNA to possess a longer 3' UTR the polyadenylation
signal utilized in the 4.6 kb mRNA should be ignored in favour of a second signal
further downstream. Analysis of approximately 800 bp of mouse genomic clone
sequence directly downstream of the known polyadenylation signal failed to
identify a second polyadenylation signal. Also, a PCR product generated to this
sequence and used as a probe for Northern blot of mouse sciatic nerve RNA failed
to identify the 5.2 kb message. It was thus concluded that the 3' ends of the 4.6 and
5.2 kb periaxin mRNAs are identical and that the difference between the two
messages must be located at a position somewhere 5' of exon 7 ie involve alternative
splicing of exons 1-6.
3.5.2 Two Periaxin mRNAs are Generated by a Retained Intron Mechanism
Using a probe encoding nts 1-599 of the 4.6 kb rat periaxin cDNA that had
been previously shown to hybridize to both mRNAs on a Northern blot of sciatic
nerve RNA from 15-day-old rat, a rat sciatic nerve cDNA library was screened for
clones corresponding to the 5' end of each periaxin mRNA. From the 3 x 10^ library
bacteriophage that were screened, 18 clones were identified and isolated.
Characterization of each clone by dideoxy sequencing and PCR using exon-specific
primers showed 13 of the clones to be identical in structure to the 5' end of the 4.6
kb mRNA ie these clones possessed no extra sequence relative to this mRNA. The
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sequence of the 5 other clones was also identical to the 5' end of the 4.6 kb mRNA
but only up to the end of sequence corresponding to exon 6. After this point, the
sequence of these clones showed great similarity to that of intron 6 of the murine
gene. Although 3 of these clones ended within this sequence, 2 extended through 597
bp, at which point the clones continued into sequence corresponding to the start of
exon 7 of the 4.6 kb mRNA, which strongly suggested that the 5.2 kb periaxin
mRNA differed from the 4.6 kb mRNA by the non-splicing of the 0.6 kb intron
located between exons 6 and 7 of the gene. To confirm this finding, sciatic nerve
RNA from 15-day-old mice was Northern blotted with a probe corresponding to the
'intronic' sequence from one of the above 5.2 kb-specific clones which had been
generated by PCR (Figure 24). The hybrization of this probe to the 5.2 kb periaxin
mRNA shows that the 'intron' is indeed present within this message.
Further confirmation of this finding can be seen from the screen itself. From the
similar abundance of the two periaxin mRNAs displayed by Northern blotting, the
library screening would be expected to identify similar numbers of 4.6 kb and 5.2
kb-specific clones. At first glance it would appear that almost three times as many
4.6 kb-related clones were isolated in comparison to those of the 5.2 kb. Ffowever,
of the 13 clones identical in structure to the 5' end of the 4.6 kb mRNA only 6
actually extended far enough to show that they did not include this 'intron'
sequence. The remaining 7 clones encoded only exons 1-6 and could therefore
actually be from either the 4.6 kb or the 5.2 kb mRNA. Thus, only 6 clones were
shown to be specifically related to the 4.6 kb mRNA compared to 5 specific to the
5.2 kb mRNA - an almost 1:1 relationship.
The deduced structural relationship of the two periaxin mRNAs and the
murine gene, is shown in Figure 25. As indicated, the 4.6 kb periaxin mRNA is
generated by constitutive splicing of the primary gene transcript, with the removal
all 6 introns and the splicing of each of the 7 exons. The 5.2 kb mRNA is an






Figure 24. Alternative splicing of an intron generates the two periaxin mRNAs. Sciatic
nerve RNA from 15-day-old mice was electrophoresed on a 0.8% agarose formaldehyde
gel (2 pg per lane), transferred to nylon membrane and probed in lane A with a 1.3 kb
restriction fragment corresponding to bases 1-1324 of the rat periaxin cDNA and in lane B
with a PCR product comprising intron 6 of the periaxin gene. Intron 6 is shown to be
specific to the 5.2 kb mRNA.
Figure 25. Processing of the periaxin gene primary transcript. Exons present in the final
processed mRNA are represented by filled boxes. Sequences removed (spliced) from the
primary gene transcript are shown as dotted lines.
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the first 5 introns are removed. The resulting message not only combines all 7 exons
as in the 4.6 kb mRNA, but also retains the 0.6 kb intron located between exons 6
and 7.
3.5.3 The 5.2 kb Periaxin mRNA encodes a Truncated Isoform
Given that the 4.6 kb mRNA encodes the previously described 147 kDa
periaxin protein (Gillespie et al, 1994) and that it does so from an open reading
frame which spans from exon 4 to the extreme 3' end of exon 7, it follows that the
position of the retained intronic sequence within the identical coding region present
in the 5.2 kb, must affect any protein translated from this message. Subsequent
analysis of the open reading frame present in the 5.2 kb sequence, assuming the
same initiation codon is used in the translation of the 4.6 kb mRNA, indicated that
a highly truncated periaxin isoform would be produced due to the presence of a
stop codon located 63 nts into the retained intron which extends exon 6. This
deduced protein would be identical to the N-terminal 127 amino acids of the 147
kDa periaxin but would diverge into a novel 21 amino acid, intron-encoded C-
terminus, giving a molecular weight of just over 16 kDa.
To rule out the possibility that the intron-derived stop codon was a
sequencing error and that the retained sequence was actually translated throughout
and in phase with exon 7, rat periaxin cDNAs corresponding to the 4.6 kb mRNA
(pAlBG; Gillespie et al, 1994) and the 5.2 kb mRNA (constructed by replacing the
Sfil/HincII restriction fragment of the pAlBG periaxin cDNA with the
corresponding fragment - which included the entire intron sequence - from one of the
2 long, 5.2 kb-specific cDNA clones isolated above) were transcribed in vitro,
generating RNAs which were subsequently translated by rabbit reticulocyte lysate in
the presence of [^S] L-methionine. Figure 26 shows the resulting gel
autoradiograph following electrophoresis of these translated proteins. The 4.6 kb
cDNA encodes a large protein with a Mr equivalent to that demonstrated by
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Figure 26. Transcription-translation and immunoprecipitation of the L- and S-periaxin
isoforms. cDNAs corresponding to the 4.6 and 5.2 kb rat periaxin messages were
transcribed with T7 RNA polymerase then translated with rabbit reticulocyte lysate in
the presence of [^S]-labelled L-methionine. A sample of each was then electrophoresed
on a 4-20% linear gradient PAGE gel. After drying, the gel was exposed to X-ray film for
48 h. Lanes A and B represent the transcription/translation products of the 4.6 and 5.2 kb
cDNAs respectively. A mixture of these two reactions and a control translation product
(ELAV; a gift from Dr S. Tait) was subsequently immunoprecipitated with the anti-
NTerm antibody. Electrophoresis and autoradiography was as before. Lane C
demonstrates that the NTerm antibody specifically immunoprecipitates the L- and S-
periaxin proteins even when other proteins are in excess (lane D; ELAV).
Gillespie and coworkers (1994) in the transcription-translation of the same clone. In
contrast, the 5.2 kb cDNA encodes a much smaller protein (approximately 16 kDa).
This correlates well with the Mr predicted from the sequence translation of the 5.2
kb mRNA. To further verify that this small protein encodes the predicted sequence
ie that it has been translated from the same initiating methionine as the 147 kDa
periaxin and is not an artefact of a misprimed translation from another position on
the 5.2 kb RNA, a quantity of the in vitro translation was immunoprecipitated with
an antibody raised to the extreme N-terminus of the large periaxin (anti-NTerm).
As Figure 26 shows, this antibody does indeed precipitate the 16 kDa protein, thus
confirming it as a truncated isoform of periaxin.
Although these experiments demonstrated a truncated form of periaxin could
be generated from the 5.2 kb mRNA, no such protein has been detected by previous
studies (Gillespie et al, 1994; Scherer et al, 1995). Flowever, given these studies both
utilized the anti-pl70 antibody which recognizes sequence within the repeat region
of the 147 kDa periaxin protein and given the truncated periaxin isoform is
predicted not to encode any of the repeat domain, this is unsurprising. Actual
expression of this isoform was demonstrated in vivo by Western blots carried out on
sciatic nerve homogenate from 15-day-old mouse using the anti-Nterm and anti-
170pepl antibodies as well as a rabbit anti-peptide antibody raised against the
unique 21 amino acid C-terminus of the small periaxin isoform (anti-SPeri;
Figure 27). Levels of the small periaxin isoform (subsequently named S-periaxin)
can be seen to be remarkably high relative to those of the large periaxin isoform
(subsequently named L-periaxin) and are probably consistent with the relative
levels of the mRNAs. The possibility that the S-periaxin band is actually a
degradation product cannot be completely discounted given the extreme
susceptibility of the 147 kDa periaxin to proteolysis (Gillespie et al, 1994).
Flowever, the presence of a cocktail of proteinase inhibitors throughout the
procedure together with the fact that the S-periaxin is the only other band and that
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Figure 27. Western blot of mouse periaxin with domain-specific antibodies. Sciatic nerves
from 15-day-old mice were homogenised and immunoblotted using antibodies raised
against peptide sequences comprising either the N-terminus of L- and S-periaxin (anti-
NTerm), the repeat region unique to L-periaxin (anti-170pepl; Gillespie et al, 1994) or the
C-terminus unique to S-periaxin (anti-SPeri). The sizes of L- and S-periaxin are indicated
in kDa.
it is also of the predicted size, makes this very unlikely. Similarly, the absence of an
S-periaxin-size band on a Western blot carried out on purified myelin with the anti-
NTerm antibody and under the same procedural conditions (not shown) would
suggest that proteolysis of the L-periaxin has not occurred. This finding, that S-
periaxin is not present within, or does not co-localize with myelin (unlike the L-
periaxin isoform) suggests a different function for this isoform during development
of the PNS. This differential localization was also supported by
immunocytochemical analysis (see section 3.6)
3.5.4 A Possible PDZ Domain at the N-terminus of L- and S- Periaxin
A comparison of the deduced amino acid sequence of both L- and S-periaxin
between rat and mouse (Figure 28) demonstrated a particularly striking similarity
between the NT-terminal 127 amino acids up to the point where the isoforms diverge.
Within this region the rat and mouse polypeptides are identical. Given that the
percentage similarity for the rest of L-periaxin is 94% (6 changes per 100 aa), with
the next largest run of identical sequence only 50 amino acids long, the N-terminus
of both isoforms appears to be highly conserved. It was thus postulated that this
region must possess some important motifs for the function of periaxin, prompting a
careful examination of the sequence, in spite of the fact that previous searches of the
complete L-periaxin polypeptide had not been informative (Gillespie et al, 1994).
A BLAST search (Macvector, Oxford Molecular Group) using the deduced amino
acid sequence for S-periaxin revealed a short region of similarity to the tight
junction-associated protein, zonula occludens (ZO-1) (Willott et al, 1993; Itoh et al,
1993; Woods and Bryant, 1993). This region was later identified as a PDZ domain
(D. Sherman, personnal communication), a motif found in a number of proteins
which are believed to associate with the plasma membrane (Fanning et al, 1996;
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GEGASSRRGR VRVRLPRVGL ASPSKVSKGQ EGDATSKSPV GEKSPKFRFP RVSLSPKARS GSRDREEGGF RVRLPSVGFS ETAVPGSTRI EGTQAAAI*
B.
MOUSE 1 MEARSRSAEE LRRAELVEII VETEAQTGVS GFNVAGGGKE GIFVRELRED SPAAKSLSLQ EGDQLLSARV FFENFKYEDA LRLLQCAEPY KVSFCLKRTV
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V
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Figure 28. Interspecies comparison of the deduced amino acid sequences of the large (A) and
small (B) periaxin isoforms. Conserved amino acids are represented by asterisks. Dashes
indicate nucleotide gaps introduced for optimal alignments. The point of sequence divergence
between the two periaxin isoforms is arrowed (V).
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has been shown to interact with the Schwann cell plasma membrane in the rat
(Scherer et al, 1995).
3.6 SUBCELLULAR LOCALIZATIONS OF S- AND L- PERIAXIN
WITHIN MYELINATING SCHWANN CELLS
3.6.1 L- and S-Periaxin Show Contrasting Localizations in Myelinating Schwann
Cells
To compare the subcellular localizations of the two periaxin isoforms, thin
transverse sections of 20-day-old mouse sciatic nerve were immunofluorescently
double-labelled for L-periaxin and MBP, and for S-periaxin and MBP. On sections
double-labelled for L-periaxin and MBP (Figure 29; A-C), bright L-periaxin
immunoreactivity was visible at the plasma membrane and both the abaxonal and
adaxonal (periaxonal) surfaces of the Schwann cells but not within compact myelin
(as defined by red-fluorescent MBP labelling). Sections double-labelled for S~
periaxin and MBP (Figure 29; D-F) show bright S-periaxin immunoreactivity within
Schwann cells showing the same strong fluorescent MBP labelling of compact myelin
but for this isoform the localization is exclusively cytoplasmic, with no plasma
membrane or abaxonal or adaxonal staining.
The subcellular localization pattern shown here for mouse L-periaxin is very
similar to that previously found for the protein in rat sciatic nerve (Scherer et al,
1995; Gillespie et al, 1994). Using the same L-periaxin isoform-specific antiserum
as this work, these investigations identified predominant labelling of the plasma
membrane and abaxonal surface of Schwann cells possessing mature myelin.
Adaxonal (periaxonal) immunoreactivity was also visible in these cells but at a
much lower level however. In young or regenerating nerves the opposite was shown,
with periaxonal labelling predominating over reduced levels of plasma membrane
and abaxonal immunoreactivity. It is important to note that in these studies,
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Figure 29. Indirect immunofluorescence confocal micrographs showing the subcellular
localization of large (L)- and small (S)-periaxin. (A-C) Transverse section of sciatic nerve
from a 20-day-old mouse, immunofluorescently double-labelled for L-periaxin (A;
fluorescein) and MBP (B; streptavidin-Texas red). The superimposed image is shown in C.
L-periaxin can be seen to be exclusively localized to the plasma membrane (arrow) and
both the abaxonal (apposing the basal lamina) and adaxonal (apposing the axon) surfaces
(arrowheads) of myelinating Schwann cells. MBP labelleling is restricted to the myelin
sheath and therefore shows no co-localization (which would appear as orange-yellow).
(D-F) Transverse section from the same sciatic nerve preparation, double-labelled for S-
periaxin (D) and MBP (E). The superimposed image is shown in F. S-periaxin distribution
is shown to be restricted to the cytoplasm of myelinating Schwann cells with no membrane
labelling and no co-localization to MBP.
immunoreactivity is simply classified as being that of 'periaxin' and not, more
accurately, as being that of the 'L-periaxin isoform'. This is due to the fact, that at
the time, only one periaxin protein was known. As the antibody used in these
previous investigations was raised against a sequence found to be absent from the
S-periaxin isoform, the immunoreactivity shown has therefore been accepted as




In this study, the gene encoding periaxin in the mouse has been isolated and
characterized and its expression analysed. It has been revealed that the gene not
only encodes the previously described 147 kDa periaxin protein (Gillespie et al,
1994) but also encodes a truncated isoform of 16 kDa which is generated by a rare
form of alternative splicing. Furthermore, these two proteins have been shown to be
differentially targeted within myelin-forming Schwann cells, implying a dual role for
periaxin.
4.1 Origin of the Periaxin Gene Structure
The mouse periaxin gene (Prx) is composed of 7 exons interrupted by 6 introns
and spans approximately 20.6 kb. The Prx intron sizes (88 bp to 7500 bp) and the
sizes of exons 1-6 (32 bp to 197 bp) are typical when compared to the size range of
introns and exons in an average vertebrate nuclear gene (Hawkins, 1988). However,
exon 7 is unusually long (4002 bp), as vertebrate coding exons are rarely over 800
bp in length. Indeed, it is this size limit which has added weight to the 'intron-early'
hypothesis for the origin of split genes (Gilbert, 1978; 1987; Darnell and Doolittle,
1986). Naora (1987) and Senepathy (1986) have calculated that there is only a very
low probability of an open reading frame generated from random nucleotide
sequences exceeding 550-600 nt without encountering an in-frame stop codon. It has
therefore been postulated that splicing has evolved to join such short open reading
frames (exons) by removal of the sequences containing the stop codons (introns).
Arguably, protein coding exons are not random sequences of nucleotides but, they
must surely have originated from random processes. A small number of exons over
this predicted length will obviously have arisen by chance but these will be a rare
occurrence. The probability that the 4002 bp of Prx exon 7 arose in this way must
be virtually nil.
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It is sensible to assume that the periaxin gene must have evolved as multiple,
short exonic sequences and that the introns separating these sequences have been
lost. From the length of exon 7 it is possible that the ancestral Prx gene contained
between 12-30 exons and therefore 5-23 introns must have been removed to
generate the present gene structure. The most plausible explanation for the deletion
of these introns is the homologous recombination of a cDNA generated by the action
of a reverse transcriptase on a partially spliced intermediate periaxin mRNA. This
mechanism has been well documented for the removal of introns from yeast genes
(Fink, 1987) and has been used to explain the structural origins of number of
vertebrate genes which are devoid of introns. Flowever, the appearance of a
characteristic A-rich tract at the 3' end of such genes (due to the addition of a
poly(A) tail before splicing and reintegration of the transcript (Nevins and Cheng-
Kiang, 1981) and lack of such a feature at the 3' end of Prx exon 7 raises the
possibility that this long exon may have originated through the action of another
unknown mechanism.
4.2 Alternative Splicing of the Periaxin Gene Involves Intron Retention
The periaxin gene is expressed during post-natal development as two distinct
mRNAs of similar abundance. It has been shown here that the mRNAs are
generated by alternative splicing of the primary gene transcript such that the last
intron is retained in the larger (5.2 kb) mRNA but is lacking from the smaller (4.6
kb) mRNA. This form of alternative splicing in effect creates a larger fusion exon.
With regards to the 5.2 kb mRNA, this means that exon 6, intron 6 and exon 7
become a single exon of approximately 4.8 kb encompassing more than 92% of the
final transcript. Clearly, the distinction between intronic sequence and exonic
sequence can be easily blurred - are not excluded 'exons' actually introns and are not
retained 'introns' actually exons?
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It has been shown that the factors determining the retention of introns are
different from those responsible for the alternative splicing of exons. A key feature
of intron retention (Dirksen et al, 1995) is the presence of suboptimal splice sites at
both the 5'- and 3'-ends of the intron ie splice sites whose sequences differ from the
consensus sequences that are known to promote splicing (Shapiro, 1987). Such
'weak' splice sites would not normally support splicing and are therefore dependent
on additional enhancer elements located in the downstream exon (Dirksen et al,
1995). These exonic splicing enhancers (ESEs) are characteristically purine-rich and
are postulated to function through interactions with transactivating factors (Dirksen
et al, 1995).
In support of this model, the splice sites of the last intron of the periaxin gene
are divergent from the consensus sequences and there is a domain downstream in
exon 7 which is highly purine rich. The sequences of the 5'- and 3'-splice sites are
CTGgtacgc and tcagG respectively which are significantly different from the
corresponding rodent splice site consensus sequences of CAGgtragt and ncagG
(Shapiro, 1987). Downstream of the acceptor site and 24 bases into exon 7 there is
a 14 base sequence GAAGAAGAAGAAGA, which is an excellent candidate for an
ESE (Dirksen et al, 1995).
This form of alternative splicing is even more complex when it is considered
that intron-containing mRNAs, which are usually restricted to the nucleus, must
now be transported to the cytoplasmic compartment. It has been proposed that
splicing and nuclear export are competing pathways (Dirksen et al, 1995). The
presence of either a strong 5' or 3' splice site kinetically favours the splicing
pathway. Only when all introns have been spliced therefore will the fully processed
mRNA be released for export. However, when both splice sites are weak, the pre-
mRNA may form the splicing complex more slowly or weakly, favouring entry into
the export pathway from the nucleus.
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4.3 The Periaxin Gene Promoter May Bind Transcription Factors Which
Regulate Myelination
Over the past decade there has been an explosion of interest in the
regulatory elements involved in coordinating the expression of those genes required
for myelination. Several key transcription factors have been identified together with
an ever increasing number of common promoter sequences. Given that periaxin has
been postulated to have a potential role in myelin deposition by Schwann cells
(Gillespie et al, 1994) it was of considerable interest to examine the promoter region
of the periaxin gene and place it in context.
A particularly intriguing finding was a binding site for the POU-domain
transcription factor SCIP/Oct-6. This factor has been implicated as a major
transcriptional regulator in Schwann cell development (Bermingham et al, 1996;
Blanchard et al, 1996; Jaegle et al, 1996). As one of the first genes to be upregulated
following axonal contact both in vitro and in vivo and responding similarly to
chemicals which raise intracellular cAMP such as forskolin (Scherer et al, 1994),
SCIP is well placed to regulate the expression of axonally dependent genes such as
those of the myelin proteins and periaxin (Lemke et al, 1988; Trapp et al, 1988;
Scherer et al, 1995), and indeed it has been shown to act as a negative repressor of
both PO and MBP expression (Monuki et al, 1993). However, the importance of a
binding site for this factor within the periaxin promoter is questionable. In a
homozygous SCIP null mutant mouse (Bermingham et al, 1996) in which most
Schwann cells arrest at the promyelinating stage (where they have arranged
themselves in a 1:1 manner but have not formed myelin), both periaxin and MAG
are found around many of the axons where they are correctly targeted to the
adaxonal surface. This would seem to suggest that SCIP is either not involved in the
regulation of expression of these early genes and the initiation of myelination or,
that it is perhaps replaceable.
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Also of great interest is the presence of a sequence which bears considerable
similarity to the consensus GCRE element found in several myelin protein genes and
which has been shown to mediate induction in response to raised levels of
intracellular cAMP (Li et al, 1994). This effect is believed to mimic some of the
axonal signals required for Schwann cell differentiation and may be indicative of a
common signalling mechanism for the activation of myelin gene expression (Lemke
et al, 1988; Trapp et al, 1988). Given that axonal contact has been shown to be
vital to maintain periaxin expression in Schwann cells in vivo (Scherer et al, 1995)
and given that periaxin is believed to be the previously described protein, P170,
which is known to be upregulated by 8-bromo cAMP in Schwann cells in vitro
(Shuman et al, 1988), the identification of this element in the periaxin core promoter
certainly suggests that periaxin is regulated by the same pathway as the myelin
genes, underlining its potential importance in the myelination process.
4.4 The Periaxin Gene Promoter Shows Suppression of the Dinucleotide 5'CG 3'
The suppression of the dinucleotide 5' CG 3' within the putative periaxin core
promoter is particularly interesting with respect to its tissue specific expression.
Transcriptional repression by methylation is known to be a common mechanism for
switching off genes in all but specific cell types or tissues (Yisraeli et al, 1986; Bird,
1987; Busslinger et al, 1983). Considerable evidence obtained from a large number
of individual cell type-specific genes correlates their expression with the degree of
undermethylation of their DNA sequences with the genes being highly methylated in
non-expressing cells but considerably undermethylated in tissues in which they are
expressed (reviewed in Yisraeli and Szyf, 1984). This is consistent with the idea
that DNA methylation functions as a general repression signal for transcription and
ensures gene inactivity in all tissues in which the gene should not be expressed. For
every case analysed, methylation is present from early development with genes
undergoing demethylation in a tissue-specific manner when they become expressed.
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An example of this in a myelin gene can be seen with MAG (Konat, 1996). In the
liver (non-expressing), the MAG genomic DNA is very heavily methylated. In
contrast, most sites are demethylated in the brain. Similarly, MAG gene methylation
is significantly less in mature oligodendrocytes than in their progenitors, indicating
progressive demethylation concomitant with differentiation (Konat, 1996). Specific
cell types must therefore contain specific proteins which recognise the gene in its
methylated form and lead to its activation through demethylation.
Evidence for the presence of methylation within a promoter can come from the
analysis of the number of CG dinucleotides. Methylation of the C residue of a CG
dinucleotide can lead to accelerated rates of mutation as cytosine is prone to
deamination and conversion to thymine when methylated (Bird, 1987). Therefore,
CG dinucleotides tend to have been lost from sequences subject to methylation. The
promoters of many cell type-specific genes are known to be CG deficient and
methylation has therefore been proposed as a mechanism for regulating this form of
expression. For instance, when a reporter gene linked to a methylated form of the
CG-deficient a-actin promoter is transfected into fibroblasts, no expression is
induced but, when transfected into myoblasts site specific demethylation is seen to
occur, leading to expression (Yisraeli, 1986).
The promoters of most house keeping genes (which lack the TATA-box
consensus) possess CG dinucleotides at a frequency predicted by random pairing
(known as a CpG island) and indeed, it is the retention of these dinucleotides which
may lead to the high G+C content of these promoters and the presence of multiple
Spl binding sites. Such promoters therefore appear not to be regulated by
methylation. It is possible that the binding of Spl to gene promoters with the
GGGCGG motif has prevented methylation and the progressive loss of CG
dinucleotides and has lead to the development of G+C rich promoters in genes
regulated by this transcription factor. As this factor is ubiquitous it follows that
these genes will also be ubiquitous; this is indeed the case for house keeping genes.
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Although the periaxin core promoter is TATA-less it has a very low proportion
of CG dinucleotides (0.6 per 100 bp compared to 6-10 for random pairing) which
strongly suggests a methylated state and indicates that the tissue-specific and
stage-specific expression of the protein is - in part - regulated by a methylation-
demethylation mechanism. A similar CG suppression is seen in the promoters of
the major myelin genes (Table 3). It is tempting to speculate that activation of a
single protein (perhaps by a cAMP dependent kinase or phosphatase) which
recognises all of these promoters in their methylated state and/or activation of a
specific demethylase could be responsible for the specific upregulation of the
transcription of these genes during the Schwann cell myelination programme. Such a
mechanism would obviously require the presence of shared features ie common
binding sites or DNA conformations. The identification of a number of sequences
common to the promoters of many of the myelin genes (as well as periaxin) with as
yet undefined properties certainly leaves this possibility open.
4.5 S- and L-Periaxin are differentially Localized Within Myelinating Schwann
Cells
An important consequence of the retention of intron 6 within the protein
coding sequence of the 5.2 kb periaxin mRNA is that it introduces an in-frame stop
codon. Translation of this mRNA therefore results in the generation of a truncated
protein which has been named S(small)-periaxin. The previously described 147 kDa
periaxin protein encoded by the 4.6 kb mRNA (Gillespie et al, 1994) has also,
logically, been renamed as L(large)-periaxin. The function of both of these proteins
in myelinating Schwann cells was subsequently addressed.
The distinct subcellular localizations of the two isoforms within myelinating
Schwann cells as demonstrated by indirect immunofluorescence appears to suggest
a contrasting function for S-periaxin. Whereas L-periaxin is seen to associate with
the Schwann cell adaxonal, abaxonal and plasma membranes, S-periaxin is diffuse
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TABLE 3
Gene Species CG/100 nt Reference
PMP2 Human 1.2 Hayasaka et al. (1993a)
Po Human 0.4 Hayasaka et al. (1993b)
Mouse 0.7 You et al. (1991)
MOG Mouse 1.0 Daubas et al. (1994)
MAG Mouse 0.3 Nakano et al. (1991)
Rat 1.5 Montag, D. (unpublished)
MBP Human 1.4 Streicher et al. (1989)
Shark 1.6 Fors et al. (1993)
PLP Rat 0.3 Boison and Stoffel (1989)
Periaxin Mouse 0.6 This thesis
The core promoters of most myelin genes are CG-suppressed. Promoter sequences were
obtained from Genbank and their dinucleotide content analysed using Macvector sequence
analysis software (Oxford Molecular Goup). By random pairing each dinucleotide should
have a frequency of approximately 6.25 ie occur 6.25 times in every 100 nt. The myelin gene
promoters (plus periaxin) have values between 4 and 30 times lower than would be
expected.
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throughout the cytoplasm. This discovery was made even more intriguing by the
finding that the sequence at the N-terminus of both isoforms shares some similarity
with the PDZ domain, a well characterized motif found in a number of proteins
(Figure 30). This domain is believed to instigate the recruitment of proteins to the
plasma membrane (Kornau et al, 1995). Similarly, PDZ domain-containing proteins
may link transmembrane proteins with the actin cytoskeleton via actin-binding
proteins (Lue et al, 1994; Marfatia et al, 1996). Given that L-periaxin was initially
identified as a potential cytoskeleton-associated protein (Gillespie et al, 1994) and
that it has been shown to be cortically targeted, it is exciting to consider the
possibility that this domain is responsible for the localization of L-periaxin within
Schwann cells. However, the presence of the same domain in S-periaxin appears
insufficient to ensure cortical targeting. It is possible that the unique, intron-
encoded C-terminus of S-periaxin might target the protein away from the plasma
membrane but, equally likely is that there must be other cortical targeting signals
present within the L-periaxin.
If the S-periaxin isoform is indeed functional in Schwann cells it is a
reasonable assumption that the PDZ domain is involved. It has been suggested that
certain PDZ domain containing proteins may play a role in nuclear signalling and
transcriptional regulation (Gottardi et al, 1996; Poulat et al, 1997) and it is
interesting to note that nuclear S-periaxin staining was occasionally visible. The
absence of any known nuclear targetting signal within S-periaxin would suggest that
this isoform is not actively transported into the nucleus but proteins of small
molecular mass may enter passively (Dingwall and Laskey, 1986), leaving this
possibility open. Given that Prx is one of the first genes to become transcriptionally
active during myelination it is perhaps feasible that as well as a possible role in the
myelin structure (the L- isoform) periaxin may also be involved in the
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Figure 30. Identification of a PDZ domain at the N-terminus of L- and S-periaxin. The
sequence of mouse L- and S-periaxin between amino acids 14 and 98 was compared with PDZ
domains in the C. elegans protein CET19B10 (residues 232-316) (Wilson et al, 1994), PSD-95
(residues 309-393) (Cho et al, 1992 ), Discs-Large (DLG) (residues 482-566) (Woods et al,
1991), SAP-97 (residues 461-545) (Muller et al, 1995 ), ZOl (residues 408-491) (Willott et al,
1993), Z02 (residues 93-176), (Jesaitis et al, 1994) and INAD (residues 361-447) (Shieh et
al, 1996). The eight segments within the domain comprise six fi strands and two a-helices
(Doyle et al, 1996). Residues shaded black indicate strong conservation within the PDZ
motif. Residues in grey indicate a conserved amino acid.
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Ongoing from the work of this thesis has been the creation of a knockout
mouse by homologous recombination. The periaxin gene of these mice lacks most of
exon 6 together with all of exon 7 and therefore any periaxin protein which is
translated is highly truncated (even more so than S-periaxin). Although these mice
form myelin, it is unusually thick (S. Gillespie, personnal communication). Moreover,
from about 4 weeks of age peripheral nerve demyelination is clearly visible and is
concomitant with a clinical phenotype. This is almost certainly, the clearest





A number of potential protein-protein and protein-DNA interactions have
been suggested here to be involved in the functioning of the two periaxin isoforms
within myelin-forming Schwann cells. It will be of great interest therefore to see if
such interactions can be demonstrated experimentally. Many protein-protein
interactions have been successfully identified using the yeast two hybrid system (see
Gietz et al, 1997; Fromont-Racine, 1997; Warbrick, 1997 for reviews). To this end,
work is currently on-going to identify the functional domains and interacting
partners of the L- and S-periaxin isoforms by this method.
With respect to the transcriptional regulation of the Prx gene it will be
necessary to identify essential core promoter sequences, enhancers and silencers
particularly those responsible for determining Schwann cell expression, for instance
by mapping DNase I hypersensitive sites, nuclear extract binding assays and
transfection of reporter gene-linked truncated promoter constructs.
As regards the knockout mouse, identifying the molecular events which lead to
the mutant phenotype will clearly be vital to our understanding of the role of each
isoform during myelination. The reintroduction of each separate isoform into the
genome of these mice by transgenics will hopefully yield some definitive answers on





Map of the Lambda DASH II Replacement Vector
Map of the Lambda DASH* II Vector
Oligonucleotide Primers Specified in Text
• CSG7: 5'GAT GTA CAG CTG TAA GCC GG 3'
Rat periaxin cDNA 122-103 (Gillespie et al, 1994; antisense)
• CSG20: 5' GAT GCA CAG CTG TAA GCA GG 3'
Mouse periaxin cDNA 136-117 (This thesis; antisense)
• LMD30: 5'CGG TGA GTC CTC TCG CAG CTC 3'
Rat periaxin cDNA 426-406 (Gillespie et al, 1994; antisense)
• 5' RACE Anchor: 5' GCC CAC GCG TCG ACT AGT ACG GGG GGG
GGG GGG GGG 3'
GIBCO BRL (Sense)
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Sequence Comparison of Mouse and Rat 4.6 kb Periaxin
NB . U indicates splice position within mouse gene.
M 3 GGAGCTC TGGAGGTGTCTGGAGGCCCACCGAGC C CCAGACCCAGGAGGCC 52
Ml 111111111II1111111111111 11111111111IIIII11111
R 1 GGAACTCTGGAGGTGTCTGGAGGCCCACTGAGCCCCAGACCCAGGAGGCC 50
11
M 53 CAGGAAGCTGGAAGTGACCCTCAGGCAGCAAGACCTCAAAGGAAGAGTGA 102
II I MINIM II1111 11II111111111111111II111111111
R 51 CAAGTAGCTGGAACTGAC CCTCAGGCAGCAAGACCTCAAAGGAAGAGTGA 100
M 103 GATTCCTGCTTACAGCTGTGCATCACCCCGAGTGGGGCTCCTGTCAGGAG 152
Mill 1111IIII1111 11IIII11111111II111111II1111II
R 101 AATTCCGGCTTACAGCTGTACATCACCCCGAGTGGGGCTCCTGTCAGGAG 150
u
M 15 3 AAAAGGCCATCACTCAAGAAGCGGCTCAGCGGCAGCTGCTCCATGAGGAG 202
Mill II I II I I II I I I I I I I I I I I II I I II II I I I I I I II I I I I I I
R 151 AAAAGACCATCACCCAGGAAGCGGCTCAGCGGCAGCTGCTCCATGAGGAG 200
M 203 CTGAAGGTGGTCCTGCAGCAGAAGGAGGAGAGGACACGGGAGCTCGAGCC 252
MINI 1111111 11II1111111111111II II Mill Mill
R 201 CTGAAGCTGGTCCTACAGCAGAAGGAGGAGAGGAAACAGGAGCCTGAGCC 250
M 253 CCAGGTGACTCTCTGCAGAGCTATGGAGGCCAGGAGCCGCAGCGCTGAGG 302
I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I II II I I II I I I I I I I I I I
R 251 CCAGGTGACTCTCTGCAGAGCTATGGAGGCCAGGAGCCGCAGCGCTGAGG 300
M 303 AGCTGAGACGGGCGGAGTTGGTGGAGATTATCGTGGAGACCGAGGCACAG 352
I I I I I I II I I I I I I I I I II I I I I I I I I I I I I I I I II I I I Mill III
R 3 01 AGCTGAGACGAGCGGAGTTGGTGGAGATTATCGTGGAGACAGAGGCGCAG 350
M 353 ACCGGGGTCAGCGGCTTCAACGTAGCAGGCGGCGGCAAAGAAGGAATCTT 402
I I I I I I I I II I I I I I I I I I I I I I I I I I II I I II I I I I II I I I I I I I I I I
R 3 51 ACCGGGGTCAGCGGCTTCAATGTAGCAGGCGGCGGCAAAGAAGGAATCTT 400
M 403 TGTCCGTGAGCTGCGAGAGGACTCACCGGCAGCTAAGAGCCTCAGCTTGC 452
R 401 TGTCCGCGAGCTGCGAGAGGACTCACCGGCCGCCAAGAGCCTCAGTTTGC 450
11 ....
M 453 AAGAAGGGGACCAGCTGCTGAGTGCCCGTGTGTTCTTTGAGAACTTCAAA 502
I I II II I I I II I II Mill I I I II I I I I I I I I I I I I I I II I I I I I I
R 451 AGGAAGGGGACCAACTTCTGAGCGCCCGTGTGTTCTTTGAGAACTTCAAA 500
M 503 TATGAGGATGCACTTCGCCTGCTGCAATGCGCAGAGCCCTACAAGGTCTC 552
II II II I I I I I I I I I I I I I I I I II I I I I II II I I I I I I I I I I I I I I I
R 501 TATGAGGATGCACTACGCCTGCTGCAATGTGCCGAGCCCTACAAGGTCTC 550
M 503 CTTCTGCTTGAAGCGCACTGTGCCCACCGGGGATCTGGCACTGAGGCCCG 602
R 551 CTTCTGCTTGAAGCGCACTGTGCCCACCGGGGACCTGGCACTGCGGCCCG 600
M 603 GGACGGTGTCTGGATACGAGATGAAGGGCCCACGGGCCAAAGTGGCCAAG 652
II II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I II I II I I II I I I
R 601 GGACGGTGTCTGGATACGAGATGAAGGGCCCGCGGGCCAAGGTGGCCAAG 650
133
4
M 653 CTGAACATCCAGAGTCTGGCCCCTGTGAAGAAGAAGAAGATGGTGACTGG 702
I I I II II II II I I I I I I I II I I I I I II I I I I I I I I I I I I I I II I I III
R 651 CTGAACATCCAGAGTCTGTCCCCTGTGAAGAAGAAGAAGATGGTGATTGG 700
M 703 GGCCCTGGGGACCCCTGCAGATTTGGCCCCTGTTGACGTCGAGTTCTCTT 752
I I I I I I I I I I I I II I I I I I I II I I I I I II I I I I I I II I I I I I I II II I I
R 701 GACCCTGGGGACCCCTGCAGATTTGGCCCCTGTTGACGTCGAGTTCTCTT 750
M 75 3 TTCCCAAGTTCTCCCGACTGCGTCGGGGTCTCAAAGCCGAGGCTGTCAAG 802
lllllllllllllllll 11111IIIII II llllllll MINIMI
R 751 TTCCCAAGTTCTCCCGATTGCGTCGGGGCCTTAAAGCCGATGCTGTCAAG 8 00
M 803 GGACCTGTCCCAGCTGCCCCTGCCCGTCGCCGCCTCCAGCTGCCTCGGCT 852
I I I I I I I I I I I I I I I I I I I I I I I I I I II II II I II I II I I II II 1 I I
R 801 GGACCTGTCCCAGCTGCCCCTGCCCGACGACGTCTCCAGCTGCCTCGGCT 850
M 8 53 GCGTGTCCGAGAAGTAGCTGAAGAGGCCCAGGTAGCCCGAATGGCTGCTG 902
I I I I II II I I I II I I I I I I I I I I I I I I I I II II I I II I I I I I I I I I I I I
R 8 51 ACGTGTCCGAGAAGTAGCTGAAGAGGCCCAGGTAGCCCGAATGGCTGCTG 9 00
M 9 03 CTGCTCCTCCCCCAAGGAAGGCCAAGGCAGAAGCTGAGGCAGCCACAGGA 952
11II1111111 I 111111IIII11 MM 11111II 111111111
R 901 CTGCTCCTCCCTCTAGGAAGGCCAAGTCAGAGGCTGAGGTAGCCACAGGG 950
M 953 GCTGGGTTCACAGCCCCTCAGATAGAGCTAGTTGGGCCTCGGCTGCCTAG 1002
Mill IIIIIIIII111111111111111111111II111111111111
R 951 GCTGGATTCACAGCCCCTCAGATAGAGCTAGTTGGGCCTCGGCTGCCTAG 1000
M 1003 TGCCGAGGTGGGTGTCCCTCAGGTCTCAGTTCCCAAGGGGACCCCATCAA 1052
II I I I I II I I I I I I I I I I I I I I I I I II I I I II I I I I I I I I I I I I I I
R 1001 CGCAGAGGTGGGTGTCCCTAAGGTCTCAGTTCCCAAGGGAACCCCATCAA 1050
M 1053 CAGAGGCAGCCAGCGGCTTTGCCCTTCACCTGCCAACCCTTGGGCTAGGT 1102
II II I I I I I I II II I I I I I I I I I I I I I II I I I I I I I I II II I I I I I I I I
R 1051 CAGAGGCAGCCAGCGGCTTTGCCCTTCACCTGCCAACCCTTGGGCTAGGA 1100
M 1103 GCCCCAGCTGCACCGGCTGTGGAGCCCCCAGCCACGGGAATCCAGGTTCC 1152
1111II11111111IIII11111111II11 MM 11111111III II
R 1101 GCCCCAGCTGCACCGGCTGTGGAGCCCCCAACCACAGGAATCCAGGTCCC 1150
M 1153 ACAAGTGGAACTCCCCACCCTGCCCTCTCTACCCACGCTTCCCACACTTC 1202
I I I I I I I I I I I I I I I I I II I I I I I I II I I I I I I I II I I I I I I I I I I
R 1151 GCAAGTGGAACTCCCCACCCTGCCCTCTTTACCCACTCTGCCCACACTTC 1200
M 1203 CATGCCTGGACACCCAGGAAGGAGCTGCAGTGGTAAAAGTCCCTACCCTG 1202
I Mill II IIIII111111 II1111 11111 MINIM Mill!
R 1201 CGTGCCTAGATACCCAGGAAGGGGCTGCAGTGGTCAAAGTCC C CACCCTG 1250
M 1253 GATGTGGCAGCTCCGTCTATGGGGGTGGACCTGGCTTTGCCGGGTGCAGA 1302
I I I I I II I I I I II I I I I I III I I I I I II I II I I II II I I I I I I I I II
R 1251 GATGTGGCAGCTCCGTCTGTGGAGGTGGACCTGGCTTTGCCAGGTGCAGA 1300
M 1303 GGTGGAGGCCCAGGGAGAGGTTCCTGAAGTGGCCCTCAAGATGCCCCGGC 1352
I II I I I I I I I I II I I I I I I I I I I I II I I I I I I I I I I I I I I II I I I I I
R 13 01 GGTGGAGGCCCAGGGAGAGGTACCTGAAGTGGCTCTCAAGATGCCCCGTC 1350
M 1353 TCAGTTTCCCCCGTTTTGGGATTCGGGGGAAGGAAGCCACTGAAGCCAAA 1402
11II11111111II111111 MM II11111II11 11111111111
R 13 51 TCAGTTTCCCCCGTTTTGGGGTTCGAGGGAAGGAAGCTACTGAAGCCAAG 1400
134
M 1403 GTAGTCAAGGGCAGCCCTGAGGCCAAAGCAAAGGGTCCCAGACTTCGAAT 1452
IIIII11II111!11!11111111111111 f! 111111II1111111! I!
R 14 01 GTAGTCAAGGGCAGCCCTGAGGCCAAAGCAAAGGGTCCCAGACTTCGAAT 1450
M 1453 GCCCACCTTTGGGCTTTCTCTCCTGGAACCCCGGCCCTCTGGCCCTGAAG 1502
I I I I I I II I I I II I I I I I I I I I I I I I I I I II I II I I I I I I I I I I I I I I I
R 1451 GCCCACCTTTGGGCTTTCTCTCCTGGAATCCCGGCCCTCTGGCCCTGAAG 1500
M 1503 CTGTTGCTGAGAGCAAGCTGAAGCTACCCACCCTCAAGATGCCCTCTTTC 1552
II I II II I I I II II II I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I
R 1501 TTGCTGCTGAGAGCAAGCTGAAGCTACCCACCCTCAAGATGCCCTCTTTC 1550
M 1553 GGCATTGGTGTGGCTGGGCCTGAAGTCAAGGCACCCACGGGGCCCGAAGT 1602
IMII I II 1111! 111III 11111 11111111 Mill Mill
R 1551 GGCATCAGCGTAGCTGGGCCTGAGGTCAAGGCACCCAAAGGGCCTGAAGT 1600
M 1603 AAAGCTCCCTAAGGTTCCTGAGGTCAAACTCCCGAAAGTGCCCGAGGCAG 1652
I I II I I II II I I I I I I I I I I I I I I I I I I I I I I I I III I I I I I I I
R 1601 GAAGCTCCCCAAAGTTCCTGAGATCAAACTCCCGAAAGCGCCAGAGGCAG 1650
M 1653 CCATTCCAGATGTGCAACTCCCTGAGGTACAGCTGCCCAAAATGTCAGAC 1702
I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
R 1651 CCATTCCAGATGTGCAACTCCCCGAGGTACAGCTGCCCAAAATGTCAGAC 1700
M 1703 ATGAAACTTCCAAAGATCCCTGAGATGGTTGTACCCGACGTTCGTCTTCC 1752
1111111111111111111111111111 111111111 Mil Mill
R 1701 ATGAAACTTCCAAAGATCCCTGAGATGGCTGTACCCGATGTTCACCTTCC 1750
M 1753 GGAAGTGCAGCTGCCCAAAGTCCCTGAGATGAAAGTCCCAGAGATGAAGC 1802
I I I I I I I I I I I I I I I II II I I I I I I I I I I I I I I I I I I I I I I I I I I I I
R 1751 GGAAGTGAAGCTGCCCAAAGTCCCCGAGATGAAAGTCCCAGAAATGAAGC 1800
M 1803 TCCCGAAGTGGCCCGAGATGGCCGTGCCCGATGTACACCTTCCAGATGTA 1852
R 1801 TTCCGAAGATCCCGGAGATGGCCGTGCCTGATGTACACCTTCCAGATATA 1850
M 1853 CAGCTCCCGAAAG TCCCAGAGATGAAGCTCCCGAA 1887
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
R 1851 CAGCTCCCGAAAGTTCCCGAGATGAAGCTCCCAGACATGAAGCTCCCGAA 1900
M 1888 GGTGCCCGAGATGGCCGTGCCCGATGTACACCTTCCAGATGTACAGCTCC 1937
I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
R 1901 GGTGCCTGAGATGGCCGTGCCTGATGTACACCTTCCAGATATACAGCTCC 1950
M 1938 CGAAAGTTCCAGAGATGAAGCTACCAGAGATGAAGCTCCCGAAGGTGCCG 1987
111111II11 III11111111 Mill 11111111111II11II111
R 1951 CGAAAGTTCCCGAGATGAAGCTCCCAGACATGAAGCTCCCGAAGGTGCCT 2000
M 1988 GAGATGGCCGTGCCGGATGTACGACTCCCGGAAGTTCAGCTGCCCAAAGT 2037
II II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II I I I I II I I
R 2001 GAGATGGCCGTGCCTGATGTACGAATTCCGGAAGTTCAGCTACCCAAAGT 2050
M 2 03 8 GTCTGAGGTGAAGCTCCCAAAGATGCCTGAGATGGCCGTGCCTGATGTCC 2087
Ml I I II I I II I I II II IMII II II II I I I I I I I I I I II I I I I
R 2051 GTCCGAGGTGAAGCTCCCGAAGATACCGGACATGGCCGTGCCTGATGTTC 2100
M 2088 ACCTCCCGGAGCTACAACTTCCCAAAATGTCCGAGGTGAAGCTCCCAAAG 2137
11II11 Mill Mill 11II1111111 11111111111111 III
R 2101 GCCTCCCAGAGCTGCAACTGCCCAAAATGTCTGAGGTGAAGCTCCCGAAG 2150
135
M 213 8 ATGCCCGAGATGGCCGTGCCCGATGTTCGCCTCCCGGAAGTTCAGCTGCC 2187
II II II MINIM II 11111111111111 II111111111 II
R 2151 ATACCGGACATGGCCGTACCTGATGTTCGCCTCCCAGAAGTTCAGCTACC 2200
M 213 8 CAAAGTGTCAGAGATGAAACTCCCTAAGATGCCAGAGATGACCATGCCCG 2237
II111111IIIII Mil IMII III MM IIIIIIIII1111111
R 2201 CAAAGTGTCAGAGCTGAAGCTCCCGAAGGTGCCTGAGATGACCATGCCCG 2250
M 223 8 ACATTCGCCTCCCAGAAGTTCAGTTGCCCAAAGTGCCTGACATTAAACTT 2287
I I I I I I I I I I I I I I I I I I I I I I I I I I II II I I I II II II II I I I I
R 2251 ACATTCGCCTCCCGGAAGTTCAGCTGCCCAAAGTGCCTGACATTAAA. . . 2297
M 22 8 8 CCTGAAATGAAGCTTCCAGAAATAAAACTCCCCAAAGTGCCTGACATGGC 23 37
1111111111111111II111111II111111 Mill
R 2298 CTTCCAGAAATAAAACTCCCCAAAGTGCCTGAGATGGC 233 5
M 23 3 8 AGTGCCTGATGTCCCCCTTCCAGAGCTGCAGCTGCCCAAAGTGTCGGACA 2387
I I I I I I I I I II I I II I I I I II I I II II I I I II I I I
R 23 3 6 CGTGCCTGATGTCCCCCTTCCAGAACTACAGCTGCCCA 2373
M 23 88 TTCGGCTGCCTGAAATGCAAGTGTCACAGGTCCCAGAGGTGCAGCTTCCC 2437
Mill II II II I II I I II Mill I II I II
R 2374 AAGTGCCACAGGTCCCAGACGTGCATCTTCCC 2405
M 243 8 AAGATGCCAGAGATGAAGTTGTCCAAGGTTCCTGAGGTACAGAGGAAATC 2487
II II I I I II I I I II II II I I I I I I I I I I I I I I I I I I I I I I I I I I II
R 2 406 AAAGTGCCAGAGATGAAGTTGCCCAAGGTTCCTGAGGCACAGAGGAAATC 2455
M 2488 TGCAGGGGCGGAGCAGGCAAAAGGGACTGAATTTAGTTTCAAGTTGCCCA 2537
I I I I I I I II II I I I I I I I I II III II II I I I I I I I I I I I I I I I I I
R 2456 TGCAGGGGCGGAGCAGGCAGAAAAGACCGAATTTAGCTTCAAGTTGCCCA 2505
M 253 8 AGATGACCATGCCCAAGTTGGGGAAAGTGGGCAAGCCTGGGGAGGCAAGT 2587
I I II I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I II I I I I I I II
R 2506 AGATGACTGTGCCCAAGTTGGGGAAAGTGACCAAGCCTGGGGAGGCAGGT 2555
M 2588 ATTGAGGTTCCAGACAAACTCATGACACTTCCCTGTCTGCAGCCAGAGGT 2637
III llllll II MM II MM III IIIIIIIIIIIII11IIIIIIIII
R 25 56 ATTGAGGTTCCAGACAAACTCCTGATACTTCCCTGTCTGCAGCCAGAGGT 2 605
M 2638 GGGCACTGAGGCATCCCATGTTGGTGTCCCTTCCCTCTCTCTCCCCTCTG 2687
I II I I I I I I I I III I I I I I I I I I I I I II I I I I I I I I I I I II MM
R 2 606 GGGCACTGAGGTGGCCCGTGTTGGTGTCCCTTCCCTCTCTCTCCCTTCTG 2655
M 2 688 TGGAGCTTGACTTGCCTGGGGCCCTGGGCCTGGAGGGACAAGTCCAAGAA 2737
I I I II I I I I I I II II I I II I I I I I I I I I I I I II I I II I I I I I I I I I II II
R 2 65 6 TGGAGCTTGACTTGCCTGGGGCCCTGGGCCTGGAGGGACAAGTCCAAGAA 2705
M 27 3 8 GCTGTCCCAGGCAAAGTGGAGAAGCCAGAGGGCCCCAGGGTAGCAGTGGG 27 87
MIMI I II111II111II11II111II11II1111111 Mill II
R 27 06 GCTGTCTCTGGCAAAGTGGAGAAGCCAGAGGGCCCCAGGGTGGCAGTAGG 2755
M 2788 TGTTGGAGAGGTGGGCTTTCGTGTGCCCTCTGTGGAGATTGTCACTCCTC 2837
I I II I I I I I I I I I I II I I I I I I I I I I I I I I I II I I I I I Mill
R 27 56 GACTGGAGAGGCGGGCTTCCGCGTGCCCTCTGTGGAGATTGTCAATCCTC 2805
M 2 83 8 AGCTGCCCACAGTTGAAGTTGAGAAAGAGCAGCTAGAGATGGTGGAGATG 2887
I I I I I I II I I II II I I I I I I II I I I I I I I I I I I II I I I I I I I I I II I
R 2 806 AGCTGCCCACGGTTGAAGTCAAGAAAGAGCAGCTAGAGATGGTGGAGATG 2 855
136
M 28 8 8 AAAGTCAAACCCTCTTCCAAGTTCTCTCTGCCCAAATTCGGACTTTCAGG 29 3 7
I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I
R 2 85 6 AAAGTCAAACCCACTTCCAAGTTCTCTCTGCCCAAATTTGGACTTTCAGG 29 05
M 293 8 GCCCAAAGCTGTCAAGGGAGAGGTGGAGGGGCCTGGGCGAGCCACCAAGC 2987
I I I I I I I I I I I II II I I I II I I II I I I I I I I I I I I I I I I I I I I I II I I I
R 29 0 6 GCCCAAAGCTGTCAAGGCAGAGGTGGAGGGGCCTC-GGCGAGCCACCAAGC 29 55
M 2988 TGAAGGTTTCCAAGTTTACCATCTCACTTCCCAAAGCTCGAGCAGGGACT 3037
lllllll II I I I II I I lllllll II I I II I I I I I I I II I I II I I I I
R 2956 TGAAGGTATCCAAGTTTGCCATCTCGCTTCCCAGAGCTCGAGCAGGGACT 3005
M 303 8 GAGGCCGAAGCGAAGGGAGCTGGGGAAGCCGGGTTGCTGCCAGCGCTGGA 3087
II II II I II I I I I I I I I I I I I I I I II I I II II II I I I II II II
R 3 006 GACGCGGACGCGAAGGGAGCTGGGGAAGCGGGGTTGCTGCCTGCCCTCGA 3055
M 3088 TCTGTCCATCCCACAGCTCAGCCTGGATGCCCAGCTGCCCTCAGGCAAGG 3137
I!1111 II1111111IIII11111111111 II 1111II1111II1111
R 3 056 TCTGTCCATCCCACAGCTCAGCCTGGATGCTCAACTGCCCTCAGGCAAGG 3105
M 313 8 TGGAAGTA GCTGATAGCAAGCCTAAATCGTCCAGATTTGCTCTG 3181
Mil III Mill 1111IIIIII11 llllllllllllllll
R 310 6 TGGAGGTAGCAGGGGCTGAGAGCAAGCCTAAAGGGTCCAGATTTGCTCTG 3155
M 3182 CCCAAGTTTGGGGTGAAAGGCCGGGACTCTGAGGCTGATGTACTGGTGGC 3231
II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II I I I I I I I I I
R 3156 CCCAAGTTTGGGGCGAAAGGCCGGGACTCTGAAGCCGACGTACTGGTGGC 3205
M 3 2 32 AGGGGAGGCTGAGCTTGAGGGAAAGGGTTGGGGCTGGGATGGGAAGGTGA 32 81
lllllllllllllll Mill I II I I II I I II II I II I I I I I I I I I I I
R 3206 AGGGGAGGCTGAGCTGGAGGGGAAGGGTTGGGGCTGGGACGGGAAGGTGA 3255
M 32 82 AGATGCCCAAGCTGAAAATGCCATCTTTTGGGTTGTCCCGAGGAAAGGAA 3331
I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II I I I I I III
R 3256 AGATGCCCAAGCTGAAGATGCCATCTTTTGGGCTGTCCCGAGGAAAAGAA 3305
M 3332 GCAGAAACTCAGGATGGACGTGTCAGCCCCGGGGAAAAGCTGGAGGCCAT 3381
IIIII11 11111II11 III1111IIII II III11111111 Mill
R 33 06 GCAGAAATTCAGGATGGGCGTGTCAGCCCAGGAGAAAAGCTGGAAGCCAT 3355
M 3382 AGCTGGGCAGCTTAAGATCCCTGCGGTGGAATTGGTCACACCGGGAGCTC 3431
I I I II I I I II I I II I I II II I II II I I I I I I II II I I II I I I I I I I I
R 3356 AGCTGGGCAGCTTAAGATCCCTGAGGTGGAACTGGTCACACCAGGAGCTC 3405
M 3432 AGGAGACAGAGAAGGTCACCAGTGGAGTGAAGCCGTCAGGCCTCCAGGTG 3481
I I I II I I II I I I II I I I I I I I I I I I I II I I I I I I I I II I II I II I I II I
R 3406 AGGAGACAGAGAAGGTCACCAGTGGAGTGAAGCCATCAGGCCTCCAGGTG 3455
M 3482 TCCACCACTGGGCAGGTGGTTGCAGAGGGCCAGGAGAGTGTGCAGAGGGT 3531
I I I I I I II I I I I II I I II I II I I I I II II I I I I I I I I I I I I I I I I I
R 3456 TCCACCACTAGGCAGGTGGTTGCAGAGGGCCAGGAGGGGGCGCAGAGGGT 3505
M 3532 GTCCACACTAGGTATCTCTTTGCCCCAGGTGGAATTGGCCAGCTTTGGGG 3581
MM II 111IIIIIII111111111II111II 111111111111111
R 3506 GTCCTCATTAGGTATCTCTTTGCCCCAGGTGGAACTGGCCAGCTTTGGGG 3 555
M 3582 AGGCAGGCCCTGAGATCGTAGCCCCTTCTGCAGAGGGCACAGCAGGCTCT 3631
I II I I I II II I I II II I I I I I I I I I I I I I I I I I II II I I I I II I I I I
R 3 556 AGGCAGGCCCTGAGATCGCAGCCCCATCTGCAGAGGGCACAGTAGGCTCT 3 605
137
M 3 632 AGGGTCCAGGTGCCACAGGTGATGCTGGAGCTACCTGGAACCCAGGTGGC 3631
III I II I II II I I I I II I I II I I I I I I I I I II I I I I I I I I II I II I
R 3 606 AGGATCCAGGTGCCACAGGTGATGCTGGAGTTGCCGGGAACCCAGGTGGC 3 65 5
M 3 682 AGGGGGTGATCTGTTAGTGGGTGAGGGCATCTTCAAGATGCCCACAGTGA 3731
I I I I I I I I I II I I I I II I I I I I I I I I I I II I I I I I I I II I I I I I I I I I I I
R 3 656 AGGGGGTGATCTGTTAGTGGGTGAGGGCATCTTCAAGATGCCCACAGTGA 3705
M 3732 CAGTGCC C CAGCTAGAGOTGGATGTGGGGCTGGGCCATGAAGCCCAGGCT 3781
11II1111111 III 11 MMIII! i Ml IIII Mil III III MMII
R 370 6 CAGTGCCCCAGTTAGAGCTGGATGTGGGGTTGGGCCATGAAGCCCAGGCT 375 5
M 37 82 GGTGAAGCAGCCAAGAGTGAGGGTGGGATAAAGTTGAAGTTGCCCACACT 3 831
llllll I I I I II I I I I I II I I I III I I I I I I I I I I I I I I I I I I I I I
R 3756 GGTGAAACAGCCAAGAGTGAGGGCGGGTTAAAGCTGAAGTTGCCCACACT 3 80 5
M 3 832 GGGGACCGGAAGCAGAGGAGAGGGCGTTGAGCCCCAGGGCCCCGAGGCCC 3 881
Mil I III III I I I I I I I I I I INI IMII I II II II I I I I I
R 3 806 GGGGGCAGGAGGCAAAGGAGAGGGTGCTGAGGCCCAGAGCCCCGAGGCCC 3 85 5
M 3882 AGCGCACCTTCCACCTCTCATTGCCCGATGTGGAACTCACGTCACCAGTG 3931
Ml I I I I I I I I I I I I I I I I I I I I II II I II I II I I I I I I I I I I I
R 3856 AGCACACCTTCCACATCTCATTGCCTGACGTAGAACTCACATCACCAGTG 3905
M 3 932 AGTAGCCACGCTGAGTACCAGGTAGTTGAGGGTGATGGGGATGGTGGGCA 3981
11111111111111111111111 III11III 11111111111 Mill
R 3906 AGTAGCCACGCTGAGTACCAGGTGGTTGAGGGCGATGGGGATGGCGGGCA 3955
M 3982 CAAACTCAAGGTTCGGCTGCCCCTGTTTGGTCTGGCAAAGGCCAAGGAAG 4031
I II I II I II I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I II I II II
R 3956 CAAACTCAAGGTGCGGCTGCCCCTGTTTGGTCTGGCAAGGGCCAAGGAAG 4005
M 4032 GGATAGAAGTTGGAGAAAAGGTTAAGAGTCCAAAGCTCAGGCTACCCCGA 4081
I I I I I II I I I I I I I I I I I I I I I I II I I I I II I II II I I I I I I I I I I
R 4006 GAATAGAAACTGGAGAAAAGGTTAAAAGTCCAAAGCTCAGGCTACCCCGA 4055
M 4082 GTGGGCTTCAGCCAGAGTGAGTCGGTCTCCGGAGAAGGCTCTCCAAGTCC 4131
11111111111111 1111111111 III 11111111111111 Mill
R 4056 GTGGGCTTCAGCCAAAGTGAGTCGGCCTCTGGAGAAGGCTCTCCCAGTCC 4105
M 4132 TGAGGAGGAGGAAGAAGGCAGTGGGGAAGGGGCTTCCAGTCGCCGGGGTA 4181
I I I II I II I II II I I I I I I I I I II I I I I I I I I I I II I I I I I I I I III
R 4106 TGAGGAGGAGGAAGAAGGCAGTGGGGAAGGGGCTTCCGGTCGCCGTGGTC 4155
M 4182 GGGTAAGGGTCCGCCTGCCTCGGGTAGGCTTGGCTTCCCCTTCTAAAGTC 4231
MM III111111 1111111 1111111II111 1111111111111 I
R 4156 GGGTCAGGGTCCGCTTGCCTCGTGTAGGCTTGGCTTCCCCTTCTAAAGGC 4205
M 4232 TCTAAGGGACAGGAGGGTGATGCAACCTCCAAGTCCCCAGTTGGGGAGAA 4281
I I II I I I I I I I I I I I I I I I I I I I I I II I I II II I II I I I I I II I I I I I
R 4206 TCTAAGGGACAGGAGGGTGATGCGGCCTCCAAGTCCCCAGTTGGGGAGAA 4255
M 4282 GTCACCCAAATTCCGTTTTCCTAGGGTGTCCTTAAGCCCCAAGGCCCGGA 4331
Ml Mill Mill I I I I I I I I I I I I I I I I I II I I II I I I I I I I I I I I
R 4256 GTCCCCCAAGTTCCGCTTTCCTAGGGTGTCCTTAAGCCCCAAGGCCCGGA 4305
M 4332 GTGGGAGTAGGGACCGGGAAGAAGGTGGATTCAGGGTCCGACTGCCCAGT 4381
I I I I I I I I I I I II I I I I I I I II I II I I I I I II I I I II I I I I II I I I I II
R 4306 GTGGGAGTAAGGACCGGGAAGAAGGTGGATTCAGGGTCCGACTGCCCAGT 4355
138
M 4382 GTGGGATTTTCAGAAACAGCAGTTCCAGGTTCCACCAGGATTGAGGGAAC 4431
I [ I! 111111111111 111111 MINI III I I 11 i! III II I! II
R 4356 GTGGGATTTTCAGAAACAGCAGCTCCAGGCTCCGCCAGGATTGAGGGGAC 4405
M 4432 CCAGGCTGCTGCCATCTGAAGCCCCAGGACAGCTGTGGATTCCCCCTCTT 4481
I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I II II I I I I I I I I I
R 4406 CCAGGCTGCTGCCATCTGAAGCCCTGGGACAGCTGTGGATTCCCCCTCTT 4455
M 4482 GTCTTTCCATTCCCCAGCCTAGCCCCCCATTTTGTGTGTGACATTACTAG 4531
mil mi Mini n ii immii iiiiii1111111111
R 4456 GTCTTCCCA.TCCCCATCCCTGCTCCCCATTTTATGTGTGACATTACTAG 4504
M 4532 CACTAATCCTCAGAGGGCTTGAAGGTGAGTAACTGACTCAGGCAGGAGCC 4581
lllllllllllllllllllllllllll I I lllllllllllllllll
R 450 5 CACTAATCCTCAGAGGGCTTGAAGGTGGGCAGCTGACTCAGGCAGGAGC. 4553
M 4582 AGTGGCCTGTGCCACCTCATTGGCCAAAGTGCCTGTATATCATGTCAAAC 4631
II II I I I I II I II I I I I I I I I llllllllllllllll III I
R 4554 ...GGTCTGTGCCACCTCATTGGCTGACGTGCCTGTATATCATGCCAAGC 4600
M 4632 TATGGGAATAAAATAATTCAAAAGTT 4657
I II lllllllllllllllllllll
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